Annual Report (ESEF) • Feb 2, 2021
Preview not available for this file type.
Download Source FileRethink tomorrow The Novozymes Report 2020 2 Novozymes A/S – Let’s rethink tomorrow Our purpose 3 ContentsNovozymes A/S Message from the Chair and the CEO “This year has proven to us that Novozymes has strong partnerships with customers, a resilient portfolio and committed employees” Collaborating with communities during COVID-19 oral use which helps reduce The highlights of the Novozymes Report 2020 – at report2020.novozymes.com 01 The big picture 5 2020 in brief 15 Five-year summary 16 Message from the Chair and the CEO 19 This is Novozymes 20 Working with the SDGs 02 Our business 23 Strategy 25 Risk management 30 Targets 34 Outlook for 2021 03 Governance 38 Corporate governance 42 Board of Directors 44 Executive Leadership Team 46 Summary of the Remuneration report 50 The Novozymes stock 04 Accounts and performance 53 Performance and consolidated 61 Performance and consolidated environmental data 63 Performance and consolidated social and governance data 65 Notes 138 Statements 143 Financial statements for Novozymes A/S 159 Glossary 160 About the report Contents Together we find biological answers for better lives in a growing world Product Launch Explore Inspire The big picture 01 The big picture 5The big picture In briefNovozymes A/S (2019: -1%) (2019: 28.1%) (2019: 2.2 DKKbn) (2019: 21.1%) of 3% in DKK compared with 2019. Resilient 2020 performance despite the COVID-19 pandemic. Return on invested capital (ROIC), including goodwill, was 18.9%, down 2.2 percentage points from 21.1% in 2019. The decrease was mainly The increase of DKK 1.2 billion was operating activities. Driven by higher cash conversion from better earnings quality, a settlement related to the former BioAg setup and positive changes 0% 18.9% 26.1% 3.4 Organic sales growth ROIC EBIT margin 2020 realized 2020 outlook 1 Sales growth, organic 0% 0% EBIT margin 26.1% 26-27% ROIC (including goodwill) 18.9% 18-19% before acquisitions, DKKbn 2.6-3.0 1. Outlook guided as of December 11, 2020. The EBIT margin ended at 26.1%, down from 28.1% in 2019. Excluding former BioAG setup, reorganization costs, acquisition-related transaction costs and an impairment loss, the underlying EBIT margin was ~27% in 2020, which was ~1 percentage point higher than the underlying EBIT margin of ~26% in 2019. The improvement was driven by a higher underlying gross margin and lower operating costs. Financial highlightsIn brief See more details on performance in Accounts and performance Outlook 2021 6The big picture In briefNovozymes A/S (three-year rolling average 2018-2020) Electricity from renewable sources accounted for 69% of our total electricity use in 2020. At our site in Franklinton, USA, we sourced 100% of our electricity from renewable sources by purchasing renewable energy In 2020, we reached 3.98 billion people with our laundry solutions that replace chemicals and contribute to cleaner water. CO in global transport. The savings achieved are equivalent In 2020, 33% of our senior management (directors or higher) a diverse workforce will drive change and a thriving culture. We are within our 2022 target for lost time injuries per million working hours. We will continue to prioritize safety across the organization. 69% 3.98 billion 33% 1.5 Electricity from renewable sources Number of people reached Tons of CO emissions saved Women in senior management Lost time injuries/ million working hours 2020 realized 2022 targets Gain food by improving table 136,000 tons of food 500,000 tons of food Reduce absolute CO from operations Develop context-based water management programs 13% of sites 100% of sites Develop zero waste programs 20% of sites 100% of sites Manage biomass in circular systems 97% 100% Develop circular management plans for key packaging materials Roadmap 100% Enable learning 78 80 Nurture diversity 83 86 Pledge employee time to local outreach Program launched ~ 1% of time Excite employees 81 81 * The target does not include sites with activities See more details on performance in Accounts and performance For more information on our In brief Sustainability highlights 7The big picture In briefNovozymes A/S North America The severe eects of COVID-19 restrictions on US ethanol production was the primary cause of the 4% organic sales decline in North America for the full-year. Also, sales in Grain & Tech Processing declined during the year, whereas the other business areas grew. Latin America Sales in Latin America grew 6% organically in 2020, driven by increased enzymatic penetration in Household Care, ethanol capacity expansion in Bioenergy and market penetration of solutions for vegetable oil processing in Grain & Tech Processing. Performance in Agriculture, Animal Health & Nutrition was weak due to lower in-market demand and inventory adjustments in animal nutrition. Europe, the Middle East & Africa Full-year sales grew 3% organically compared to 2019. Growth in the region was primarily driven by a strong performance in Household Care but with contributions from most of the other business areas as well. Asia Pacic Organic sales declined 1% in 2020 primarily due to the COVID-19 related eects on the textile industry, which had a negative eect on Grain & Tech Processing. Sales in Agriculture, Animal Health & Nutrition also declined, whereas Bioenergy and Household Care both grew. Sales by geography Europe, Middle East & Africa Asia Pacic Latin America 9% of sales 6% Organic sales growth 39% of sales 3% Organic sales growth 20% of sales -1% Organic sales growth North America 32% of sales -4% Organic sales growth 8The big picture In briefNovozymes A/S Sales by business area grew in 2020. Household Care delivered solid organic sales growth. Sales in Food, which reduced ethanol and textile production. 35% 14% 20% 13% 18% of sales 2019: 33% of sales 2019: 15% of sales 2019: 19% of sales 2019: 13% of sales 2019: 20% Household Care Processing Human Health Bioenergy -1% 5% 1% -9% 1% * Organic sales growth 9The big picture In briefNovozymes A/S 2020 performance Household Care sales grew 5% organically and 3% in reported DKK in 2020. Sales performance was mainly driven by the rollout of the Freshness technology in Europe and broader enzymatic penetration of detergents, especially in emerging markets. Growth from the Freshness platform was additionally fueled by the introduction of a new liquid and pod format. Increased consumer focus on cleanliness and more at-home dish washing induced by the COVID-19 pandemic also contributed to sales growth. 2021 outlook Organic sales growth is expected to be driven by market penetration, focusing on emerging markets and a continued rollout of the Freshness technology, with a broad-market launch in the second half of the year. The broad-market launch is an important milestone, that is expected to become a signicant growth contributor in future years. The 2021 outlook for Household Care builds on improving the underlying performance on top of a better than expected performance in 2020. Product launches in 2020 Remify® Everis – our rst enzyme solution for cleaning surgical instruments and devices to help prevent healthcare associated infections Microvia™ - a bacterial bio- cleaning solution for hard surface cleaners Key trends Strong interest in freshness solutions for the removal of malodor and grime in clothing Renewed industry focus on sustainable detergents by replacing chemicals with biological alternatives Increased focus on household cleaning during COVID-19 pandemic Compaction of laundry detergents remains a strong trend, driven in part by increased sales through online retailers Growing consumer and professional interest in microbial and bio-based cleaning solutions Our solutions in Household Care are being used by more than half the world’s population to improve the overall cleaning of clothes and dishes while reducing the consumption of water, energy and the usage of traditional chemicals. Read more about our contributions to the SDGs Household Care Read more about our Household Care solutions at Novozymes.com SDG impact 35% of 2020 sales 10The big picture In briefNovozymes A/S 2020 performance Full-year sales in Food, Beverages & Human Health grew 1% both organically and in reported DKK. Sales benetted from moderate growth in the food-related business areas which was to a large extent oset by declining sales in beverages. The growth in food was mainly driven by increased market penetration and the success of tailored solutions in baking as well as higher demand for low-lactose solutions, such as Saphera ® , in dairy. COVID-19 restrictions resulted in more at-home and less out-of- home consumption of foods and beverages. This had a minor positive eect on the food business but resulted in declining beverage sales as especially the global brewing industry was adversely aected. The human health opportunity progressed well during the year and contributed positively to sales although from a small base. 2021 outlook 2021 organic sales growth is expected to be broad-based. Innovation and emerging market penetration, supported by increasing consumer dietary-health- awareness, are the main drivers of growth in the food business. Beverages is expected to gradually recover following a 2020 severely aected by COVID-19 implications. The PrecisionBiotics Group and Microbiome Labs acquisitions are both estimated to contribute to growth in reported DKK and to grow organically by solid double-digits. Product launches in 2020 Saphera ® Fiber - a new solution for dairy products to increase ber content while reducing sugar, providing added value to brands of yoghurt and functional milk Protana ® Prime - a new biological solution that brings out the natural umami avor from plant proteins and enable food manufacturers to produce tasty, label-friendly meat alternatives with less salt Gluzyme ® Fortis - Enhances dough handling and allows for salt reduction. The high product stability even at high storage temperatures makes it perfect for warm climates BioFresh ® 4+ - Clinically proven enzymatic solution that eliminates bad breath for up to four hours Optiva ® LS - Cuts costs on added sugar by >30% for every loaf of bread Key trends Strong consumer demand for new plant-based proteins drives industry innovation Focus on improved product quality and taste Consumers demand better and more convenient food with attention to natural, healthy and sustainable ingredients The healthcare industry is pivoting from symptoms treatment towards preventive measures with biology as a key part of the solution Our solutions in Food, Beverages & Human Health make food consumption more sustainable by reducing food waste and enabling the use of local raw materials. In addition, our solutions enable consumers to live healthier lives free from additives, unwanted compounds and by adding dietary benecial bacteria and enzymes for improved gut health. Read more about our contributions to the SDGs SDG impact Food, Beverages & Human Health Read more about our Food, Beverages & Human Health solutions at Novozymes.com 35% of 2020 sales 20% of 2020 sales 11The big picture In briefNovozymes A/S 2020 performance Bioenergy sales declined 9% organically and 13% in reported DKK in 2020. COVID-19 restrictions, severely disrupted US gasoline and ethanol production and Bioenergy sales. Monthly US ethanol still ended the year well below 2019 levels. penetration with yeast solutions, expansion of corn-based ethanol production capacity in Brazil and China contributed positively to full- year sales. 2021 outlook Organic sales growth in 2021 is expected to be driven by a gradual recovery in the US ethanol industry, following the severe disruption organic sales range roughly digit growth in the US ethanol production. The growth contribution expected to be positive. Product launches in 2020 Fortiva ® Hemi starch for ethanol conversion Key trends US ethanol industry is under strong pressure due to the due to trade barriers public agendas, leading to energy Follow-through on increased the transport sector. converting grains and straw into fuel ethanol, enabling a saving of 1,100– liters of gasoline. Read more about our contributions to the SDGs SDG impact 18% of 2020 sales Bioenergy Read more about our Bioenergy solutions at Novozymes.com 12The big picture In briefNovozymes A/S Our solutions in grain processing improve yields and save energy. Our solutions for technical industries help save chemicals, water, steam and electricity. For example, one of our solutions for textile production saves 350 kg of CO2 per ton of fabric produced. Read more about our contributions to the SDGs SDG impact 2020 performance Sales in Grain & Tech Processing declined 1% organically and 4% in reported DKK in 2020. Solid growth in grain did not fully compensate for a decline in tech. The broad-based growth in grain was driven by strong performance in grain milling and vegetable oil processing. COVID-19 severely aected the global textile industry and subsequently also resulted in a signicant downturn in sales of enzymes for textile production, which was the main reason for the decline in tech. 2021 outlook Organic sales growth is expected to be broad-based, with both grain and tech contributing positively. The grain business is expected to outgrow a roughly at underlying market, driven by innovation and increased local presence across key regions. Tech is expected to gradually recover aer the signicant disruption of the global textile industry in 2020. Product launches in 2020 Quara ® Boost - a solution for vegetable oil processors to increase their protability by retaining oil that is usually wasted in the gum fraction LpHera - next generation enzyme (alpha amylase) for starch processing that reduces the need for chemicals and drives higher fermentation yields Frontia ® GlutenEx - Better wheat separation increases gluten protein recovery by 2% in grain milling Key trends Focus on cost reductions, process optimization and yield enhancement including increased protein extraction from grain processing Increased demand for sugar replacements Water scarcity and pollution driving legislation and demand for solutions that reduce water consumption and improve water quality Increased public interest for sustainability in fashion leading to consumer pull and renewed interest for biological alternatives to the harsh chemicals currently being used Grain & Tech Processing Read more about our Grain & Tech Processing solutions at Novozymes.com 18% of 2020 sales 14% of 2020 sales 13The big picture In briefNovozymes A/S 2020 performance Full-year sales in Agriculture, grew 1% organically and declined 2% in reported DKK. Organic sales increased slightly as solid growth in nutrition. Growth in agriculture was driven by increased demand across solutions. the second quarter related to the former BioAg setup. The continued rollout of Balancius™ contributed to the sales nutrition, but it was not enough to compensate for lower in-market demand and inventory adjustments in animal nutrition. Novozymes did not recognize any deferred income as revenue in 2020 in 2019. As the BioAg Alliance was terminated in April of 2019, the remaining and related balance of the deferred income of DKK 287 million was recognized as other operating income in the second quarter of 2019. 2021 outlook Organic sales performance in 2021 will be driven by the continued expansion of the BioAg business across crops and regions, resulting in solid underlying double-digit organic sales growth when adjusted the second quarter of 2020. Nutrition includes some uncertainty as to stocking levels in the value chain, further accentuated by the pandemic. A strong innovative product portfolio and partnership setup coupled with signs of improving farmer economics make us carefully optimistic about the years to come. Product launches in 2020 Taegro ® - a microbial foliar fungicide launched by Syngenta in Europe and Latin America, enabling fruit and vegetable growers to protect against diseases such as powdery mildew and botrytis, while reducing the chemical load of crop protection programs World population growth and changing dietary habits and other food sources Stricter regulatory requirements for more sustainable farming practices and animal welfare with less use of antibiotics Continued focus on animal nutrition, soil health and Our bio-based solutions improve yields in agriculture by improving plants’ access to nutrients in the soil and by improving animals’ access to energy, proteins and minerals in the feed. This saves agricultural land for food and feed production and reduces emissions to the environment from manure in livestock production. Enzymes can save approximately 130 kg of CO emissions per 1,000 chickens by increasing the animals’ access to starch in the feed. Read more about our 13% of 2020 sales solutions at Novozymes.com 14The big picture In briefNovozymes A/S was returned to society. The remaining 10% was reinvested in Novozymes to future value generation for distribution among key stakeholders. Economic Contribution I n 2020 Novozymes returned 12% of the value generated to our capital providers. The main part of this was our dividend payment Novozymes bought back shares worth 1,500 million in 2020. At the end of 2020, the Novo Nordisk Foundation owned - through Novo Holdings A/S - 25.5% of the share in Novozymes (see The Novozymes Stock). The Novo Nordisk social and humanitarian purposes, and the Foundation contributes to communities in large scale through donations and impact investments, to which we indirectly contribute through our dividend payments. A responsible approach to tax Novozymes’ tax policy supports a positive tax contribution to society and governments. obligations in the countries in which it operates. We seek to obtain a competitive tax level in a responsible manner, and with full regard to national and international laws and regulations. Besides taxes, our economic contributions include duties, VAT, employee taxes, employee from local vendors and job creation. In 2020, Novozymes incurred corporate income taxes and other taxes and duties that In addition, Novozymes collected and withheld tax contributions on dividends and wages Novozymes’ total tax contribution therefore amounted to approximately DKK 2,850 million, compared with approximately DKK 3,000 million in 2019. Tax transparency Tax is a core part of corporate responsibility and governance at Novozymes. The Board of Directors approves the tax policy and is accountable for it. Novozymes is committed to being open and transparent about its tax policy to our stakeholders about our approach to tax and taxes paid. Novozymes supports and complies with the transparency requirements on taxes, including the OECD Country-by-Country tax initiative. The Country-by-Country reporting is submitted to the tax authorities and not made public. Novozymes is transparent about the total tax contribution of the Novozymes Group, divided into taxes paid by Novozymes and taxes collected on behalf of employees and shareholders. Further, Novozymes is transparent about the entities owned around the world and the activity of each subsidiary, see note 6.8. We also provide information on taxes paid in Denmark vs rest of the World, see Note 2.6. 43% Suppliers used to purchase goods and services from our suppliers 99% Sales 1% Financial & other income 25% Employees used for employee wages, pensions, etc. 12% Capital providers in dividends and financial costs for our capital providers 10% Community returned to the community by paying corporation tax, other taxes and duties 10% Reinvested in Novozymes reinvested in Novozymes for future value generation 14,094 million DKK DKK 15The big picture Five-year summaryNovozymes A/S 2016 2017 2018 2019 2020 Income statement Revenue 8,126 8,255 7,853 EBITDA 5,158 5,292 3,652 Financial items, net (157) (117) (235) (127) 3,050 3,120 3,227 3,155 2,826 Balance sheet Total assets 18,659 18,373 19,697 20,510 Shareholders’ equity 11,267 Invested capital 12,880 13,953 15,507 Net interest-bearing debt 990 2,535 3,871 3,679 3,196 Purchases of property, plant and equipment 1,076 1,593 1,332 862 Net investments excluding acquisitions 1,188 1,665 1,388 991 936 and securities 2,652 2,398 2,291 2,205 Business acquisitions, divestments (161) (3) (588) 2,395 2,287 2,635 2,831 Revenue growth, DKK % 1 3 (1) 0 (3) Revenue growth, organic % 2 (1) 0 % 13.2 13.2 13.0 13.7 13.8 Gross margin % 57.5 57.9 55.3 56.0 EBITDA margin % 35.1 35.2 35.8 36.8 35.1 Five-year summary 2016 2017 2018 2019 2020 EBIT margin % 27.9 27.9 28.3 28.1 26.1 % 19.5 18.0 17.0 19.7 Equity ratio % 62.9 61.3 58.1 56.2 NIBD/EBITDA x 0.2 0.3 0.5 0.8 0.8 Return on equity % 26.1 27.1 27.5 ROIC including goodwill % 25.1 25.6 21.1 18.9 Earnings per share (EPS), diluted DKK 10.06 11.03 11.01 10.02 Dividend per share (2020 proposed) DKK 5.00 5.25 5.25 as described in the Glossary. 2018 have not been restated. 2016 2017 2018 2019 2020 Total number of employees No. 6,125 6,185 Rate of employee turnover % 11.9 8.8 12.7 8.7 Frequency of occupational injuries with absence per million working hours 2.2 1.6 0.9 1.3 Women in senior management % 25 26 30 31 33 16The big picture Message from the Chair and the CEONovozymes A/S Unlocking Novozymes’ potential Novozymes delivered a resilient 2020 pandemic. We have reorganized the company intending to move even closer to our customers and solidify our position as the leading provider of biotech solutions. Having laid the believe Novozymes is in a strong position going into 2021. Message from the Chair and the CEO Jørgen Buhl Rasmussen Chair Ester Baiget CEO Message from the Chair and the CEO continues on the next page Message from the Chair and the CEO 17The big picture Message from the Chair and the CEONovozymes A/S T here has not been a year like 2020 in recent memory. And while we did not see the sales growth we wanted, we’re extremely proud of the way our employees have handled we made during the year are a testament to Novozymes' strong purpose, culture and well- business helped us to withstand at least Household Care delivered solid growth driven by the rollout of the Freshness platform, growth in emerging markets and COVID-19 induced changes to consumer behavior. In human health grew while beverages declined. At the same time, organic sales declined in and textile production. Our organic sales growth came in at 0% for the year, and the reported EBIT margin was a solid 26.1% despite currency headwinds. We also achieved very strong cash generation acquisitions. In 2020, the COVID-19 pandemic overshadowed many things, but at Novozymes we did not lose focus on creating the best possible foundation for a business that is here for the long term. Customer-focused and solutions-driven We reorganized Novozymes in September, refocusing the company around our customers and geographies. As we continue to build on our strategy, Better business with biology, this new setup leads to reduced complexity, increased accountability, faster decision- making and empowers our employees to a greater degree. We now organize around two new divisions, Industrial Biosolutions, headed by Anders Lund and Tina Sejersgård Fanø respectively to wide range of industries we serve. For years, Novozymes has been associated mainly with the production of enzymes, but the reality is that we provide a range of solutions within the biotech space. What our customers need may be an enzyme, a microbe, a yeast or even a digital solution. For example, in Bioenergy, we not only supply customers with enzymes or yeast for bioethanol production, we also have the digital tools to ensure optimal conditions for applying our solutions during our customer’s production process. We always take a holistic approach to market needs and provide our customers with the exact solution - or combination of solutions – that will help them succeed. As part of the reorganization, we aligned our regional commercial set-up and created new roles, especially in emerging markets, to get closer to where our customers are. We have also ensured a stronger regional voice in core decision-making processes. As a global company, it is vital that employees in all regions are able to accelerate decisions and Changes to the Executive Leadership Team composition We brought in new members to the Executive Leadership team. Claus Crone Fuglsang, Head and Graziela Chaluppe dos Santos Malucelli, both appointed executive vice president and joined the Executive Leadership Team this year, creating a stronger connection between the back and front ends of our company. We also announced the appointment of Amy Byrick as Executive Vice President of Strategy Enggaard Rasmussen as Executive Vice They will join Novozymes in April 2021, and we look forward to seeing them make their mark on these very important areas for Novozymes’ future. They will both succeed Thomas Videbæk, who will be leaving Novozymes in 2021. We are immensely grateful for everything Thomas has contributed to Novozymes during his many years with the company and we wish him well in the future. Embracing our responsibility At Novozymes, sustainability is at the root of our solutions. We use biotechnology to enable our customers to deliver more sustainable solutions to society. Every day, in over 30 industries and 130 countries, our enzymes and microbes help reduce energy, water, chemical and raw material consumption, help improve performance of customer products and give people healthier and more sustainable choices for living better lives. By laying the foundation for a sound business and future growth we are, by default, also ensuring a more sustainable future for the world. I see a healthy and well- positioned company with a strong technology platform and impressive innovation capabilities. I also see a my goal is to fully unleash the true potential of the company.” Ester Baiget CEO 18The big picture Message from the Chair and the CEONovozymes A/S In 2020, for example, we launched Taegro ® in Europe and Latin America in collaboration with Syngenta, providing farmers with a chemical-free fungicide that protects fruit and vegetables from disease, thereby reducing waste in the food production cycle. We also based products, thereby enabling producers to accommodate consumer demand for tasty, greener alternatives to meat-based foods. But our responsibility does not stop with delivering innovative, sustainable solutions to our customers. In our own production, we continue to do everything we can to reduce the negative impact of our production processes. We are proud to have ensured that, in 2020, 69% of our electricity globally came from renewable sources. We also partnered with WWF to assess and address water risks at our sites by setting up targets for the sustainable management of water in our production. These achievements are steps on our journey towards becoming even more sustainable, and we need to keep up a determined pace to honor our commitments to our customers, consumers and the world. Working together In 2020, the COVID-19 pandemic had a as a responsible corporate citizen, Novozymes stepped in where possible. We worked together with the Novo Nordisk Foundation to get the COVID-19 testing capacity up and running in Denmark. In other parts of the world, we made direct donations to NGOs, either monetary or in the form of essential equipment. Our primary focus during this uncertain year has been to keep our employees safe whether they were working in production, in labs or from home. Novozymes’ employees have shown so much care for each other, and we want to acknowledge what a fantastic job they have done. Through our Inspire program, our employees have also managed to reach out to their communities and help those in need, whether it be collecting funds for educate children virtually. The promotion of equal opportunities for all people has been on Novozymes’ agenda for many years, but we can still do more. There are always new aspects or new groups of people and backgrounds to consider when prioritizing diversity. It is important to consider diversity and inclusion in all aspects of business. That also applies in times of change, so to strengthen the collective capabilities of our dedicated employees, we set diversity criteria for everyone involved in the formation of new roles and teams during our re-organization in September. We also collaborated with America’s Job Exchange to reach a more diverse pool of candidates with our job ads, and we set up focus groups with employees to discuss where we are, where we want to be, and how we intend to get there. A truly diverse workforce will contribute to driving change and building a thriving culture. Thank You We want to thank all our stakeholders for what we were able to achieve together in a year unlike any we have ever seen before. In times it is your weaknesses or your strengths. This year has proven to us that Novozymes has strong partnerships with customers, a resilient portfolio and committed employees who are able to adapt and be innovative in challenging times. That’s a great foundation from which to grow. We expect that we will return to growth in 2021, supported by a more streamlined organization, stronger commercial presence, innovation, as well as a gradual recovery in those areas this, we have set a sales growth expectation of between 2% to 6% in 2021, provided we do not see another extended global lockdown. We look forward to working with our customers solutions to the challenges we all face. Ester Baiget CEO Jørgen Buhl Rasmussen Chair ”While the pandemic we are currently facing is an urgent must not lose sight of the long-term needs of the world. Novozymes’ purpose is now in 2020 we moved closer to unlocking the full potential of the company.” Jørgen Buhl Rasmussen Chair 19The big picture This is NovozymesNovozymes A/S New organization to strengthen customer focus and innovation process. This is Novozymes A t Novozymes, we produce enzymes and microorganisms for a diverse range of industries. In fact, our biological solutions can be found everywhere, from the products that clean your clothes, to the food you eat, and the ethanol that powers your car. So, it goes without saying that the industries consumer demands, including the need for more sustainable solutions, while others focus on how to save resources, optimize performance and improve sustainability in their production processes. In order to best meet customer needs and bring more customer-generated ideas into our innovation process, we created two new divisions in September 2020: Consumer Biosolutions. In Agriculture and Industrial Biosolutions, we focus on improved performance in agriculture and industrial processes, including higher yields, less waste and better health for plants and animals. We strive to translate our customers’ needs into solutions that improve their return on investment and increase of an improved understanding of our customers businesses. We meet customers’ needs through a combination of a world class product portfolio, digital solutions and a comprehensive service package. Consumer Biosolutions Consumer Biosolutions unites consumer-facing industries at the front of the value chain such as Household Care, Baking, Beverages, Food and Protein, with a focus on making consumer products better, healthier and higher performing, based on clear end-consumer needs. We have a strong understanding of our customers and the consumer groups they serve. This understanding enables us to guide our customers on a journey towards the perfect biological solution for them by activating a combination of our existing products, new technology, marketing support and know-how that can help them help grow their market share. Read more about our business model at Novozymes.com 20The big picture Novozymes A/S Sustainability has been integral to Novozymes for decades. We are proud that our solutions contribute business and right through our operations. W hen 193 UN member states created the SDGs in 2015, we immediately saw the SDGs as a common framework that could enable the world to work towards the sustainable future we all want. The SDGs have inspired our purpose, strategy and targets and, by the very nature of our business, we have goals since then. Novozymes produces a wide range of enzymes and microorganisms for many applications. Our solutions enable our customers to produce energy and chemicals as well as CO emissions. We live our purpose when we help our customers make their production processes and products better for the world, thereby contributing to the SDGs as well. Through our strategy, Better business with biology, we are committed to developing Working with See also “Novozymes and the global goals” for more details about how we solutions that can contribute to solving three global challenges: Climate, Water and Production and Consumption. We are also committed to operating our business responsibly and investing to minimize our negative environmental footprint. We are investing in new strategic opportunity and Specialty Alternative Proteins. These are opportunities that are inspired by the challenges embodied in the SDGs. They cater to a growing desire among consumers to live lives that are better for themselves and the environment. Here are some examples of how our business and solutions contributed to the SDGs in 2020. Supporting sustainable food production and resilient agricultural practices cleaner water Enabling a low carbon future Enabling our customers to produce more from less Partnering for impact 21The big picture Novozymes A/S Supporting sustainable food production and resilient agricultural practices Goal 2: Zero hunger Our solutions enable our agriculture customers to improve performance across the value chain from farm to table. Microbial solutions for agriculture help farmers increase the production, reduce environmental impacts and improve climate resilience. In 2020, we launched for fruit and vegetables which enables farmers to protect their yield while reducing the use of fossil-based chemical fertilizers. cleaner water Goal 6: Clean water and sanitation Goal 14: Life below water Our solutions help our customers reduce their consumption of water, reduce wastewater and reduce aquatic pollution by reducing the use of harsh aquatic environments. a bacterial bio-cleaning solution for hard surface cleaners which reduces the use of chemicals. Our launches in agriculture and food production also reduce the use of chemicals and the resulting nutrient pollution impact from our customers. We also partnered with WWF to help us develop programs for water management challenges and current and future conditions of water – at all our sites. Enabling a low carbon future Goal 7: Aordable and clean energy Goal 13: Climate action Novozymes is committed to help the world limit global warming through our actions across the value chain. We are committed to playing our part to limit the increase in global warming to 1.5°C. and to making Novozymes carbon-neutral by 2050. Many of our solutions reduce the carbon intensity of the processes they are applied in. Our solutions enable the development of low-carbon fuels for the transport sector, which of the global energy mix and related CO emissions. In 2020, our bioenergy solutions helped . We are also a member of the RE100, a global initiative working with companies that have committed to 100% renewable electricity. Enabling our customers to produce more from less Goal 12: Responsible production and consumption Our solutions enable our customers to produce more from less across many industries. In ® and Lphera ® which help food processors produce more oils and starch from their feedstocks, while reducing their use of energy and processing chemicals. We celebrated the 30th anniversary of our baking solution Novamyl ® in 2020. Over the years, it has saved 80 billion loaves of bread from being thrown out, which - in addition to the reduced food waste – has also saved an . Partnering for impact Goal 17: Partnership for the goals contributions to society are driven through collaborations with our customers, governments, suppliers and academia to learn, develop and deliver solutions to the most pressing needs of society. In the EU, Novozymes has worked strategically with the EU Green Deal through various industry organizations and supported the EU Commission's action plan to address climate change and environmental degradation. In 2020, we joined the ‘Climate Biotech’ partnership, one of many climate partnerships put forward by the Danish government. We also co-drive an open innovation platform, Hello Science, where we invite partners and innovators to solve the key Our business 02 Our business 23Our business StrategyNovozymes A/S Strategy We believe the future is shaped by the promise of day to make good on this business and the world. T he year 2020 was unlike what anyone could have predicted. However, while it was a year characterized by uncertainty, at Novozymes we remain certain of one thing: the world needs sustainable solutions and our ambition for a more sustainable future remains intact. answers for better lives in a growing world – Let’s rethink tomorrow” – serves as the guiding principle for the way we do business. By continually expanding the reach of our solutions, we can ensure we remain true to our purpose and to rethinking the world of tomorrow. Our strategy, Better business with biology, guides clear priorities as well as growth and areas. We strive to maximize value creation through the commercialization of our core business while investing in a more focused areas outside the core. In 2020, we prioritized enhancing a value-chain focused and customer- centric approach. This was the year of aligning more with the needs of customers, focusing on the most important innovations and advancing promising new business areas. Moving even closer to customers I n September, our organization was reshaped to better address customer needs across the full value chain. Our two divisions, Consumer Biosolutions, allow for a more integrated common characteristics and value drivers. Consumer Biosolutions caters to industries that supply sustainable solutions with clear Biosolutions cover industries that supply sustainable solutions focused on maximizing yields and optimizing processes for our customers. In Consumer Biosolutions, we announced a joint launch with Firmenich, the world's largest 24Our business StrategyNovozymes A/S amid the pandemic. We hosted livestreams on the Alibaba 1688 online platform which attracted thousands of unique visitors, and we will continue to strengthen the partnership between Novozymes and Alibaba. The launch of Microvia™, our bacterial bio-cleaning solution for hard surface cleaners, addresses for cleaning at home and at work during the pandemic and is a showcase for our capabilities in the relatively new space of probiotic cleaners. Several of our bioethanol customers saw the demand for ethanol rise as the need for hand sanitizers and disinfectants increased dramatically during the pandemic. We supported customers who donated ethanol for the production of hand sanitizers and products for the ethanol production. Although 2020 was a unique year, there have been learnings we take with us to stay agile, S ince 2019, we have been investing in what we call strategic opportunity areas – or SOAs. Finding biological solutions for improved human oral and gut health is one such SOA and has been a key focus in 2020. Maturing human health Accelerating the digital agenda privately-owned perfume and taste company, of a solution that brings unprecedented sugar- reduction in dairy products. The partnership is an example of how to bring new solutions to market faster while also tapping into a growing global consumer trend. We also entered into a research partnership with Givaudan, the to work on the research and development of Beverages and Household Care. we launched our Fiberex ® platform, a new platform for enzymes and yeast strains that Fiberex ® , customers are able to expand the boundaries of corn-based ethanol by extracting more corn oil from kernels and converting streams for ethanol producers. We also forged a stronger connection between the back and front ends of our company by having the heads of our Research Leadership Team. In the new divisional structure, we allocate more resources to our regions. Stronger geographical representation in our core decision processes will improve decision- making and bring more tailor-made solutions to our customers. T he COVID-19 pandemic has accelerated the need for digital communication in order to overcome lockdowns and travel restrictions, and this is a development we embrace. By enhancing and expanding the use of digital tools, we were able to improve collaboration within the organization, strengthen customer relationships and drive new leads without notable interruption. Our webinar platform – a tool to help our employees conduct webinars for existing and gaining leads that would previously have been hard to reach. The data and insights collected from webinars have been used to nurture new and existing customers along the customer decision journey. In Brewing, we strived to reach out to more, smaller breweries using digital tools. On the website Brewing with enzymes, we share the brewing process and potential customers can enter a live chat with experts. COVID-19 is also on the minds of many of our customers, and we reached out to the American laundry market with articles and webinars about cleaning and buying habits and trends shaped by the pandemic. In BioFresh ® the Novozymes OneHealth brand. Novozymes established the Novozymes OneHealth brand to market solutions within human health under one umbrella, with consumer insights at the heart of product development. Studies show that up to 50% of consumers have been concerned about bad breath at some point in their life. BioFresh ® of its kind on the market, it addresses a growing gap between consumers’ expectations available on the market. In June, Novozymes acquired PrecisionBiotics Group Limited. Based in Cork, Ireland, PrecisionBiotics Group holds a leading position within probiotics for human gut health and is well positioned with several clinically backed products already on the market. In January 2021, we acquired Microbiome Labs, based in Illinois, US. With Microbiome Labs’ comprehensive portfolio of proprietary probiotic and microbiome solutions, Novozymes gains a broader portfolio and a strong position in the North American probiotics market. The combined capabilities and our innovation portfolio serve as a promising foundation for future growth. Source: Novozymes OneHealth proprietary insights 2019 “In which situations are you most concerned about bad breath?” 25Our business Risk managementNovozymes A/S Risk management N ovozymes’ risk management process is designed to ensure that we identify, assess and mitigate key business risks in a timely manner. We do this to ensure risks do targets and deliver value to our stakeholders. In addition to monitoring and addressing our risks, we also monitor longer-term threats and trends. The Board of Directors has the overall responsibility for overseeing risks and for maintaining a robust risk management and internal control system. Risk management framework Novozymes operates an Enterprise Risk Management (ERM) process whereby the organization. We monitor most risks by means of biannual reviews, although some risks may materialize within a short period of time and require more frequent updates, the COVID-19 pandemic in 2020 being a case in point. responsible for identifying risks in collaboration with the organization and for ensuring that senior management promotes risk awareness, engagement and ownership across the organization. Risks are assessed based on a two-dimensional heat map rating system that estimates the potential impact of a given risk on that risk materializing. Each key risk is assigned a risk owner from the Executive Leadership Team and a Risk Responsible, usually a Vice President, responsible for mitigating all risks relevant to their respective areas. assessed by the Executive Leadership Team and the Board of Directors, who are also of the risk management and internal control processes throughout the year. In 2020, the Audit Committee, on behalf of the Board of Directors, made deep dives into selected risks and risk processes. Although the COVID-19 pandemic had a risk on ‘worldwide pandemic disease’ is not included as a key risk. In general, pandemic outbreaks are rare events and so have not rated highly on likelihood. The COVID-19 will continue to do so in 2021. The Executive Leadership Team will continue to monitor and address potential business risks arising from the COVID-19 situation, e.g., changed consumer behaviors, declining GDP growth, while our global and local crisis response teams safeguard our people and communities. Our four key risks for 2021 are unchanged from 2020: Competition and market consolidation; Volatility of agriculture- related business; Cyberattacks and Global political and economic instability. See note 5.1 for information on management Potential impact Probability Volatility of agriculture- related business Competition and market consolidation Cyberattacks Global political and economic instability Risk assessment heat map 26Our business Novozymes A/S Competition and market consolidation Novozymes is the market leader in the global enzyme market, which remains highly competitive. Our position in the market may be challenged by competition from both existing and potential new competitors, sometimes formed through consolidation. We continue to see a risk of competitors operating under less regulated market conditions. Potential impact We could face increased competition from other enzyme manufacturers players with technology platforms that are broader than ours. With increased digitalization, competition could also relate to how solutions are implemented in customer production. Although consolidation can make the market more stable, it could also increase a bargaining power. Mitigating actions In 2020, we preserved our market-leading position by introducing new innovations, strengthening our commercial relationships – even during global lockdowns – and re-shaping our organization to be even more customer-centric and value chain focused. As part of our organizational changes in September 2020, we increased regional empowerment to ensure further agility in markets where we see strong potential for our solutions. In 2021, we will continue to improve our go-to- market strategies, accelerate regional innovations to strengthen our position in certain markets, nurture partnerships and build on our strong relationships with key customers. Volatility of agriculture- related business conditions, commodity prices, political mandates for ethanol blends, etc. In addition, ongoing geopolitical uncertainty adds to the overall volatility of the industry. Potential impact In 2020, our bioenergy business in the US experienced a steep decline from a sharp drop in gasoline consumption due to COVID-19 restrictions. If global lockdowns, volatility of the agricultural- related markets, and poor global farm economics persist, it could challenge our ability to grow in the industry. Mitigating actions In 2020, we worked to leverage our industry- leading enzyme portfolio in combination with yeast technologies to strengthen our position in the bioethanol industry. In September 2020, we launched Fiberex ® , a platform solution low-carbon fuel. go-to-market approach in our agriculture still. However, we are seeing good traction with launch of the biocontrol product Taegro ® in Europe and South America, in partnership with Syngenta. In 2021, we remain focused on building strong relations with our customers in the agriculture-related business, while also increasing our internal commercial competences, including technical sales support. 27Our business Novozymes A/S Cyberattacks As for most major companies, the threat of cyberattacks to our business operations has grown Preserving business continuity and safeguarding sensitive business data and critical assets against this global threat is extremely important to Novozymes. Potential impact As a technology-driven company, we rely on the integrity and availability of computers and networks, and the sharing of data. Cybercrime and hacker attacks may negatively impact Novozymes’ productivity if systems are inaccessible for an extended period. Furthermore, fast digitalization continuously exposes Novozymes to cybersecurity threats. Business opportunities with customers could be adversely impacted if information about Novozymes’ unique technologies or production strains is stolen. We actively seek to learn from other companies’ experiences and, upon reviewing incidents of cyberattacks and technology developments, we have reassessed and adjusted the potential impact of this risk. Mitigating actions Our ability to identify, protect, detect and improved in recent years. In 2020, we gained more quantitative insights into potential security threats and vulnerabilities at Novozymes, enabling of security. Key focus areas have been to test and improve our IT emergency response, implement comprehensive and consistent information risk management and expand our detection capabilities and automation of cyber incident handling to mitigate the impact of cyberattacks. While cyberattacks can be seen to raise granted or pending patents remain a strong defense of our solutions. In 2021, we will continue to mitigate the risk of cyberattacks through an updated protection and data. As our operations become even more dependent on digitization and data analytics, we will increase the focus on operational technologies in our production facilities to ensure they stay operational at all times. Global political and economic instability to mitigate risk. Adding to this, the COVID-19 pandemic has a potential negative impact on global economic growth. Potential impact As a global company, polarization and trade protectionism can have an adverse impact on Novozymes’ ability to operate. Long-term decision- making is complicated, both for us and for our customers, if world leaders struggle to agree and to work together to strengthen global and regional institutions. We have yet to see the full global economic impact of the COVID-19 pandemic, but we have already felt the We could ultimately see price sensitivity grow among customers and consumers. There is also a risk of exchange partners and suppliers risking or facing insolvency. Mitigating actions In 2020, Novozymes closely monitored political and economic developments, such as the US–China trade negotiations. We emphasized e.g., handling bilateral relations and image/ perception. In addition, we focused on customs handling to ensure fast response and optimizing of customs paid. Pricing continues to be an area of focus in our commercial organization. We have strengthened which includes increased pricing transparency strengthened in 2021 with a cross divisional global focus on pricing. We remain engaged in global forums on globalization and shared commitments, and we continuously promote the importance of working together globally for a sustainable future. For 2021 and beyond, the global outlook remains uncertain, as the full impact of e.g. Brexit and COVID-19 remains unclear at the time of to ensure political stability and free trade. We will further seek to improve our data analysis and general monitoring for better predictability and speed of reaction. 28Our business Emerging risksNovozymes A/S E merging risks are mainly assessed through our enterprise risk management process and integrated sustainability trendspotting exercise. We engage with relevant stakeholders in a timely manner to develop strategies and ensure that we are prepared to take adequate action and respond to those risks. There is a renewed focus on the risk climate change poses to the world. Businesses face increased scrutiny on climate-related disclosures and actions, and this is an area of continued focus for Novozymes. Science has long proved that the impact of climate change is already being felt across the world, for etc. To tackle climate change, the world needs to limit the increase in global warming to 1.5°C. At Novozymes, we are committed to doing our part and to helping the world reach the goals business and we disclose details on this in our annual response to the CDP Climate Change questionnaire. Novozymes is also closely monitoring the ongoing dialogue on nature and biodiversity loss. Going forward, we will seek to understand the implications of this trend and understand the potential impact on our business. Additionally, the following continue to be our key emerging risks: Concerns regarding new and emerging technologies There is growing consumer demand for natural products, low-carbon solutions and bio- based innovation. Industrial biotechnology is a key enabling technology for delivering these solutions. At the same time, we also see tighter regulatory control in the biotechnology and chemical sectors. Over the coming years, innovation, including gene editing, and to face increasing government and NGO scrutiny, which can limit or slow the application of biotechnology. Emerging risks sustainability that have the potential to impact our business in the longterm. We see tighter regulatory control in the biotechnology and chemical sectors in the coming years 29Our business Emerging risksNovozymes A/S Novozymes’ research and business are based on bio-innovation and through these answers to some of the planet’s most pressing challenges. We are committed to sharing our knowledge about the potential of biology and industrial biotechnology with the public, as well as other stakeholders outside of Novozymes. Our position statement on industrial biotechnology describes how industrial biotechnology and gene technology can contribute to sustainable development. We acknowledge the concerns related to the use of gene editing, so we apply and promote safe and sustainable use of gene editing technology. We support a science-based regulatory framework for products involving gene editing and operate in compliance with legislation. Novozymes is committed to using to humans, animals and the environment. We are open about what we do, and we engage in dialogue on any concerns raised. As we explore the increased use of biotechnology, we will continue to engage in while also developing best practices together with stakeholders to mitigate the potential risks. Water-constrained future Global freshwater resources have come under pressure due to climate change, industrialization, urbanization and a growing population. According to the World Economic Forum, water crises have for many years been impact. Governments are responding with stricter regulations and the private sector is driving action through various initiatives such as the CEO Water Mandate, World Wide Fund for Nature (WWF) and Science Based Targets Network (SBTN). Novozymes recognizes local approach that is informed by science, context and collective action from a number of stakeholders. Water is material for Novozymes across our entire value chain. Many of the raw materials required in our operations are agriculture- based and thus water-intensive to produce. assessments to identify water-stressed sites and regions and included analysis of upcoming regulation related to water to inform about our water stewardship strategy. Besides the risk that water-related issues pose to our operations, increasing demand for clean water solutions also serves as an opportunity for our business as some of our solutions can contribute to solving several water-related is how we enable our customers to reduce water consumption and improve wastewater quality by replacing chemicals with biological solutions. The COVID-19 pandemic validated the responses. Though a pandemic risk was not top of mind going into 2020, we had considered the possibility of such an event. Our crisis response setup proved robust, with a global task force that outlines and coordinates Novozymes’ global instructions, and local task forces that ensure actions and guidelines aligned with local authorities’ and the local situation. This employees, business, and customers as well as support our communities, and to proactively prepare as the pandemic grew in intensity. Overall, our production has not been disrupted by the pandemic. Our production setup is structured to minimize the allowing us to honor our commitment to our customers. Our employees have been working in a safe setting, either to meet the personal and community challenges that have arisen due to COVID-19 restrictions and concerns. We have also emphasized Novozymes’ contribution and role as a good with the pandemic. Risk management during a pandemic “Global freshwater resources have come under pressure and a growing population.” 30Our business TargetsNovozymes A/S A t Novozymes, we measure progress towards our 2022 targets, which focus on the world, our business, our employees and our own operations. A sound business To shape a future of better business for us, our customers and the world, we need to have Targets to enable our customers to be more sustainable while at the same time reducing our own environmental footprint. mitigating climate change by enabling low- carbon fuels for the transport sector, as this sector accounts for about 25% of global energy-related CO emissions. Climate change is also considered in our own operations, as industrial production processes are energy-intensive. Therefore, we have set a absolute CO emissions in line with the most ambitious decarbonization pathway. water use by providing solutions that replace chemicals, particularly in laundry. Water is also a fundamental resource for our production processes. We are committed to pioneering a context-based approach to water management across all sites and have therefore set a target to have all our sites manage water in balance with local conditions. We know we will only be able to achieve the help of a healthy, diverse and engaged workforce, so we have also set 2022 employee targets. While most of our solutions enable improved solutions that let us enable sustainable Consumption target. We also aim to drive our business towards more circularity. Therefore, all our key materials and waste will be managed in circular systems by 2030. Climate Water Employees Consumption Our focus areas Go to Novozymes.com for a full list of our 2030 commitments a sound, balanced and growing business. This will allow us to continue investing in our leadership position within biotechnology and capture new opportunities in the industries we serve. By 2022, we aim to have an EBIT margin of 28% or higher, and ROIC including goodwill of growth per year. Looking ahead into 2021, we expect to grow sales by 2% to 6% organically. The guidance is wide and based on a gradual recovery from the pandemic impact in 2020 but would not cover a situation with another extended global lockdown. We also expect a solid reported EBIT margin of 25% to 26% in 2021 (2020: 26.1%), which includes a negative year-on-year impact to 1 percentage point each. ROIC, including goodwill, in 2021 is expected at around 19% (2020: 18.9%) which includes totaling roughly 2 percentage points. put us on the path to accomplish our 2030 commitments. Our commitments and targets Consumption and Employees and are guided by the Sustainable Development Goals (SDGs). Within each of these areas, we have set 2022 believe our solutions have on the world, as well as the care we know we must show to ensure we minimize the environmental impact of our production processes and our operations in general. In addition to the areas highlighted by the targets, we are committed to being a responsible corporate citizen and engage locally as well as globally for a better world with biology. On the following pages, we elaborate on targets. 31Our business TargetsNovozymes A/S T the world is rapidly moving towards an unsustainable rise in temperature. To halt this development, we must reduce CO emissions in the atmosphere. Novozymes’ commitment to provide the world with biological solutions that can help limit global warming to 1.5°C has been validated by the Science Based Targets Initiative. 2020 highlights • by enabling low carbon fuels in the transport sector in 2020. The COVID-19 pandemic caused a slowdown in the use of liquid transportation fuels. Hence, the demand for ethanol and the resulting reduction of CO emissions has declined this year. • In 2020, our Franklinton site in North Carolina, USA purchased Green-e ® (RECs) from two local solar farms. This purchase covers the full annual electricity consumption of the site and supported renewables on the local grid in North Carolina. With this, we are now sourcing 69% of our electricity globally from renewables. • At our Fuglebakken site in Denmark, a newly installed heat pump will be used to transfer excess heat from our operations to the district heating network, delivering heat to around 2,000 households. W ater is a scarce resource, and, in lack of access to clean water. Water is also a fundamental component of our production processes, so we must manage our water use responsibly. 2020 highlights • In 2020, we progressed towards our Reach target and managed to reach 3.98 billion people with our laundry solutions. This development was mainly driven by increased penetration of enzymatic detergents in Africa and Latin America. • We developed context-based water management plans for two sites in China. • In September, we partnered with WWF to assess water risks and develop contextual water targets and action plans for our sites globally. • Novozymes now endorses the UN Global Compact’s CEO Water Mandate which is the leading multi-stakeholder platform driving action on water stewardship. This focus today than we did in previous years. * The target does not include sites with activities not considered to have Climate Water World: Save 60 million tons of CO by enabling low-carbon fuels in the transport sector in 2022 Operations: By 2022, reduce absolute CO World: providing laundry solutions in 2022 that replace chemicals Operations: By 2022, develop context-based water management programs at 100% of our sites 32Our business TargetsNovozymes A/S T he world’s resources are under pressure, not least due to unsustainable consumption patterns and the large amounts of waste this consumption leads to. 2020 highlights • We estimate that 136,000 tons of food was gained in 2020 using our solutions. We will continue to deliver improved gains through our solutions but foresee that the prolonged impacts of COVID-19 will limit our contributions towards this target. • In 2020, we secured a new contract to increase the amount of biomass to be recovered by local farmers for land applications. • for three of our sites in Denmark. • We increased our capacity to process solid waste both in TEDA, China and in Kalundborg, Denmark, transforming enzyme waste into a form which can be used to generate biogas or be converted into fertilizer. * The target does not include sites with labs, etc. T o continue to grow as a company and contribute to a better world, Novozymes must enable its employees to thrive, grow and perform. This will ensure that we have the skills needed to deliver on our purpose. 2020 highlights • In our annual employee survey, we achieved a score of 78 on learning. Throughout the year we encouraged learning and development through a new online learning platform, through our leadership development programs and through webinars on learning culture. • On our diversity index, which is based on gender and nationality, we achieved a score of 83. • Occupational injuries were at 1.5, measured as a three-year rolling average of lost time injuries per million working hours. • Our Inspire target focuses on helping our communities respond to local challenges, by pledging 1% of our time to local outreach. In 2020, the COVID-19 pandemic was the biggest global crisis, and employees in all regions contributed time, resources and creativity to help communities deal with the pandemic. See the following page for more details. • We achieved a score of 81 on our Zymer Spirit index. time injuries per million working hours Employees World: Gain 500,000 tons of food to table in 2022 Operations: By 2022, achieve 100% circular management of our biomass, develop plans for circular management of 100% of key packaging materials and develop programs to reach zero waste by 2030 at 100% of our sites Enable learning: Achieve a score of 80 on learning in our annual employee survey by 2022 Nurture diversity: Achieve a score of 86 on our diversity index by 2022 Ensure safety and wellbeing: Inspire the world: Pledge 1% of our time to local outreach activities by 2022 Excite employees: Achieve a score of 81 on our Zymer Spirit index by 2022 33Our business TargetsNovozymes A/S A s societies all over the world in 2020, we focused challenge to raise money for daily-wage earners. Observing local rules and guidelines, our employees walked almost 2.3 million steps in a day, each step sparking a proportional contribution towards a donation totaling INR 1.7 million. The sum was donated to state funds and organizations in Mumbai and Bangalore engaged in disaster management and eradication of hunger. In Brazil, we collaborated with Contagious Smiles (Contagiando Sorrisos), a project that works with local artists to design face masks to bring hope and positivity to the local community. In North America, employees have developed for at-home schooling for families enduring school closures. In North Carolina, Novozymes partnered with North Carolina State University’s (BTEC) to produce hand sanitizer, helping to keep students and faculty at NC State University healthy. In Denmark, employees were encouraged to partake in a national COVID-19 antibody test, which could be done on Novozymes’ premises. We also donated lab coats to healthcare assistants as well as essential equipment to a new testing facility at SSI, the national serum institute. In China, we donated RMB 1 million via Red Cross to help build hospitals in Huoshenshan and Leishenshan, procure supplies, and provide support for frontline workers battling the pandemic. our communities - giving back when possible. This has now been formalized through our Inspire target of pledging 1% of our time to local outreach. 34Our business Outlook for 2021Novozymes A/S Novozymes expects to grow sales by 2% to 6% organically in 2021. The outlook is based on a gradual recovery from the pandemic impact in 2020. An incremental pickup or a further slowdown of the expected gradual recovery, Outlook for 2021 Sales outlook Household Care organic sales growth is expected to be driven by market penetration, focusing on emerging markets and a continued rollout of the Freshness technology, with a broad-market launch in the second half of the year. The broad- market launch is an important milestone, that is expected to become a signicant growth contributor in future years. The 2021 outlook for Household Care builds on improving the underlying performance on top of a better than expected performance in 2020. Food, Beverages & Human Health 2021 organic sales growth is expected to be broad-based. Innovation and emerging market penetration, supported by increasing consumer dietary-health-awareness, are the main drivers of growth in the food business. Beverages is expected to gradually recover following a 2020 severely aected by COVID-19 implications. The PrecisionBiotics Group and Microbiome Labs acquisitions are both estimated to contribute to growth in reported DKK and to grow organically by solid double-digits. Bioenergy organic sales growth in 2021 is expected to be driven by a gradual recovery in the US ethanol industry, following the severe disruption caused by the COVID-19 pandemic. The mid-point of the Bioenergy organic sales range roughly corresponds to mid-single digit growth in the US ethanol production. The growth contribution from regions outside of the US is expected to be positive. Grain & Tech Processing organic sales growth is expected to be broad- based, with both grain and tech contributing positively. The grain business is expected to outgrow a roughly at underlying market, driven by innovation and increased local presence across key regions. Tech is expected to gradually recover aer the signicant disruption of the global textile industry in 2020. Agriculture, Animal Health & Nutrition organic sales performance in 2021 will be driven by the continued expansion of the BioAg business across crops and regions, resulting in solid underlying double- digit organic sales growth when adjusted for the DKK ~60 million one- o in the second quarter of 2020. The outlook for Animal Health & Nutrition includes some uncertainty as to stocking levels in the value chain, further accentuated by the pandemic. A strong innovative product portfolio and partnership setup coupled with signs of improving farmer economics make us carefully optimistic about the years to come. especially in the areas most impacted by the pandemic in 2020, would imply a performance in the high- respectively low-end of the outlook range. However, the outlook range would not cover a situation with another extended global lockdown. Sales in reported DKK are expected to be ~1 percentage point less, net of currency and M&A-related eects, compared to the 2-6% organic sales growth outlook. Organic sales in the rst quarter is expected to decline by mid-single digits year-on-year following the relatively high comparator of the rst quarter of last year, especially in Household Care, Bioenergy and in Food, Beverages & Human Health. Food, Beverages & Human Health and Grain & Tech Processing are both expected to grow organically by mid-single-digits while Bioenergy is expected to grow by mid-to-high single digits in 2021. The growth outlook for Household Care is in the low-single-digits following the better than expected performance in 2020. Agriculture, Animal Health & Nutrition is expected at at to low-single-digit growth. 35Our business Outlook for 2021Novozymes A/S For 2021, Novozymes expects a solid reported EBIT margin of 25 - 26% (2020: 26.1%), which includes a negative year-on-year impact from currency and M&A-related eects of around 1 percentage point each. Hence, the implied underlying EBIT margin for 2021 of 27- 28% should be compared with the underlying 2020 EBIT margin of ~27%, and the underlying 2019 EBIT margin of ~26%. Supportive margin contributions from sales growth and productivity improvements are expected to be partly oset by slightly higher input costs and continued re-investment in the business. Return on invested capital (ROIC), including goodwill, is expected at around 19% (2020: 18.9%; underlying ~20%) and includes negative currency and M&A-related eects totaling roughly 2 percentage points. Free cash ow (FCF) before acquisitions is expected to be in the DKK 2.7-3.1 billion range (2020: DKK 3.4 billion), supported by higher sales and an improved operational cash ow. Cash ow is expected to be somewhat lower than in 2020 as higher net investments and the timing of working capital will lower the 2021 cash generation following a stronger than expected performance in 2020. For modeling purposes, the following is provided: The eective tax rate is expected at around 20% for 2021 (2020: 19.7%). 2021 outlook Sales growth, organic % 2 to 6 EBIT margin % 25 to 26 ROIC (including goodwill) % ~19 Free cash ow before acquisitions, DKKbn DKKbn 2.7 to 3.1 For modelling purposes: Eective tax rate % ~20 Net nancials, DKKm DKKm ~50 Net investments, DKKbn DKKbn 1.0 to 1.2 Stock buyback program DKKbn up to 1.5 * Assuming the exchange rates for the company's key currencies remain at the rates prevailing on February 1 for the rest of 2021. Prot outlook Net nancial costs are expected to be DKK ~50 million (2020: DKK 127 million), with roughly DKK 150 million relating to interest expenses, banking fees, leasing and nancial costs related to acquisition earn-outs. This is oset by a positive eect from USD/DKK currency hedging. Net investments in 2021 are expected to be DKK 1.0-1.2 billion (2020: DKK 0.9 billion). This reects maintenance as well as expansion and optimization investments. A stock buyback program of up to DKK 1.5 billion has been initiated for 2021. 36Our business Outlook for 2021Novozymes A/S Climate Water In 2021, we will continue to invest in developing solutions that support better lives in a growing world and progress on our 2022 targets on: 2022 targets Status World Save CO emissions by enabling low carbon fuels in the transport sector 60 million tons of CO On track Reach people by providing laundry solutions that replace chemicals On track 500,000 tons of food More to do Operations Reduce absolute CO On track Develop context-based water management programs 100% of sites 2 On track Develop zero waste programs 100% of sites 2 On track Manage biomass in circular systems 100% On track Develop circular management plans for key packaging materials 100% On track Employees Enable learning 3 80 On track Nurture diversity 86 On track Occupational injuries 5 On track Pledge employee time to local outreach 6 ~ 1% of time On track Excite employees 3 81 On track 1 Compared to 2018 baseline. 2 3 Measured by score to relevant questions in annual survey. Index calculated based on gender and national representation at various professional levels. 5 6 Sustainability outlook We will work to further expand the reach and deliver an even greater impact by replacing chemicals and enabling CO 2 reductions. We foresee that a prolonged impact of COVID-19 may limit our contributions towards our target to GAIN 500,000 tons of food by improving 2022, but we will continue to strive to deliver improved gains also in 2021. We will further develop our employee programs focused on learning, well-being and improving their engagement towards our sustainability commitment. Governance 03 Governance 38Governance Corporate governanceNovozymes A/S Corporate governance A proactive and transparent corporate governance structure promotes responsible sustainable business behavior and long-term value creation. B oard composition and responsibilities In accordance with Danish legislation, Novozymes has a two-tier management system comprising the Board of Directors and the Executive Leadership Team, with no individual being a member of both. The division of responsibilities between the Board of Directors and the Executive Leadership Team is clearly outlined and described in the Rules of Procedure for the Board of Directors and the Rules of Procedure for the Executive Leadership Team. Both of these rule sets are available at Novozymes.com responsibilities are to: • Ensure the right management and organizational structure • performance, and the Executive Leadership Team’s operational management of Novozymes • Supervise the overall management and strategic development of Novozymes Novozymes’ Articles of Association require the Board of Directors to have from four to eight members elected at the Annual Shareholders’ Meeting. The Board currently has seven members elected by the shareholders. Individuals are elected for terms of one year reaching the age of 70. Nominations are based on an evaluation of factors such as competencies, diversity, independence and performance. In accordance with Danish law, the Board also has three employee-elected members, who serve four-year terms. The Board of Directors is accountable to the company’s shareholders for the management of the company. The composition of the Board must therefore be such that the combined competencies of the Board enable it to inspire, guide and oversee Novozymes’ development, and diligently address and resolve the issues and challenges facing Novozymes at any time. The individual competencies of the members of the Board are shown in the presentation of At least 50% of the shareholder- elected board members must be Danish Recommendations on Corporate Governance At least 40% of the shareholder-elected board members must have substantial international experience from the management of large corporations or institutions headquartered outside Denmark At least 33% of the shareholder- elected board members must be female, and at least 33% of the shareholder-elected board members shall be male All three targets were met in 2020, and the composition of the Board of Directors meets the gender diversity requirements set out in Danish legislation. Further, reporting on gender diversity at other management levels can be found in Note 8.1 Labor practices governance data section. The competencies and targets are personal characteristics, skills and experience. Targets The composition of the Board must be such that the combined competencies of guide and oversee Novozymes’ address and resolve the issues and challenges facing Novozymes at any time. 39Governance Corporate governanceNovozymes A/S the Board of Directors. Novozymes' statutory report on diversity pursuant to section 107d of the Danish Financial Statements Act is available at https://investors.novozymes. com/investors/corporate-governance/ articles-of-association-and-reports-on- corporate-governance/default.aspx. Governance structure In accordance with the Articles of Association and the Rules of Procedure for the Board of Directors, the Board has a Chairmanship consisting of two members – the Chair and the Vice Chair – who are responsible for assisting the Board in matters concerning the Executive Leadership Team’s operational management and for reporting back to the Board. The Chairmanship is also responsible for planning and preparing the meetings of the Board. The Board of Directors has three committees: The Nomination and Remuneration Committee, the Audit Committee and the Innovation Committee. The Nomination and Remuneration Committee assists the Board in the nomination of candidates for the Board of Directors, Board committees and the Executive Management as well as in determining the remuneration of Board members, Board committee members and members of the Executive Management. The Audit Committee assists the Board in overseeing aspects relating to accounting, environmental, social and governance data. The Innovation Committee was created in 2020 and assists the Board with the review of Novozymes’ overall capabilities and strategic direction in matters of technology, science and innovation. The Innovation Committee held its inaugural meeting in 2020, where focus was on the corporate innovation pipeline and on the innovation strategy for the OneHealth Brand. Further information about the three Board committees can be found at Novozymes.com Charters and recommendations When laying down the management principles for Novozymes, the Board of Directors followed the Recommendations on Corporate Governance that form part of the disclosure requirements applicable to companies listed on Nasdaq Copenhagen. These recommendations are available at corporategovernance.dk. A detailed review of Novozymes’ position on each of the recommendations and a description of the internal control and risk management found in the statutory report on corporate governance prepared pursuant to section 107b of the Danish Financial Statements Act at https:// investors.novozymes.com/investors/ corporategovernance/articles-of-association- and-reports-on-corporate-governance/ default.aspx. These recommendations require companies to explain any deviations. Novozymes exception being: • Due to the limitations imposed by the Novo Nordisk Foundation’s Articles of Association and Novozymes’ ownership structure, the Board of Directors reserves the right in certain circumstances to reject takeover bids without consulting shareholders. (Recommendation 1.3.1) Furthermore, under the Danish Financial Statements Act (sections 99a and 99b), it is mandatory for large companies to report on corporate social responsibility and Novozymes is committed to the ten principles of the UN Global Compact (UNGC) and as a Audit Committee meetings Committee member Meetings attended Heine Dalsgaard Cees De Jong Agnete Raaschou-Nielsen 2 Jørgen Buhl Rasmussen Nomination and Remuneration Committee meetings Committee member Meetings attended Jørgen Buhl Rasmussen Cees De Jong Kasim Kutay 1 Agnete Raaschou-Nielsen 2 Kim Stratton 1. New member as of February 26, 2020. 2. Resigned from the Board on February 26, 2020 Extraordinary board meetings Board meetings Monthly reports Annual Shareholders' Meeting Strategy work Review of financial performance Evaluation of collaboration between the Board of Directors and the Executive Leadership Team Organizational performance review and succession planning Next year's budget January February March April May June July August Sep tember October November December 40Governance Corporate governanceNovozymes A/S continuing member of the UNGC we prepare a Communication on Progress (CoP). Our integrated annual report together with our Sustainability Report com/en/about-us/sustainability/transparency- serves as our CoP and meets the requirements of sections 99a and 99b of the Danish Financial Statements Act. Other Board-related information The Board of Directors held 10 meetings in 2020, with an overall attendance rate of 99%. Since March, all meetings have been held virtually due to restrictions brought on by the COVID-19 pandemic. This has worked well, but the Board looks forward to meeting up again when circumstances allow it. Any amendments to the Articles of Association require that shareholders representing at least two-thirds of the total number of votes in the company are represented at a shareholders’ meeting, and that at least two-thirds of the votes, as well as two-thirds of the voting capital represented at the meeting, are cast in favor of the proposal to amend the Articles of Association. The Annual Shareholders’ Meeting has authorized the Board of Directors to allow the company to acquire treasury stock on an ongoing basis, provided the nominal value of the company’s total holding of treasury stock does not exceed 10% of its share capital at any time, cf. section 198 of the Danish Companies Act. The purchase price must not deviate by more than 10% from the price quoted on Nasdaq Copenhagen A/S at the date of acquisition. This authorization applies until April 1, 2021. In addition, the Board of Directors is authorized to reduce the share capital. Each year, one of the responsibilities of the Board of Directors is to assess whether the 1. From industrial biotechnology or related industries (but not pharma). 2. From industrial biotechnology, pharma or related industries. 3. Within or outside industrial biotechnology. Nationality - board members elected by shareholders Danish 29% Swedish 14% British 29% Australian 14% Dutch 14% Tenure - board members elected by shareholders 1-4 years 71% +4 years 29% Gender - board members elected by the shareholders Men 71% Women 29% Board governance structure (elected by the shareholders) Independent boardmembers 57% Non-independent boardmembers 43% Primary experience – board members elected by shareholders (number of board members) General board and/or executive management¹ R&D executive management² B2B and industry marketing and sales Governance and risk management³ Stakeholder relations management (beyond customers and investors)³ Financial management and investor relations³ Alliance strategy and acquisitions³ Total value and supply chain management³ Innovation and pipeline management³ Emerging market strategy³ Digitalization strategy and/or management³ 4 5 6 4 2 5 7 6 4 6 0 41Governance Corporate governanceNovozymes A/S In 2020, the annual evaluation of the Board was conducted by the Chair interviewing each Board member and member of the Executive Leadership Team. The evaluation revealed an overall good performance by the Board of Directors and good collaboration between the Board of Directors and the Executive Leadership Team. The recommendations from the interviews included keeping a high focus on sales growth, innovation pipeline and strategy implementation. capital and share structure of Novozymes is optimal. The Board of Directors believes that the share structure with A and B common stock continues to be the best way in 2020 to safeguard Novozymes’ long-term strategy and shareholders and other stakeholders. Regarding capital structure, Novozymes will continue to favor a rather conservative balance bearing debt of around 1x EBITDA. Thus the capital structure is in line with the target. Novozymes is party to a number of partnership contracts that can be terminated by the other ownership or control of Novozymes. A few of these contracts contain provisions that restrict technology in such situations. Board member Audit Committee Nomination and Remuneration Committee Innovation Committee Nationality Board meetings attended Board tenure Election period Share trading in 2020 Number of shares end of 2020 Jørgen Buhl Rasmussen (Chair) 1,2 Danish 2011 1 year 3,500 5,500 Agnete Raaschou-Nielsen Danish 2011 1 year - - Cees de Jong 1,2,5 Dutch 2020 1 year 2,000 2,000 Heine Dalsgaard 1,5 Danish 2020 1 year 3,000 3,000 Sharon James 1, 2, 5 British 2020 1 year - - Kasim Kutay 1 British 2017 1 year - - Kim Stratton 1,2 Australian 2017 1 year - - Mathias Uhlén 1 Swedish 2007 1 year - 650 Lena Bech Holskov 3 Danish 2013 - 1,100 Anders Hentze Knudsen 3 Danish 2013 (356) - Lars Bo Køppler 3 Danish 2010 - 360 42Governance Novozymes A/S Jørgen Buhl Rasmussen Born 1955. Chair of the Board since 2017. Adjunct Professor at Copenhagen Business School. Member of the Audit Committee and chair of the Nomination and Remuneration Committee. Member of the Board since 2011. Elected for a term of one year. Board positions Chair: F. Uhrenholt Holding A/S and advisory Board of Blazar Capital Member Special competencies Extensive international business and within sales, marketing, branding, accounting expertise across many businesses, sectors and geographies. Cees de Jong Born 1961. Vice Chair of the Board since 2020. Member of the Audit Committee and the Nomination and Remuneration Committee. Member of the Board since 2020. Elected for a term of one year. Board positions Chair: Mediq B.V., ForFarmers N.V. and A-Mansia Biotech S.A. Special competencies Extensive international business and management experience from a range of industries, such as the food, food ingredient and industrial biotech industries, as well as Born 1971. CFO, Carlsberg A/S. Chair of the Audit Committee. Member of the Board since 2020. Elected for a term of one year. Board positions Chair: Carlsberg Ejendomme Holding A/S and Carlsberg Global Business Services A/S Member: Carlsberg Breweries A/S, Carlsberg Byen Komplementar ApS and Carlsberg Byen P/S Special competencies experience and accounting expertise, as well as extensive experience in driving strategic results for international businesses. This board member is not regarded as independent in the sense Recommendations on Corporate Governance that apply to Danish listed companies Sharon James Born 1961. Former Senior Vice Consumer Health. Chair of the Innovation Committee. Member of the Board since 2020. Elected for a term of one year. Board positions Member: Mölnlycke Health Care Special competencies Broad international experience in commercial research and innovation pipeline management in the consumer goods and consumer product sector. Born 1965. CEO, Novo Holdings A/S. Member of the Nomination and Remuneration Committee. Member of the Board since 2017. Elected for a term of one year. Board positions Member: Novo Nordisk A/S and Evotec SE Special competencies Broad experience within biotechnology, strategy, business development, mergers and accounting expertise. This board member is not regarded as independent in the sense Recommendations on Corporate Governance that apply to Danish listed companies Meeting and three employee-elected members. The Board represents many years of international management 43Governance Novozymes A/S Born 1962. Member of the Nomination and Remuneration Committee and the Innovation Committee. Member of the Board since 2017. Elected for a term of one year Board positions Member: Vifor Pharma AG Special competencies Broad global commercial experience, including emerging markets, innovation pipeline management Mathias Uhlén Institute of Technology (Sweden), Karolinska Institutet (Sweden) and the Technical University of Denmark (DTU). Member of the Innovation Committee. Member of the Board since 2007. Elected for a term of one year. Board positions Chair: Antibodypedia AB, ScandiBio Therapeutics AB and ScandiEdge Therapeutics Vice Chair: Member: Atlas Antibodies AB Special Competencies Broad experience in research and biotechnology. His research interests cover antibody engineering, proteomics and precision medicine. This board member is not regarded as independent in the sense Recommendations on Corporate Governance that apply to Danish listed companies Lene Bech Holskov Born 1967. Employee representative. Safety Adviser. Member of the Board since 2013. Elected for a term of four years. In accordance with Danish law, the Board of Directors includes three employee-elected members, who serve four-year terms. Born 1959. Employee representative. Senior Operator. Employee representative. Member of the Board since 2013. Elected for a term of four years. In accordance with Danish law, the Board of Directors includes three employee-elected members, who serve four-year terms. Born 1962. Employee representative. Technician. Member of the Board since 2010. Elected for a term of four years. In accordance with Danish law, the Board of Directors includes three employee-elected members, who serve four-year terms. 44Governance Executive Leadership TeamNovozymes A/S Executive Leadership Team Ester Baiget Born 1971. President and CEO Education Holds a chemical engineering degree and an MBA from the Rovira i Virgili University, Spain. Special competencies Novozymes’ CEO since 2020. Ester Baiget is an experienced international leader with a strong business and technical background. With more than 25 years of international experience as a technical and commercial business leader, Ester has driven transformational change and enhanced businesses. Her leadership develops a culture of inclusion, engagement and of delivering Tina Sejersgård Fanø Born 1969. Executive Vice President, Education Holds an M.Sc. in Chemical Engineering from the Technical University of Denmark (DTU) and a diploma degree in Innovation, Strategy and SIMI (CBS executive, Copenhagen, Denmark). Board positions Chair: Danish Innovation Fund Member: Special competencies Tina Sejersgård Fanø is responsible for application research, technical service, sales Biosolutions. developing and managing global partnerships and has been instrumental in negotiating several major business deals for Novozymes over the years. She has gained strong biotech sales. Claus Crone Fuglsang Born 1968. CSO and Executive Vice President, Education Holds an M.Sc. in Biochemistry from the University of Copenhagen and an MBA from Heriot-Watt University, Edinburgh Business School, Scotland. Board positions Member: Microbiogen Ltd. Australia, Biobased Industries Consortium, EuropaBio, Erhvervspræsidiet for TekTanken and the Danish governmental panel on Bio-economy Special competencies Claus Crone Fuglsang is responsible for Claus has strong leadership experience leading partnership innovation programs. He business experience from working in the US for several years. Lars Green Born 1967. CFO and Executive Vice President Education Holds an M.Sc. in Business Administration from Aarhus University, Denmark. Board positions Member: Board of trustees of the LEO Foundation and LEO Holding A/S Special competencies legal functions. Lars has in-depth knowledge of the Novo Group’s business, international experience from managing global biotechnology and biopharma companies, and leverages his across the company. Our seven-member Executive Leadership Team comprises broad and expertise and in-depth knowledge of Novozymes’ business. 45Governance Executive Leadership TeamNovozymes A/S Anders Lund Born 1973. Executive Vice President, Consumer Biosolutions Education Holds an M.Sc. in Economics from Aarhus University, Denmark. Special competencies Anders Lund is responsible for application research, technical service, sales and marketing in Consumer Biosolutions. Anders has a strong commercial and strategic background and has played a Novozymes’ strategies over the last two decades. He also has extensive experience in building customer relationships in several of Novozymes’ business areas. Graziela Chaluppe dos Santos Malucelli Born 1973. COO and Executive Vice President, Education Holds an M.Sc. in Food Engineering from Special competencies Graziela Chaluppe dos Santos Malucelli is globally responsible for production, supply chain and quality. Graziela has extensive experience from international leadership roles in Brazil, Denmark and China and has been heading up Supply Operations since 2016. She has been driving continuous productivity at all levels in the production and customer focus in supply operations. Thomas Videbæk Born 1960. Executive Vice President, Strategy Education Holds a Ph.D. and an M.Sc. in Chemical Engineering from the Technical University of Denmark (DTU), as well as a B.Com. in International Business from Copenhagen Business School. Board positions Member: The Danish Chamber of Commerce Special competencies Thomas Videbæk is responsible for our people agenda, sustainability leadership and brand, as well as business building, strategy and digital transformation. Thomas has extensive leadership experience and knowledge spanning both the commercial and operational side of the business. He has been responsible for developing a broad range of key functions within the organization, with a keen interest in new business development. In April 2021, Amy Byrick and Morten Enggaard Rasmussen will join Novozymes as Executive Vice President of Strategy & Business Transformation and Executive Vice President of People, Sustainability & Brand respectively. Executive Leadership Team 46Governance Summary of the Remuneration report Novozymes A/S Summary of the Remuneration report and established a new long-term incentive program for the management and all other employees. Novozymes delivered ratio of the short-term cash-based incentive program for the Executive Management. I n 2020, Novozymes adopted a new policy for the remuneration of Novozymes’ Board of Directors and Executive Management. In designing the policy, we collected external benchmarks and sought independent advice from external experts on executive remuneration in Denmark and Europe and consulted a representative group of shareholders for input. We believe the new remuneration policy ensures alignment with the best practice expectations of investors, creates a strong link between performance and remuneration and provides clarity and simplicity of the remuneration arrangements. General remuneration policy Novozymes’ remuneration policy for managers and other employees is designed to both encourage strong individual performance and support Novozymes’ overall value creation. Remuneration consists of a base salary, pension contributions, a cash bonus and stock- based incentive programs. These components are linked to employees' individual performance and to the level of achievement of targets. The remuneration policy aims to provide managers and other employees with a regularly against external benchmarks. 47Governance Summary of the Remuneration report Novozymes A/S New remuneration report In 2020, we have prepared the Novozymes Remuneration Report 2020, which is disclosed as a separate report. The content of the report has been prepared so as to meet the requirements of section 139b of the Danish Companies Act and holds information and details on the remuneration of the Board of Directors and the Executive Management. The Novozymes Remuneration Report 2020 will be presented for an advisory vote at the Annual General Meeting to be held in 2021. The following is a summary of the Novozymes Remuneration Report 2020. The remuneration of the Board of Directors based. This ensures that the Board of Directors safeguards the company’s long-term interests without taking into consideration what this may mean in terms of the value of incentive- based remuneration. The Board of Directors’ fee is set at a market-conformant level that of the role, given the complexity of the Novozymes Group, the scope of the work, and the number of Board meetings held. Overview of Committee members Audit Committee Nomination and Remuneration Commitee Innovation Committee Chair Heine Dalsgaard Jørgen Buhl Rasmussen Sharon James Members Jørgen Buhl Rasmussen Cees de Jong Cees de Jong Kasim Kutay Kim Stratton Kim Stratton Mathias Uhlén the same as it has been since 2015. The Chair receives a fee that is three times the base fee and the Vice Chair a fee that is two times the base fee. For committee work on the Audit Committee and the Nomination and Remuneration Committee, the committee chair and other committee members receive a further base fee and half a base fee respectively. However, the Chair and the Vice Chair of the Board do not receive such additional fee if appointed to the Nomination and Remuneration Committee. In August 2020, the Board of Directors decided to establish an Innovation Committee. The Board of Directors determined that the Chair of the Innovation Committee would receive a further base fee (for 2020 pro rata adjusted to the relevant part of the year) and that members of the Innovation Committee would each receive half a base fee (similarly adjusted). During 2019, Patricia Malarkey and Lars Green resigned from the Board, and at the Annual General Meeting held in February 2020, Agnete Raaschou-Nielsen, resigned from the Board as well. Cees de Jong, Sharon James and Heine Dalsgaard were elected as new board members. Cees de Jong was appointed Vice Chair. The number of board members was thereby reestablished at seven member elected at the Annual General Meeting which, together with the newly established Innovation Committee, resulted in an increase of the total fees paid to the Board of Directors from DKK 7.0 million in 2019 to DKK 8.2 million in 2020. The individual board members' fees and their shareholdings can be found in the Novozymes Remuneration Report 2020. Remuneration of the Executive Management As per 31 December 2020, the Executive Management of Novozymes A/S consisted of: • • • Thomas Videbæk, Executive Vice President Ester Baiget replaced Peder Holk Nielsen as CEO on February 1, 2020. Thomas Videbæk will transition his roles as Executive Vice President of People, Transformation during the second quarter of We are immensely grateful for Thomas’ contributions to Novozymes during his many years with the company. The total remuneration to members of Executive Management comprises: • A base salary plus pension, company car • A short-term incentive program (cash bonus) - STIP • A long-term incentive program (stock-based program) - LTIP In 2020, the members of the Executive Management received a 2.3% increase in their base salary. The increase was only given to executives with an employment start date prior to January 1, 2020. Ester Baiget and Lars Green will in addition to their ordinary remuneration receive compensation for lost incentives from their previous employers. The compensation is 48Governance Summary of the Remuneration report Novozymes A/S subject to certain conditions. Over the period 2020-2023, Ester Baiget may receive up to a total of DKK 9.6 million in extraordinary sign- on compensation for lost incentives from her was paid out in 2020. Over the period 2020- 2023, Lars Green may receive up to a total compensation for lost incentives from his previous employer, of which DKK 0.7 million was paid out in 2020. Thomas Videbæk will leave Novozymes during 2021. His severance package, totaling DKK 35 million, was fully expensed in 2020. The severance package consists of salary, pension and bonuses during the notice period (12 months) as well as termination compensation part of a stock-based program in 2020 and 2021. Severance pay of DKK 9 million was paid out in 2020, while the remaining DKK 26 million will be paid out in 2021. Furthermore, the remaining value of awarded stock and stock options, DKK 2 million, has been expensed. 31, 2020. The severance payment of DKK 32 million was made in 2020. contribution pension scheme of 11% of their base salary. In 2019, the pension scheme was between 25% and 27.6% of the base salary and short-term cash-based incentive. The targets for the short-term incentive program (STIP) are set by the Board of Directors in connection with the review of the business plan for the year. Good performance will result in target payout (65%) while maximum payout is only achieved for delivering an extraordinary performance. Maximum payout equals 9.5 months’ salary. In 2020 the targets for the STIP were split on 15% weight) and targets for the individual Novozymes resulted in the EBIT target being The payout related to these targets was 65% and 100%, respectively. The level of achievement of individual performance targets and thus the size of remuneration payment to the individual executive is determined by the Board of Directors based on recommendations from the Nomination and Remuneration Committee. Based on its assessment, the Board determined that the pay-out based on individual targets would be 90% for Ester Baiget, 80% for Lars Green and 67% for Thomas Videbæk. The total payout ratio on the STIP 2020 is shown on the next page. Remuneration paid to individual members of the Executive Management Fixed Variable Salary Contribution based pension Other Cash bonus Incentive 2020 Total Remuneration Compensation for lost incentives Severance Package 2019 Total Remuneration Severance Package Ester Baiget (from 1/2-2020) 6.9 0.8 0.2 7.1 19.4 - - - Lars Green 5.9 0.6 0.2 3.6 5.9 16.2 0.7 - 5.5 - Thomas Videbæk 6.8 0.7 0.2 3.9 - 11.6 - 35.2 - Former executives Peder Holk Nielsen (to 31/1-2020) 0.7 0.2 - - - 0.9 - - 19.1 31.9 Prisca Havranec-Kosicek (to 30/8-2019) - - - - - - - - 16.2 20.3 2.3 0.6 11.9 13.0 48.1 35.2 42.7 on IFRS recognition principles where the long-term incentive programs are expensed over the year of grant and the subsequent years of vesting. The long-term incentive included in the above table is the cost of the 2020 program measured at market value at the grant date. * Peder Holk Nielsen and Prisca Havranec-Kosicek’s severance packages were fully expensed in 2019. The severance packages consisted of salary, pension and bonuses during the notice period as well as termination compensation and compensation for not being part of the stock-based incentive program in 2020. 49Governance Summary of the Remuneration report Novozymes A/S The targets for the long-term incentive program covering the period 2017-2019 were partly met, and 61% of the program was awarded in January 2020. As a result, 38,857 shares associated with the program were released to the Executive Management in January 2020. Going forward, the Board of Directors will issue annual long-term incentive program (LTIP) grants with overlapping three-year performance periods. This allows the Board of Directors to re-assess targets for each annual demanding and aligned with the strategy. In 2020, the new LTIP for the Executive Management began covering the performance period 2020-2022. The LTIP consists of 50% shares and 50% share options. Relative to the previous long-term incentive program (2017- of LTIP), a lower but still prominent weight on LTIP), and an explicit weight on sustainability (weight of 20% of LTIP). The targets are aligned with the updated strategy and the measures of business success for the period 2020-2022. The stock was allocated in March 2020 and will be released in the beginning of 2023 in accordance with the level of target achievement, while the stock option program is a three-year incentive program with annual allocations. In 2020, 135,280 stock options were granted to the Executive Management. The allocations for 2020-2023 will be adjusted in the beginning of 2023 in relation to the level of target achievement. The annual LTIP cannot exceed 19 months’ base salary. Further, the program includes a maximum-value clause allowing the Board of Directors to choose to limit the total allocation of stock options and stock if the intrinsic value exceeds twice the annual conditional grant. The members of the Executive Management have contracts of employment containing Danish listed companies, including the periods of notice that both parties are required to give and noncompetition clauses. If an executive by the company without any misconduct on addition to the notice period, the executive of 12 months’ base salary and pension contributions. However, as Thomas Videbæk was appointed before 2016 he was entitled to termination compensation of two years' base salary and pension contributions. Remuneration of senior leadership The remuneration of Novozymes’ senior leadership (195 vice presidents and directors) is consistent with the general remuneration policy. Incentive programs for vice presidents and directors have been established for the 2020- 2022 period. The programs follow the same mechanisms as the program for the Executive Management. Further information on the incentive programs for these employee groups can be found in Note 6.2 to the consolidated overview of outstanding stock options. Short-term incentive program – Target achivement Weight Target Ester Baiget Lars Green Thomas Videbæk EBIT % of maximum / (index compared to target performance) 65 (100) 65 (100) 65 (100) 15% 100 100 100 Individual targets 90 (138) 80 (123) 67 (103) Total, % of max 80% (123) 76% (117) 71% (109) Total, DKK million 4.4 3.6 3.9 50Governance The Novozymes stockNovozymes A/S The Novozymes stock The total shareholder return in 2020 was 9% with the share price increasing S tock performance The Novozymes total market cap reached share price (NZYM B) increased by 7% from the closing price of DKK 326 at the end of 2019 to The total shareholder return was 9% including the share price appreciation and dividend payments made during the year. Over the past annual return (compounded) to shareholders of 6%. The average daily trading volume of the stock was 557,617 shares or DKK 198 million, making it the 13th most actively traded company on Nasdaq Copenhagen, down one spot from 12th place in 2019. Share and ownership structure Novozymes’ common stock consists of carry 20 votes each and B shares carry 2 votes each. Both A and B shares have a nominal value of DKK 2 per share. At the end of 2020, Novozymes had more than shares were held outside Denmark mainly investors, including Novo Holdings A/S, held approximately 60% of the B shares. Novo Holdings A/S held 25.5% of the total common of the votes. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation, an independent Danish foundation whose objectives are to provide a stable base for the companies within the Novo Group and to A stock B stock Total Share capital (DKK) 570,000,000 Number of shares 285,000,000 Held by Novo Holdings A/S (%) 100.0% 8.2% 25.5% Number of votes Voting rights (%) 69.9% 30.1% 100.0% Held by Novo Holdings A/S (%) 69.9% 2.5% Share price development 2020 Novozymes OMX C25 CAP Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 75 85 95 105 115 125 135 51Governance The Novozymes stockNovozymes A/S Stock buyback programs from February 10 to August 21, as part of the DKK 1.5 billion stock buyback program for 2020. The repurchased shares were added to treasury shares, or 2.0% of the total stock capital, at the end of 2020. A new stock buyback program worth up to a total of DKK 1.5 billion or a maximum of 15 million shares will be initiated in 2021. The Board of Directors proposes that the Annual Shareholders’ Meeting approve a dividend of DKK 5.25 per share for a total corresponds to a payout ratio of 51.9% which proposal is in line with the previously stated plan to increase the payout ratio to ~50%. If approved, the 2020 dividend will be disbursed on March 16, 2021, with March 11, 2021, as the last trading day cum dividend for 2020. The Novo Nordisk Foundation is an independent Danish foundation with corporate interests. The objective of the Novo Nordisk Foundation is twofold: to provide a stable base for the commercial and research activities conducted by the companies within the Novo Group and to Investor Relations Novozymes’ Investor Relations maintains an ongoing dialogue with sell-side equity analysts as well as major institutional and retail shareholders. Ownership structure A list of the current analysts covering Novozymes can be found at Investors.novozymes.com. Novo Nordisk Holding A/S Novo Nordisk Foundation Institutional and private investors 74.5% of total shares 27.6% of votes 25.5% of total shares 72.4% of votes Total shareholder return including for dividends % 0 10 20 30 40 50 (30) (20) (10) 2016 2017 2018 2019 2020 -25% 47% -16% 14% 9% Ownership by geography (B shares) Denmark 24% UK & Ireland 30% Rest of Europe 20% North America 22% Rest of World 4% Accounts and performane 04 Accounts and performance 52Novozymes A/S Accounts and performanceAccounts and performance Sales Total sales in 2020 were DKK 14,012 million, at organically and a decline of 3% in DKK compared with 2019. “Resilient 2020 performance despite the COVID-19 pandemic.” The overall eect from COVID-19 on Novozymes’ sales performance was negative, however, with a dampened eect as a result of diversied end-market exposure. Solutions for Household Care benetted from an increased demand for cleaning solutions, whereas solutions for Bioenergy and Textile production declined due to the COVID-19 pandemic induced drop in gasoline consumption, especially in the US, and lower demand and production of textiles. Salesandsalesgrowth DKK million % • Sales • Sales growth, organic (%) Gross prot and margin Gross prot decreased by 1% to DKK 7,853 million from DKK 7,954 million in 2019, driven by lower sales. The gross margin was 56.0%, up from 55.3% in 2019. The increase was mainly due to lower input costs, improved production eciency and a one-o settlement related to the former BioAg setup that was partly oset by adverse currency developments. Operating costs Operating costs decreased by 4% to DKK 4,257 million. Operating costs as a percentage of sales were 30%. • Sales and distribution costs decreased by 3%, accounting for 11.3% of sales • Research anddevelopment costs decreased by 1%, accounting for 13.8% of sales • Administrative costs decreased by 12%, accounting for 5.3% of sales Operating costs were negatively impacted by reorganization costs, acquisition-related transaction costs and an impairment loss, and positively impacted by savings on employee and travel costs. Other operating income Other operating income was DKK 56 million, compared with DKK 520 million in 2019. Other operating income in 2020 was positively impacted by DKK 42 million from the contingent income related to the divestment of the pharma-related royalty. 2019 was impacted by the termination of The BioAg Alliance and the divestment of the pharma-related royalty. EBITDA EBITDAdecreased by 7% to DKK 4,918 million, down from DKK 5,292 millionin 2019. Depreciation, amortization and impairment losses were DKK 1,266 million in 2020, up 1% from DKK 1,253 million in 2019. EBIT and EBIT margin EBIT decreased by 10% to DKK 3,652 million, down from DKK 4,039 million in 2019. The EBIT margin ended at 26.1%, down from 28.1% in 2019. Excluding the one-o settlement related to the former BioAG setup, reorganization costs, acquisition-related transaction costs and an impairment loss, the underlying EBIT margin was ~27% in 2020, which was ~1 percentage point higher than the underlying EBIT margin of ~26% in 2019. EBITandEBITmargin DKK million % • EBIT • EBITmargin (%) Net nance Net nancial costs were DKK 127 million in 2020, compared with DKK 235 million in 2019. In 2020, Novozymes realized a DKK 35 million currency hedging/revaluation net loss, compared with a net loss of DKK 205 million in 2019. Tax The eective tax rate was 19.7%, up from 17.0% in 2019. In 2019, Novozymes had a positive impact from reduced uncertain tax positions related to bilateral advance pricing agreements. Earnings per share (diluted) Earnings per share (diluted) were DKK 10.02, compared with DKK 11.01 in 2019. 53Novozymes A/S Sales and earnings Accounts and performanceSales and earnings 54Novozymes A/S Consolidated statements of income Income statement DKK million Note 2020 2019 Revenue 2.1, 2.2 14,012 14,374 Cost of goods sold 2.3, 3.1, 3.2, 4.1 (6,159) (6,420) Gross prot 7,853 7,954 Sales and distribution costs 2.3, 3.1, 3.2 (1,581) (1,631) Research and development costs 2.3, 2.4, 3.1, 3.2 (1,937) (1,966) Administrative costs 2.3, 3.1, 3.2 (739) (838) Other operating income, net 2.5 56 520 Operating prot / EBIT 3,652 4,039 Share of result in associates (4) (5) Financial income 5.2 26 112 Financial costs 5.2 (153) (347) Prot before tax 3,521 3,799 Tax 2.6 (695) (644) Net prot 2,826 3,155 Attributable to Shareholders in Novozymes A/S 2,825 3,154 Non-controlling interests 1 1 2,826 3,155 Proposed dividend per share DKK 5.25 DKK 5.25 Earnings per share 2.7 DKK 10.07 DKK 11.06 Earnings per share, diluted 2.7 DKK 10.02 DKK 11.01 Statement of comprehensive income DKK million Note 2020 2019 Net prot 2,826 3,155 Items that may subsequently be reclassied to the income statement: Currency translation adjustments Subsidiaries and non-controlling interests (786) 143 Tax on currency translation adjustments 1 (1) Currency translation adjustments (785) 142 Cash ow hedges Fair value adjustments 154 (107) Tax on fair value adjustments (34) 24 Cash ow hedges reclassied to nancial costs 5.2 (15) 164 Tax on reclassied fair value adjustments 3 (36) Cash ow hedges 108 45 Other comprehensive income (677) 187 Comprehensive income 2,149 3,342 Attributable to Shareholders in Novozymes A/S 2,149 3,342 Non-controlling interests - - 2,149 3,342 Accounts and performanceSales and earnings Cash ow from operating activities The cash ow from operating activities was DKK 4,355 million, up from DKK 3,196 million in 2019, an increase of DKK 1,159 million. The improvement in operating cash ow was mainly due to higher cash conversion from better earnings quality, a settlement related to the former BioAg setup and positive changes and timing eects in working capital. The change in net working capital was caused by lower receivables and lower inventories, partly oset by lower other liabilities. Net investments Net investments excluding acquisitions were DKK 936 million, down from DKK 991 million in 2019. Net investments in property, plant and equipment amounted to DKK 790 million, compared with DKK 856 million in 2019. Free cash ow before acquisitions and divestments The free cash ow before acquisitions and divestments amounted to DKK 3,419 million, compared with DKK 2,205 million in 2019. The increase of 55% was mainly due to higher cash ows from operating activities. Free cash ow The free cash ow was DKK 2,831 million in 2020, compared with DKK 2,635 million in 2019. Free cash ow was negatively impacted by the acquisition of PrecisionBiotics Group. Financing activities The cash ow from nancing activities was negative at DKK 2,314 million, compared with a negative cash ow of DKK 2,644 million in 2019. The negative cash ow from nancing activities was mainly due to the 2020 stock buyback program (DKK 1,500 million) and dividend payments (DKK 1,483 million). Cash position Cash and cash equivalents at December 31, 2020, amounted to DKK 1,181 million, up from DKK 711 million at December 31, 2019. Undrawn committed credit facilities were DKK 5,344 million at December 31, 2020. 55Novozymes A/S Cash ow Cash ow from operating activities DKK million * The comparatives for 2016-2018 have not been restated for IFRS 16 Free cash ow before acquisitions DKK million Netinvestments DKK million % • Netinvestments • Netinvestments(%of sales) Accounts and performanceCash flow 56Novozymes A/S Consolidated statement of cash ows DKK million Note 2020 2019 Net prot 2,826 3,155 Reversal of non-cash items 6.6 2,220 1,321 Income tax paid 2.6 (951) (1,116) Interest received 10 64 Interest paid (62) (88) Cash ow before change in working capital 4,043 3,336 Change in working capital (Increase)/decrease in receivables 395 (238) (Increase)/decrease in inventories 181 218 Increase/(decrease) in payables, deferred income and contract liabilities (265) (124) Currency translation adjustments 1 4 Cash ow from operating activities 4,355 3,196 Investments Purchase of intangible assets 6.6 (146) (135) Purchase of property, plant and equipment 6.6 (794) (862) Sale of property, plant and equipment 4 6 Business acquisitions, divestments and purchase of nancial assets 6.6 (588) 430 Cash ow from investing activities (1,524) (561) Free cash ow 2,831 2,635 DKK million Note 2020 2019 Financing Borrowings 999 1,915 Repayment of borrowings (434) (1,028) Overdra faclilities, net (293) (59) Repayment of lease liabilities (111) (108) Shareholders: Purchase of treasury stock (1,500) (2,000) Sale of treasury stock 508 75 Dividend paid (1,483) (1,439) Cash ow from nancing activities (2,314) (2,644) Net cash ow 517 (9) Unrealized gain/(loss) on currencies and nancial assets included in cash and cash equivalents (47) (3) Net change in cash and cash equivalents 470 (12) Cash and cash equivalents at January 1 711 723 Cash and cash equivalents at December 31 1,181 711 Accounts and performanceCash flow Total assets Total assets increased from DKK 20,437 million at December 31, 2019, to DKK 20,510 million at December 31, 2020. The increase was mainly driven by net investments and the acquisition of PrecisionBiotics Group, partly oset by depreciations and amortizations, changes in currency and a decrease in net working capital. Invested capital Invested capital decreased from DKK 15,507 million in 2019 to DKK 15,094 million in 2020. This was mainly a result of a decrease in net woking capital. ROIC Return on invested capital (ROIC), including goodwill, was 18.9%, down 2.2 percentage points from 21.1% in 2019. The decreasewas mainly driven by lower net prot and higher average invested capital. Net working capital Novozymes’ net working capital decreased to DKK 2,901 million, down from DKK 3,478 million in 2019, due to lower trade receivables, lower inventories, partly oset by lower other payables. Net interest-bearing debt Novozymes had net interest-bearing debt of DKK 3,871 million at December 31, 2020, compared with DKK 4,049 million at December 31, 2019. Net interest-bearing debt was impacted by cash outows from dividend payments of DKK 1,483 million, stock buybacks of DKK 1,500 million and the acquisition of PrecisionBiotics Group, which was more than oset by cash inows from operating activities. Net interest-bearing debt-to-EBITDA Net interest-bearing debt-to-EBITDA was 0.8x at December 31, 2020, on par with December 31, 2019. 57Novozymes A/S Balance sheet and nancial position Netinterest-bearing debt(NIBD)andnetinterest- bearing debt- to- EBITDA DKK million NIBD/EBITDA • NIBD • NIBD/EBITDA Net working capital % of sales • Inventories • Payables and deferred income • Receivables • Networkingcapital ROICandaverage investedcapital DKK million % • Average invested capital • ROIC (%) Accounts and performanceBalance sheet and financial position 58Novozymes A/S Consolidated balance sheet Assets DKK million Note Dec. 31, 2020 Dec. 31, 2019 Intangible assets 3.1 2,554 1,926 Land and buildings 3.2 3,853 4,056 Plant and machinery 3.2 4,136 4,501 Other equipment 3.2 941 993 Assets under construction and prepayments 3.2 682 662 Deferred tax assets 2.6 1,339 1,161 Other nancial assets 21 22 Investments in associates 33 37 Other receivables 4.3 40 29 Non-current assets 13,599 13,387 Inventories 4.1 2,361 2,613 Trade receivables 4.2 2,549 2,864 Contract assets 4.2 6 243 Tax receivables 2.6 460 273 Other receivables 4.3 212 269 Other nancial assets 119 15 Cash and cash equivalents 1,181 711 6,888 6,988 Assets held for sale 4.5 23 62 Current assets 6,911 7,050 Assets 20,510 20,437 Liabilities and shareholders’ equity DKK million Note Dec. 31, 2020 Dec. 31, 2019 Common stock 5.5 570 582 Currency translation adjustments (727) 57 Cash ow hedges 127 19 Retained earnings 11,263 10,810 Equity attributable to shareholders in Novozymes A/S 11,233 11,468 Non-controlling interests 11 12 Shareholders’ equity 11,244 11,480 Deferred tax liabilities 2.6 1,204 879 Provisions 3.4 115 115 Contingent consideration 3.5 146 - Lease liabilities 386 453 Other nancial liabilities 5.3 3,254 2,775 Non-current liabilities 5,105 4,222 Lease liabilities 136 163 Provisions 3.4 90 128 Other nancial liabilities 5.3 1,309 1,411 Trade payables 1,100 1,117 Contract liabilities 67 74 Tax payables 2.6 336 431 Other liabilities 4.4 1,123 1,411 Current liabilities 4,161 4,735 Liabilities 9,266 8,957 Liabilities and shareholders’ equity 20,510 20,437 Accounts and performanceBalance sheet and financial position Shareholders’ equity At December 31, 2020, shareholders’ equity was DKK 11,244 million, down from DKK 11,480 million at December 31, 2019, as dividend payments and net stock buybacks more than oset comprehensive income in 2020. Equity ratio Shareholders’ equity accounted for 55% of the balance sheet total at December 31, 2020, down from 56% at December 31, 2019. Return on equity Return on equity was 24.9%, down 2.6 percentage points from 27.5% in 2019. The decrease was a result of lower net prot. Treasury stock At December 31, 2020, the holding of treasury stock was 5.7 million B shares, equivalent to 2.0% of the common stock. Dividend The Board of Directors proposes that the Annual Shareholders’ Meeting approve a dividend of DKK 5.25 per share for the 2020 nancial year, same as in 2019. This will result in an expected total dividend payment of approximately DKK 1,466 million, corresponding to a payout ratio of 51.9%. Stock buyback program In 2020, Novozymes bought back 4.3 million B shares at an aggregate transaction value of DKK 1,500 million under the stock buyback program initiated on February 10, 2020, and completed on August 24, 2020. The shares acquired under the program will be used to reduce the common stock and to meet obligations arising from employee stock-based incentive programs. 59Novozymes A/S Equity and shareholder return Movementsinequity 2020 DKK million Payoutratioanddividendgrowth % • Payout ratio • Dividendgrowth Shareholder return DKK million * Dividend for 2020 is the proposed dividend. • Dividend • Stock buyback program Accounts and performanceEquity and shareholder return 60Novozymes A/S Attributable to shareholders in Novozymes A/S DKK million Common stock Currency translation adjustments Cash ow hedges Retained earnings Total Non-controlling interests Total equity Shareholders’ equity at January 1, 2020 582 57 19 10,810 11,468 12 11,480 Net protfor the year 2,825 2,825 1 2,826 Other comprehensive income for the year (784) 108 (676) (1) (677) Total comprehensive income for the year (784) 108 2,825 2,149 - 2,149 Purchase of treasury stock (1,500) (1,500) (1,500) Sale of treasury stock 508 508 508 Write-down of common stock (12) 12 - - Dividend (1,482) (1,482) (1) (1,483) Stock-based payment 53 53 53 Tax related to equity items 37 37 37 Changes in shareholders’ equity (12) (784) 108 453 (235) (1) (236) Shareholders’ equity at December 31, 2020 B/S 570 (727) 127 11,263 11,233 11 11,244 Shareholders’ equity at January 1, 2019 594 (86) (26) 10,943 11,425 13 11,438 Net protfor the year 3,154 3,154 1 3,155 Other comprehensive income for the year 143 45 188 (1) 187 Total comprehensive income for the year 143 45 3,154 3,342 - 3,342 Purchase of treasury stock (2,000) (2,000) (2,000) Sale of treasury stock 75 75 75 Write-down of common stock (12) 12 - - Dividend (1,438) (1,438) (1) (1,439) Stock-based payment 45 45 45 Tax related to equity items 19 19 19 Changes in shareholders’ equity (12) 143 45 (133) 43 (1) 42 Shareholders’ equity at December 31, 2019 B/S 582 57 19 10,810 11,468 12 11,480 The proposed dividend of approximately DKK 1,466 million for 2020 is included in Retained earnings. Consolidated statement of shareholders’ equity Accounts and performanceEquity and shareholder return Operational ecoeciency Novozymes strives to decouple environmental impact from business growth, and we dene targets and metrics that measure and drive our sustainability performance. Climate change Novozymes’ total CO 2 emissions were 268,000 tons in 2020, a decrease from 365,000 tons in 2019. Energy In 2020, Novozymes’ energy consumption was 4,475,000 GJ, a decrease of 2% compared with 2019. Renewable sources accounted for 43% of the energy consumption in 2020, up from 30% in 2019. The main contributor is renewable electricity which has gone up from 49% in 2019 to 69% in 2020, as our production site in Franklinton, USA have started procuring renewable electricity in 2020. In addition, all electricity in Denmark, Brazil and Tianjin, China come from renewable sources e.g. oshore windfarms and hydropower. Energy by source 2020 (2019) • Electricity – conventional 18% (29%) • Electricity – renewable 39% (29%) • Steam 22% (21%) • Fuels – conventional 15% (15%) • Heat – conventional 2% (4%) • Fuel and heat – renewable 4% (2%) Water In 2020, Novozymes’ water consumption increased by 2% from 7,845,000 m 3 in 2019 to 7,998,000 m 3 . The increase is partly driven by extra cleaning at all sites due to product mix changes and a higher cleaning requirement related to food safety. The total volume of wastewater generated in 2020 increased by 5%. Waste In 2020, 97% of our biomass volume was handled in a circular set-up (recycled), on par with 2019. For solid waste, the rate of recycling across our global production sites decreased to 48%, compared with 52% in 2019. Environmental compliance The number of breaches of regulatory limits recorded worldwide increased to 20 in 2020 from 17 in 2019. Most of these breaches were related to wastewater treatment. Novozymes is addressing these incidents. In addition, we received ten neighbor complaints in 2020, compared with seven in 2019, mostly related to air pollution and waste management. 61Novozymes A/S Environmental performance Five -yearoperational emissions(CO 2 -eqv.) 1,000 tons • Scope 2 • Scope 3 • Scope 1 Accounts and performanceEnvironmental performance 62Novozymes A/S Note 2020 2019 Climate change Greenhouse gas emissions 7.1 1,000 tons CO 2 -eqv. 268 365 Energy Energy consumption 7.2 1,000 GJ 4,475 4,574 Renewable energy 7.2 % 43 30 Water Water consumption 7.3 1,000 m 3 7,998 7,845 Volume of wastewater 7.3 1,000 m 3 6,471 6,147 Waste Solid waste 7.4 1,000 tons 15 13 Recycling rate for solid and hazardous waste 7.4 % 48 52 Biomass volume 7.4 1,000 tons 465 513 Biomass handled in circular set-up (recycled) 7.4 % 97 97 Environmental compliance, etc. Breaches of regulatory limits 7.5 No. 20 17 Neighbor complaints 7.5 No. 10 7 References to notes without data Bioethics& biodiversity 7.6 n.a. n.a. Product stewardship 7.7 n.a. n.a. Consolidated environmental data Accounts and performanceEnvironmental performance Labor practices & human rights At December 31, 2020, the total number of employees were 6,185, compared with 6,125 in 2019. Number of employees In 2020, the employee absence rate was 1.9% on par with 2019. Novozymes promotes equal opportunities and strengthens diversity in the global workplace. At December 31, 2020, 33% of senior management (directors and higher) were women, up from 31% in 2019. Occupational health & safety The frequency of occupational injuries increased to 1.3 per million working hours in 2020, compared with 0.9 per million working hours in 2019. The three-year rolling average is within the 2022 target of a frequency of 1.5 per million working or less. Frequency of accidents (per million working hours) Innovation Novozymes is committed to delivering bioinnovation and launched 12 new products in 2020. In 2020, Novozymes had 963 active patent families, which comprise the number of inventions that have active patent applications or active patents. The number of active patent families has increased from 951 in 2019. Business ethics In 2020, Novozymes reinforced our commitment to business integrity. During the year 99% of Novozymes’ employees in scope completed business integrity training, on par with 2019. As in 2019, there were no breaches of competition law in 2020. Community engagement In 2020, Novozymes contributed to local communities responding to local challenges. In China, for example, we donated RMB 1 million to Red Cross to build hospitals and in Latin America we provided 100 PCs with internet access to unprivileged students. Customer engagement Novozymes conducts an annual customer satisfaction survey and tracks progress on its Net Promoter Score (NPS), which is assessed on a scale from -100 to +100. In 2020, we received an NPS of +50, which conrms our solid relationships with our customers. The COVID-19 pandemic does not seem to have aected customers perceptions of Novozymes in 2020 compared to previous years. 63Novozymes A/S Social and governance performance Accounts and performanceSocial and governance performance 64Novozymes A/S Note 2020 2019 Labor practices & human rights Employees, total 2.3 No. 6,185 6,125 Women 2.3 % 37.8 37.6 Rate of absence 8.1 % 1.9 1.9 Women in senior management 8.1 % 33 31 Occupational health & safety Fatalities No. - - Frequency of occupational injuries with absence 8.2 Per million working hours 1.3 0.9 Frequency of occupational diseases 8.2 Per million working hours 0.4 0.1 Three-year rolling average of occupational injuries with absence 8.2 Per million working hours 1.5 1.7 Innovation New products 2.4 No. 12 9 Active patent families 2.4 No. 963 951 Business ethics Completion of business integrity training for employees in scope 8.3 % 99 99 Breaches of competition law 8.3 No. - - Customer engagement Customer satisfaction, Net Promoter Score (NPS) 8.4 No. 50 54 Reference to notes without data Community engagement 8.5 n.a. n.a. Responsible sourcing 8.6 n.a. n.a. Consolidated social and governance data Accounts and performanceSocial and governance performance 1 Basis of reporting 1.1 Signicantchangesandevents 1.2 Basisofreporting 2 Net operating prot aer tax 2.1 Segment 2.2 Revenue 2.3 Employees 2.4 Researchanddevelopmentcosts 2.5 Otheroperatingincome,net 2.6 Tax 2.7 Earningspershare 3 Invested capital 3.1 Intangibleassetsandimpairment testofgoodwill 3.2 Property,plantandequipment 3.3 Leases 3.4 Provisions 3.5 Businessacquisitions 4 Net working capital 4.1 Inventories 4.2 Tradereceivablesandcontractassets 4.3 Otherreceivables 4.4 Otherliabilities 4.5 Assetsheldforsale 5 Capital structure and nancing 5.1 Financialriskfactors andrisk management 5.2 FinancialincomeandFinancialcosts 5.3 Othernancialliabilities 5.4 Derivatives–hedgeaccounting 5.5 Commonstockandtreasurystock 5.6 Financialassetsand liabilitiesbycategory 6 Other nancial notes 6.1 Managementremuneration 6.2 Stock-basedpayment 6.3 Commitmentsandcontingencies 6.4 Relatedpartytransactions 6.5 Feestostatutoryauditors 6.6 Cashow 6.7 Eventsaerthereportingdate 6.8 Groupcompanies 7 Environmental data 7.1 Climatechange 7.2 Energy 7.3 Water 7.4 Waste 7.5 Environmentalcompliance 7.6 Bioethics&biodiversity 7.7 Productstewardship 8 Social and governance data 8.1 Laborpractices&humanrights 8.2 Occupationalhealth&safety 8.3 Businessethics 8.4 Customerengagement 8.5 Communityengagement 8.6 Responsiblesourcing Notes 65Novozymes A/S Accounts and performanceNotes 66Novozymes A/S Building the Novozymes OneHealth brand On June 25, 2020, Novozymes acquired PrecisionBiotics Group Limited to advance Novozymes’ activities in the area of biological solutions for oral and gut health. PrecisionBiotics Group holds a leading position within probiotics for human gut health and is well positioned with several clinically-backed products already on the market. On January 7, 2021, Novozymes acquired Microbiome Labs adding a broad range of proprietary microbiome solutions to its human health activities and securing an attractive entry point into the North American probiotics market. Both acquisitions are related to human health and are key steps in building the OneHealth brand, which also comprises the 2016 acquisition of Organobalance GmbH along with research and development activities based on Novozymes’ existing technology. Reference is made to Note 3.5 for a description of the two acquisitions and their impact on the consolidated nancial statements. New organization On February 1, 2020, Ester Baiget was appointed new President and CEO of Novozymes. On September 1, 2020, Novozymes announced a new organizational structure directing the organization to a more value-chain focused and customer-centric approach to support and deliver on our Better business with biology strategy. This new structure allows for a stronger dierentiation between sustainable solutions with clear consumer benets, and sustainable solutions focusing on maximizing yields and optimizing processes for our customers. As a part of the new organizational structure, changes were made to the Executive Leadership Team; see Note 6.1. The sales reporting has been updated to reect the new organization; see Note 2.2. COVID-19 pandemic Novozymes delivered a resilient 2020 performance despite the COVID-19 pandemic. See the section on sales and earnings for more details on COVID-19 impacts on 2020 sales. Novozymes has only made use of unavoidable nancial governmental relief packages, resulting in an negligible impact. All major postponed tax payments etc. were settled before the end of the year. The COVID-19 pandemic was not a triggering event for impairments in 2020. The COVID-19 pandemic was a challenge for occupational health and safety in 2020. Task force teams were in place, focused on keeping employees safe and labs and production running; see Note 8.2 for more details. Throughout the year, Novozymes maintained close communications with customers on measures taken within the organization to prevent impact on production and delivery. Novozymes also focused on exercising its responsibility as a corporate citizen to support authorities in mitigating the eects of the pandemic. Reference is made to Note 8.4 and Note 8.5. 1.1 Signicant changes and events Basis of reporting Notes Accounts and performance Accounts and performanceNotes 67Novozymes A/S This section provides an overview of Novozymes’ principal accounting policies, the critical accounting estimates and judgments applied, a denition of materiality as well as the impact of new or amended IFRS standards and interpretations. The symbols I/S , B/S and ESG show which amounts in the notes can be found in the income statement, the balance sheet, and in environmental data and social and governance data respectively. The accounting policies described below apply to the consolidated nancial statements as a whole. Accounting policies and critical accounting estimates and judgments are described in the notes to which they relate to enhance understanding. The descriptions of accounting policies in the notes form part of the overall description of accounting policies. ACCOUNTING POLICIES Consolidation The consolidated nancial statements comprise the nancial statements of Novozymes A/S (the Parent Company) and subsidiaries controlled by Novozymes A/S, prepared in accordance with Group accounting policies. The consolidated nancial statements are prepared by combining items of a uniform nature and subsequently eliminating intercompany transactions, internal stockholdings and balances, and unrealized intercompany prots and losses. Consolidation of the environmental, social and governance data follows the same principles as the nancial reporting. Translation of foreign currencies The consolidated nancial statements are presented in Danish kroner (DKK). Exchange rate dierences arising between the exchange rate at the transaction date and the reporting date are recognized as Financial income or Financial costs. Foreign currency transactions are translated into the functional currency dened for each company using the exchange rates prevailing at the transaction date. Monetary items denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the reporting date. Financial statements of foreign subsidiaries are translated into DKK at the exchange rates prevailing at the reporting date for assets and liabilities, and at average exchange rates for income statement items. The following exchange rate dierences, arisingfrom translation usingthe exchange rate prevailing at the reporting date, are recognized in Other comprehensive income: • Translation of foreign subsidiaries’ net assets at the beginning of the year • Translation of foreign subsidiaries’ income statements from average exchange rates Non-IFRS nancial measures Novozymes uses certain nancial measures that are not dened in IFRS to describe the Group’s nancial performance, nancial position and cash ows. These nancial measures may therefore be dened and calculated dierently from similar measures in other companies, and may thus not be comparable. The non-IFRS nancial measures presented in the annual report are: • Organic sales growth • Operating costs • Economic prot • ROIC • Free cash ow before acquisitions Denitions of non-IFRS nancial measures are provided in the Glossary. iXBRL reporting From 2020, Novozymes is required to le the annual report in the new European Single Electronic Format (‘ESEF’) and the Annual report in 2020 is therefore prepared in the XHTML format that can be displayed in a standard browser. The primary statements in the consolidated nancial statements are tagged using inline eXtensible Business Reporting Language (iXBRL). The iXBRL tags comply with the ESEF taxonomy, which is included in the ESEF Regulation and developed based on the IFRS taxonomy published by the IFRS Foundation. Where a nancial statement line item is not dened in the ESEF taxonomy, an extension to the taxonomy has been created. Extensions are anchored to elements in the ESEF taxonomy, except for extensions which are subtotals. The annual report submitted to the Danish Financial Supervisory Authority consists of the XHTML document together with certain technical les, all included in a le named NOVOZYMES-2020-12-31.zip. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS The preparation of the consolidated nancial statements and the environmental, social and governance datarequires Management to make estimates and assumptions that can have a signicant eect on the application of policies and reported amounts of assets, liabilities, income, expenses and related disclosures. The estimates and underlying assumptions are based on historical experience and various other factors. Actual results may dier from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Changes in estimates may be necessary if there are changes in the circumstances on which the estimate was based, or if more detailed information becomes available. Such changes are recognized in the period in which the estimate in question is revised. Basis of reporting 1.2 Basis of reporting Accounts and performanceNotes 68Novozymes A/S The application of the Group’s accounting policies may require Management to make judgments that can have a signicant eect on the amounts recognized in the consolidated nancial statements. Management judgment is required in particular when assessing the substance of transactions that have a complicated structure or legal form. The critical accounting estimates and judgments could potentially have a signicant impact on the consolidated nancial statements. Basis of reporting The consolidated nancial statements of theGroup have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU and further requirements in the Danish Financial Statements Act. The scal year for the Group is January 1 – December 31. The consolidated nancial statements have been prepared on a going concern basis and under the historical cost convention, with the exception of derivatives and securities, which are measured at fair value. The accounting policies are unchanged from last year. The consolidated environmental, social and governance data have been prepared in accordance with principles that adhere to internationally recognized voluntaryreporting standards and principles such as the UN Global Compact (UNGC). Novozymes is a signatory to the UNGC, a voluntary policy initiative for businesses that are committed to aligning their operations and strategies with ten universally accepted principles in the areas of human rights, labor, environment and anti-corruption. We also take inspiration from the Task Force on Climate Related Financial Disclosures (TCFD) framework for climate-related disclosures. Our reporting and materiality assessments have also been inspired by the GRI framework. The principles are unchanged from last year. Dening materiality Novozymes’ annual report is based on the concept of materiality, to ensure that the content is material and relevant. If items are individually immaterial, they are aggregated with other items of a similar nature in the statements or in the notes. Novozymes provides the specic disclosures required by IFRS unless the information is considered immaterial to the economic decision-making of the readers of the annual report. The disclosures on environmental, social and governance (ESG) issues include information on our management approach, targets, initiatives and related progress. Various global movements and the COVID-19 pandemic has led to an increased focus on how companies manage ESG issues, specically on social issues for eg. occupational health & safety and labor practices. As a responsible corporate citizen, Novozymes considers these issues to be highly material, and we continuously strive to strengthen our governance and management of these issues. Novozymes’ materiality assessment is a systematic and rigorous process that integrates input from external stakeholders, trend analyses and internal engagement with relevant departments including Investor Relations, Risk Management & Controls, Quality and Sustainability and leadership from our commercial divisions. This process results in a materiality matrix of nancial and ESG issues and reects the importance of those issues to our key stakeholders versus their impact on Novozymes. We use our materiality matrix to guide our strategy and reporting. During our assessment in 2020, no new issues were added to or deleted from our matrix. For more information, refer to www.novozymes. com/en/about-us/sustainability/materiality. In the following table, we highlight some of the material issues, for which, we have external targets/agship initiatives and make a contribution to relevant SDG(s). Basis of reporting 1.2 Basis of reporting (continued) Accounts and performanceNotes The table below showscritical accounting estimates and judgments and their level of potential impact on the consolidated nancial statements: Note Critical accounting estimates and judgments Estimate/ judgment Potential impact from estimates and judgments 2.2 Revenue Prot-sharing in partnerships Estimate 2.6 Tax Group tax charge Estimate 3.1 Intangible assets and impairment test of goodwill Impairment of intangible assets and goodwill Estimate 3.1 Intangible assets and impairment test of goodwill Intangible assets recognized at fair value Estimate 3.5 Business acquisitions Fair value measurement Estimate 4.1 Inventories Cost of work in progress and nished goods Estimate 4.2 Trade receivables and contract assets Allowances for doubtful trade receivables Estimate Material issues with external targets or agship initiatives External target(s)/agship initiative SDGs Innovation • HelloScience - open innovation platform Protable growth • Organic sales growth 5+% per year • EBIT margin 28% or above by 2022 • ROIC incl. goodwill 23% or above by 2022 Climate change and energy • 50% reduction in absolute emissions from operations by 2030 • 100% renewable electricity by 2030 • 15% reduction in absolute emissions from purchased goods and services by 2030 Water • 100% of sites manage water in balance with local conditions by 2030 Responsible sourcing • 100% of key materials and waste managed in circular systems by 2030 Community engagement and social investment • Pledge 1% of our time to local outreach activities by 2022 Occupational health and safety • Occupational injuries = < 1.5, dened as three- year rolling average of lost time injuries per million working hours. Labor practices and human rights • 86 on our diversity index by 2022 • 80 on learning in employee survey in 2022 Waste • Develop programs to reach zero waste by 2030 at 100% of sites * The target does not include sites with activities considered not to have a signicant environmental impact, e.g sales oces, R&D labs etc. Limited reporting scope The environmental data cover those activities that could have a signicant impact on the environment. Sites with activities considered not to have a signicant environmental impact are not included. Such sites comprise sales oces, R&D labs, and sites with limited blending and storage of products. However, measures are taken to ensure that at least 97% of the total Novozymes quantity of the measured environmental parameter is included in the reported numbers. Impact of new accounting standards Novozymes has adopted the following new or amended standards and interpretations from January 1, 2020: • Amendments to IFRS 3 – Business Combinations, claries the denition of a business. • Amendments to IAS 1 and IAS 8 – Denition of Material, claries the denition of material. • Amendments to IFRS 9, IAS 39, and IFRS 7 – Interest Rate Benchmark Reform (IBOR), which modify specic hedge accounting requirements to provide relief from potential eects of the uncertainty caused by the IBOR reform, and requires additional information to be provided about hedging relationships which are directly aected by these uncertainties. The adoption of the new and amended standards and interpretations has not had a signicant impact on recognition, measurement or disclosures in the consolidated nancial statements for 2020 and is not anticipated to have a signicant impact on future periods. New standards and interpretations not yet adopted IASB has issued new or amended accounting standards and interpretations that have not yet become eective and have consequently not been implemented in the consolidated nancial statements for 2020. Novozymes expects to adopt the accounting standards and interpretations when they become mandatory. None of the new or amended standards or interpretations are expected to have a signicant impact on the consolidated nancial statements. 69Novozymes A/S 1.2 Basis of reporting (continued) Basis of reporting Accounts and performanceNotes 70Novozymes A/S Net operating prot aer tax 2 ROIC NOPAT EBIT Tax NWC Invested capital excl. NWC Invested capital Net operating profit after tax DKK million Note 2020 2019 Revenue 2.2 14,012 14,374 Cost of goods sold (6,159) (6,420) Gross prot 7,853 7,954 Sales and distribution costs (1,581) (1,631) Research and development costs 2.4 (1,937) (1,966) Administrative costs (739) (838) Other operating income, net 2.5 56 520 Operating prot (EBIT) 3,652 4,039 Exchange gains/(losses) (35) (205) Tax on adjusted operating prot (714) (650) Share of loss in associates (4) (5) Adjusted operating prot (NOPAT) 2,899 3,179 Average invested capital (see Invested capital section) 15,301 15,038 ROIC 18.9% 21.1% Accounts and performanceNotes 26.1% 56.0% 0% EBIT margin down from 28.1% in 2019 to Gross margin up from 55.3% in 2019 to Organic sales growth up from -1% in 2019 to 71Novozymes A/S 2.1 Segment Segment reporting The internal reporting framework used for reporting on revenue and expenses to the Executive Leadership Team and the Board of Directors has been established to reect and report on the global functional responsibility setup at Novozymes. This setup consolidates functions by type, and Management reviews the results of the Group as a whole to assess performance. Thus, there is only one operating segment. Worldwide operations The Group operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacic and Latin America. From a revenue perspective, theUS is the largest single market, contributing ~29% of the Group’s revenue (2019: ~31%). The geographical distribution of revenue is based on the country in which the goods are delivered. For a number of customers, central deliveries are made to specied locations and the nal destination is unknown. The stated geographical distribution of revenue may therefore vary from year to year if the delivery destination for these customers changes. Most of the Group’s intangible assets and property, plant and equipment are located in Denmark, the US and China at ~48%, ~27% and ~13% respectively (2019: ~50%, ~30% and ~13%). Intangibleassetsandproperty,plantand equipment2020(2019) DKK million • Denmark 5,790 (6,007) • Rest of Europe, Middle East & Africa 833 (51) • North America 3,498 (3,935) • Latin America 101 (142) • AsiaPacic 1,944 (2,003) Net investments2020(2019) DKK million • Denmark 452 (495) • Rest of Europe, Middle East & Africa 6 (13) • North America 312 (271) • Latin America 12 (21) • Asia Pacic 154 (191) Revenue 2020 (2019) DKK million • Denmark 175 (166) • Rest of Europe, Middle East & Africa 5,361 (5,174) • North America 4,441 (4,750) • Latin America 1,280 (1,407) • Asia Pacic 2,755 (2,877) Net operating profit after tax Accounts and performanceNotes 72Novozymes A/S The majority ofNovozymes’revenue is derived from the sale of goods to customers, where revenue is recognized when goods are delivered. Less than 1% of Novozymes’ total revenue arises from royalties. In 2020, changes were made to the BioAg setup and the partnerships Novozymes has entered into within BioAg are no longer based on prot-split arrangements. At January 1, 2020, contract liabilities amounted to DKK 74 million (2019: DKK 374 million), of which DKK 5 million was recognized as revenue in 2020 (2019: DKK 26 million). 2.2 Revenue Net operating profit after tax Salesgrowth2020 DKK million Salesbycurrency2020 (2019) DKK million • DKK ~10% (~10%) • USD ~35% (~35%) • Other ~10% (~10%) • EUR ~35% (~35%) • CNY ~10% (~10%) Accounts and performanceNotes Novozymes has entered into partnerships where Novozymes manufactures and sells products to a partner, who undertakes the sales to end customers, and where the prot on products sold to end customers is shared between the partner and Novozymes based on predetermined prot-sharing mechanisms. Revenue related to this type of partnership comprises approximately 9% of Novozymes’ total annual revenue (2019: approximately 11%). A minor part of the revenue, related to the expected prot-share on products sold to the partner, requires signicant judgment and estimates by Management. This involves estimating future selling prices to end customers, along with their impact on rebate schemes, and estimating product returns from end customers. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS DKK million 2020 2019 Consumer Biosolutions Household Care 4,882 4,758 Food, Beverages & Human Health 2,767 2,745 Agriculture & Industrial Biosolutions Bioenergy 2,522 2,901 Grain & Tech Processing 2,007 2,089 Agriculture & Animal Health 1,834 1,881 Revenue I/S 14,012 14,374 Emerging markets 4,711 4,938 Developed markets 9,301 9,436 Revenue I/S 14,012 14,374 Revenue to the ve largest customers as a percentage of revenue 27% 27% The industry split of revenue has been updated to reect the new structure in Novozymes, which was implemented in 2020. Comparative numbers has been restated. 73Novozymes A/S 2.2 Revenue (continued) Net operating profit after tax Accounts and performanceNotes Novozymes produces a wide range of industrial enzymes and microorganisms. Revenue includes the sale of goods and related services and royalties, and is recognized at an amount that reects the consideration to which Novozymes expects to be entitled. Revenue from the straightforward sale of goods to customers isrecognized when control of the goods is transferred to the customer, i.e.whengoods are delivered. Variable considerations are included in revenue to the extent that they are not subject to signicant uncertainty. The performance obligations in the contracts are to deliver enzymes and microorganisms to customers, and each batch delivered is considered a separate performance obligation, as each batch is distinct. Discounts Enzymes and microorganisms are sometimes sold at a rebate. A rebate agreement can be set up in various ways, but common to all agreements is that revenue is recognized based on the price specied in the contract, net of the estimated rebate. The rebates are estimated based on experience, as well as information related to expected orders 3-12 months in advance. The estimated rebates are reassessed at the end of each reporting period. Returns A few of Novozymes’ partnerships are granted a right of return. No revenue is recognized for the goods expected to be returned, as a refund liability is recognized. Estimates of the expected level of returns are based onanalysis of historical returns and knowledge of the relevant markets/ products. These estimates are updated at the end of each reporting period. As the goods returned are usually scrapped, no inventory asset is recognized. Prot split Novozymes has entered into partnerships where Novozymes manufactures and sells products to a partner, who undertakes the sales to end customers. Theprot on products sold to end customers is shared between the partner and Novozymes based on predetermined prot-sharing mechanisms. Revenue from these arrangements consists of sales of products to the partner and the shared prot, and isrecognized in full when the goods are delivered to the other contracting party. This is done by calculating the expected prot based on insights,experience and otherinput factors. The calculated prot is recognized as a contract asset or contract liability until an invoice is issued. The realized prot is settled periodically. Commission Novozymes has entered into commission agreements where agents undertake sales to third parties in return for a commission on realized sales. Revenue from such agreements is recognized when the goods are delivered, as the nature of the performance obligation is to provide the specied goods. Other Revenue collected on behalf of third parties is not recognized as revenue. Novozymes’ obligation to provide a refund for products that are not of the agreed quality or according to agreed specications under the standard warranty terms is recognized as contract liabilities. A trade receivable is recognized when the customer obtains control of the goods and an invoice is issued, as this is the point in time when the consideration becomes unconditional and only the passage of time is required before payment is due. Typical payment terms are around 60 days. Contract liabilities consist of advance payments,deferred revenue and liabilities for refund goods. The contract liabilities are recognized as revenue as the performance obligations under the contracts are fullled. ACCOUNTING POLICIES 74Novozymes A/S 2.3 Employees DKK million 2020 2019 Wages and salaries 3,047 3,195 Pensions – dened contribution plans 282 292 Other social security costs 234 284 Other employee costs 114 117 Stock-based payment 54 46 Employee costs 3,731 3,934 Recognized in the income statement under the following items: Cost of goods sold 1,469 1,447 Sales and distribution costs 792 869 Research and development costs 1,046 1,122 Administrative costs 458 504 3,765 3,942 Change in employee costs recognized in Inventories (34) (8) Employee costs 3,731 3,934 Employee costs 2020 (2019) DKK million • Denmark 2,058 (2,084) • Rest of Europe, Middle East & Africa 149 (171) • North America 964 (1,065) • Asia Pacic 472 (500) • Latin America 88 (114) Number of employees end of year 2020 (2019) No. of employees • Denmark 2,646 (2,640) • Rest of Europe, Middle East & Africa 203 (191) • North America 1,185 (1,195) • Asia Pacic 1,833 (1,792) • Latin America 318 (307) Net operating profit after tax Accounts and performanceNotes The employee costs in 2020 included severance costs of DKK 87 million related to organizational changes, of which DKK 65 million was related to the changes to the Executive Leadership Team announced in 2020. The employee costs in 2019 included restructuring costs related to organizational changes of around DKK 200 million. The one-o impact in 2019 was partly oset by reduced employee costs during the remainder of the year. In addition, changes to the Executive Leadership Team during 2019 resulted in severance costs of DKK 58 million. 75Novozymes A/S 2.3 Employees (continued) 2020 2019 Average number of employees in the Group 6,099 6,341 Average number of employees who work with R&D 1,411 1,522 Number of employees outside Denmark as a percentage of total number of employees 57% 57% Part-time employees 282 292 Full-time employees 5,903 5,833 Employees at December 31 ESG 6,185 6,125 Senior management 198 189 Management 1,210 1,136 Professional 1,724 1,711 Administrative 605 579 Skilled workers, laboratory technicians and other technicians 1,249 1,294 Process operators 1,199 1,216 Employees by category ESG 6,185 6,125 Employee gender distribution2020 (2019) • Women 38% (38%) • Men 62% (62%) Senior management gender distribution2020 (2019) • Women 33% (31%) • Men 67% (69%) Net operating profit after tax Accounts and performanceNotes The number of employees is derived from contractual obligations, but does not include employees on unpaid leave, temporary replacements, student interns, agency employees, consultants or PhD students. In calculating the number of full- time employees, employees with a working- time ratio of 95% or more are counted as full-time employees. The average number ofemployees is calculated as the average of the number of permanent employees at the end of each month. Job categories are dened as follows: Senior management comprises the CEO, executive vice presidents, vice presidents and directors. Management comprises middle managers and specialists. Professional comprises employees with academic backgrounds as well as team leaders.Process operators comprises operators and unskilled workers. ACCOUNTING POLICIES 76Novozymes A/S 2.4 Research and development costs In 2020, Novozymes launched twelve new products (2019: nine new products). New products comprise products with new or improved characteristics. In 2020, Novozymes had 963 active patent families (2019: 951). Active patent families comprise the number of inventions for which Novozymes has one or more active patent applications or active patents at December 31. DKK million Note 2020 2019 Internal and external research and development costs 576 519 Employee costs 2.3 1,046 1,122 Amortization and impairment losses, intangible assets 3.1 154 170 Depreciation and impairment losses, property, plant and equipment 3.2 161 155 Total research and development costs I/S 1,937 1,966 As a percentage of revenue 13.8% 13.7% Net operating profit after tax Accounts and performanceNotes Research and development costs primarily comprise employee costs, internal and external costs related to the development of new products and to the ongoing optimization of production processes for existing products, and amortization, depreciation and impairment losses related to intangible assets and property, plant and equipment used in the research and development activities. Research and development costs are expensed as incurred unless the criteria for capitalization are deemed to have been met. Due to signicant uncertainty associated with the development of new products, research and development costs are not capitalized. Income received from research and collaboration agreements is recognized in Other operating income. ACCOUNTING POLICIES 77Novozymes A/S 2.5 Other operating income, net In 2020, Other operating income was impacted by DKK 42 million from the contingent consideration relating to the divestment of the pharma-related royalty. Contingent consideration has been recognized, where entitlement has been obtained due to completion of patent registrations. In 2019, a net gain of DKK 194 million related to the divestment of the pharma-related royalty was recognized. The net gain comprised the selling price less contingent consideration, transaction costs and the disposed goodwill. Furthermore, other operating income was signicantly impacted by the termination of The BioAg Alliance at a net gain of DKK 300 million. The net gain mainly comprised the release of the remaining deferred revenue of DKK 287 million originating from the formation of the Alliance. Furthermore, the net gain comprised the income related to assets recognized at fair value oset by impairment losses and transaction costs. DKK million 2020 2019 Income and grants concerning research projects/ collaborations 9 11 Other secondary income, net 5 15 Net gain from divestment of the pharma-related royalty 42 194 Net gain from termination of The BioAg Alliance - 300 Other operating income, net I/S 56 520 Accounts and performanceNotes Net operating profit after tax Other operating income comprises income that is not product-related.This includes income from research and collaboration agreements, government grants,sale of licenses, patents, etc., and other income of a secondary nature in relation to the main activities of the Group. This item also includes non-recurring income items in respect of damages, outlicensing, etc., and gains and losses on divestments. ACCOUNTING POLICIES Tax risks Novozymes operates in many markets via sales companies and distributors, while production is located in a few countries. This leads to transactions between group companies. Novozymes follows the OECD principles in setting internal transfer prices for these transactions. This is a complicated area and entails a tax risk,because the transactions are subject to judgment in each country. The tax controversy risk for Novozymes is signicantly reduced through the use of bilateral advance pricing agreements (APAs). Bilateral APAs As stated in our tax policy, Novozymes proactively engages in bilateral APAs negotiated at competent authority level to increase predictability and to mitigate transfer pricing risks. Most of the intercompany transaction value within the Novozymes Group is covered by bilateral APAs. An APA is an agreement between a taxpayer and a tax authority determining the transfer pricing methodology for pricing the taxpayer’s international transactions for future years. The methodology is applied for a certain period based on the fullment of certain terms and conditions (called critical assumptions). An APA can be unilateral or bilateral. Novozymes only enters into bilateral APAs, meaning that they are negotiated between the competent tax authorities of the two countries involved in the transaction. An APA provides assurance with respect to the tax outcome of our international transactions, by agreeing in advance the arm’s length pricing and pricing methodology to be applied to the international transactions. Novozymes has entered into bilateral APAs with the tax authorities in the countries where internal transactions are most signicant. Among APA covered transactions are group internal transactions between Denmark and the US, China and India, respectively. Joint taxation Novozymes A/S and its Danish subsidiaries are jointly taxed with the Danish companies of the Novo Holdings A/S Group. Joint taxation also covers withholding taxes in the form of dividend tax, royalty tax and interest tax. The Danish companies are jointly and individually liable for the joint taxation liability. Any subsequent adjustments to income taxes and withholding taxes may increase the liability. Tax for the individual companies is allocated in full on the basis of the expected taxable income. Tax in the income statement Transfer of intellectual property from Switzerland to Denmark had a positive impact on the eective tax rate of 2.9% in 2020 (2019: 2.9%). This is recognized in Dierence in foreign tax rates. In 2019, Novozymes had a positive impact from uncertain tax positions related to APAs, recognized in Other adjustments. 78Novozymes A/S 2.6 Tax Net operating profit after tax Accounts and performanceNotes Tax in the income statement DKK million 2020 2019 Tax payable on net prot (817) (894) Change in deferred tax 144 262 Prior-year adjustments - current tax 98 21 Prior-year adjustments - deferred tax (120) (33) Tax in the income statement I/S (695) (644) Calculation of eective tax rate: Corporate tax rate in Denmark (22.0)% (22.0)% Non-taxable income less non-deductible expenses 0.2% 0.6% Dierence in foreign tax rates 2.5% 2.6% Other adjustments (0.4)% 1.8% Eective tax rate (19.7)% (17.0)% 79Novozymes A/S 2.6 Tax (continued) The tax value of the unrecognized share of tax loss carry-forwards, tax credits, etc. that do not expire amounted to DKK 25 million (2019: DKK20 million). Deferred tax Deferred tax assets Deferred tax liabilities DKK million 2020 2019 2020 2019 Intangible assets and property, plant and equipment 1,091 947 (1,479) (1,265) Inventories 357 427 (179) (197) Tax loss carry-forwards 41 42 - - Stock options 82 109 - - Other 284 274 (62) (55) 1,855 1,799 (1,720) (1,517) Osetting items (516) (638) 516 638 Deferred tax at December 31 B/S 1,339 1,161 (1,204) (879) Net operating profit after tax Accounts and performanceNotes As the Group operates across many dierent countries, the calculation of the Group’s total tax charge in the income statement inherently involves estimation. Tax and transfer-pricing disputes with authorities in various countries may occur, and Management’sassessment is applied to assess the possible outcome of such disputes. Payments in respect of tax liabilities for an accounting period result from payments on account and on the nal resolution of open items. As a result, there may be substantial dierences between the tax charge in the consolidated income statement and actual tax payments. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS DKKmillion 2020 2019 Deferred tax at January 1 282 46 Currency translation adjustments (35) 2 Eect of business acquisitions (80) - Tax related to the income statement 24 229 Tax on shareholders’ equity items (56) 5 Deferred tax at December 31 135 282 Deferred tax assets B/S 1,339 1,161 Deferred tax liabilities B/S (1,204) (879) Deferred tax at December 31 135 282 80Novozymes A/S 2.6 Tax (continued) Tax receivables and payables DKKmillion 2020 2019 Tax payables, net, at January 1 (158) (401) Currency translation adjustments (14) (2) Tax related to the income statement (719) (872) Tax on shareholders’ equity items 64 1 Tax paid for the current year, net 951 1,116 Tax payables, net, at December31 124 (158) Tax receivables B/S 460 273 Tax payables B/S (336) (431) Tax payables, net, at December31 124 (158) Of which due within 12 months 25 (32) Of which due aer more than 12 months 99 (126) Tax payables, net, at December31 124 (158) Corporate income taxes paid are specied as follows: Income taxes paid in Denmark 593 701 Income taxes paid outside Denmark 358 415 Total income taxes paid 951 1,116 Net operating profit after tax Accounts and performanceNotes Corporation tax, comprising the current tax liability, change in deferred tax for the year and possible adjustments relating to prior years, is recognized in the income statement, unless it relates to items recognized either in Other comprehensive income or directly in Shareholders’ equity. Uncertain tax positions are assessed individually and recognized if it is probable that an amount will be paid or received. Deferred tax is measured using the balance sheet liability method and comprises all temporary dierences between the carrying amount and the tax base of assets and liabilities. No deferred tax is recognized for goodwill, unless amortization of goodwill for tax purposes is allowed. The tax value of tax loss carry-forwards is included in the calculation of deferred tax to the extent that the tax losses can be expected to be utilized in the future. Deferred tax is measured according to current tax rules and at the tax rate expected to be in force on elimination of temporary dierences. Changes in deferred tax due to tax rate changes are recognized in the income statement, unless they relate to items recognized either in Other comprehensive income or directly in Shareholders’ equity. ACCOUNTING POLICIES 81Novozymes A/S 2.7 Earnings per share DKK million 2020 2019 Net prot for the year 2,826 3,155 Less net prot attributable to non-controlling interests (1) (1) Net prot attributable to the shareholders in Novozymes A/S 2,825 3,154 Average number of shares Weighted average number of shares in circulation 280,427,908 285,110,290 Average dilutive eect of outstanding stock options and stock awards 1,595,499 1,441,008 Average number of diluted shares 282,023,407 286,551,298 Earnings per share DKK 10.07 DKK 11.06 Earnings per share, diluted DKK 10.02 DKK 11.01 Net operating profit after tax Accounts and performanceNotes Earnings per share is calculated as net prot attributable to shareholders in Novozymes A/S divided by the average number of shares in circulation. Diluted earnings per share is calculated as net prot attributable to shareholders in Novozymes A/S divided by the average number of shares in circulation, including the dilutive eect of stock options “in the money”. ACCOUNTING POLICIES 82Novozymes A/S Invested capital 3 ROIC NOPAT EBIT Tax NWC Invested capital excl. NWC Invested capital Invested capital DKK million Note 2020 2019 Intangible assets 3.1 2,554 1,926 Property, plant and equipment 3.2 9,612 10,212 Investments in associates 33 37 Net working capital (see Net working capital section) 2,901 3,478 Financial assets, non-interest-bearing 119 15 Provisions 3.4 (205) (243) Contingent consideration 3.5 (146) - Derivatives (33) (42) Tax, net 259 124 Invested capital 15,094 15,507 Average invested capital 15,301 15,038 Accounts and performanceNotes 936 263 18.9% Net investments excl. acquisitions down from DKK 991 million in 2019 to DKK million Increase in average invested capital of DKK million ROIC down from 21.1% in 2019 to Impairment In 2020, an impairment loss of DKK 32 million on patents was recognized and included in Research and development cost. The impaired asset was part of a project that has been terminated, and the asset has been fully written o. Impairment test of goodwill Novozymes has one cash-generating unit (CGU). Since 2016, Management had identied two CGUs: Novozymes’ main activities and the Biopharma CGU.With the divestment of the pharma-related royalty, and thereby the remaining activity within the Biopharma CGU in April 2019, only one CGU remained. As the market value of Novozymes is signicantly higher than its equity, no further key assumptions are used to determine whether impairment of goodwill exists (2019: no impairment). 83Novozymes A/S 3.1 Intangible assets and impairment test of goodwill Invested capital Accounts and performanceNotes Management assesses the risk of impairment of the Group’s intangible assets. This requires judgment in relation to the identication of cash-generating units (CGUs) and the underlying assumptions in the Group’s impairment model. If there is any indication of impairment, value in use is estimated and compared with the carrying amount. The calculation of value in use is based on the discounted cash ow method using estimates of future cash ows from the continuing use. The key parameters are the expected revenue streams and the rate used to discount the cash ows. As a consequence of the termination of The BioAg Alliance in 2019, intellectual property from The BioAg Alliance was recognized at fair value. Measuring the fair value of these assets required Management’s assessment of business plans for the individual assets. The key parameters were expected cash ows and the WACC used to discount the cash ows. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS DKK million Goodwill Acquired patents, trademarks, licenses and know-how, etc. Completed IT development projects IT development projects in progress Total Cost at January 1, 2020 965 2,648 664 29 4,306 Currency translation adjustments (25) (26) (1) - (52) Additions from business acquisitions 158 639 - - 797 Additions during the year - 2 30 114 146 Disposals during the year - (28) (7) - (35) Transfers to/(from) other items - - 59 (59) - Cost at December 31, 2020 1,098 3,235 745 84 5,162 Amortization and impairment losses at January 1, 2020 (1,905) (475) (2,380) Currency translation adjustments 20 1 21 Amortization during the year (179) (73) (252) Impairment losses (32) - (32) Disposals during the year 28 7 35 Amortization and impairment losses at December 31, 2020 (2,068) (540) (2,608) Carrying amount at December 31, 2020 B/S 1,098 1,167 205 84 2,554 84Novozymes A/S 3.1 Intangible assets and impairment test of goodwill (continued) Due to the termination of The BioAg Alliance, intellectual property from The BioAg Alliance has been transferred to Novozymes free of charge. These assets have been recognized at fair value amounting to DKK 95 million and the corresponding income is recognized in Other operating income. The goodwill disposal is related to the divestment of the pharma-related royalty. Impairment In 2019, impairment losses of DKK 71 million were recognized on two specic assets. As theseare related to the termination of The BioAg Alliance, the impairment losses are recognized and included in Other operating income. The impairment losses were the result of impairment tests performed on assets where the termination of The BioAg Alliance has resulted in reduced sales projections for the assets in question. The cash ow used to test one of the assets for impairment was based on business plans for the period 2019-2025, and the terminal value used was based on the expected lifetime and cash ow over that period. For the other impaired asset, the cash ow ceased in 2019 with the termination of The BioAg Alliance. A pre-tax WACC of 7% was used to calculate the discounted cash ows. DKK million Goodwill Acquired patents, trademarks, licenses and know-how, etc. Completed IT development projects IT development projects in progress Total Cost at January 1, 2019 1,086 2,942 533 59 4,620 Currency translation adjustments 2 2 - - 4 Additions during the year - 129 47 54 230 Disposals during the year (123) (425) - - (548) Transfers to/(from) other items - - 84 (84) - Cost at December 31, 2019 965 2,648 664 29 4,306 Amortization and impairment losses at January 1, 2019 (2,062) (428) (2,490) Currency translation adjustments (1) - (1) Amortization during the year (163) (47) (210) Impairment losses (71) - (71) Disposals during the year 392 - 392 Amortization and impairment losses at December 31, 2019 (1,905) (475) (2,380) Carrying amount at December 31, 2019 B/S 965 743 189 29 1,926 Recognition of amortization and impairment losses by function 2020 (2019) DKK million • Cost of goods sold 82 (82) • Sales and distribution 14 (3) • Research and development 154 (170) • Administration 34 (26) Invested capital Accounts and performanceNotes 85Novozymes A/S 3.1 Intangible assets and impairment test of goodwill (continued) Invested capital Accounts and performanceNotes Intangible assets other than goodwill are measured at cost less accumulated amortization and impairment losses. Goodwill and IT development projects in progress are not subject to amortization. Costs associated with large IT projects for the development of soware for internal use are capitalized if incurred with a view to developing new and improved systems. Amortization is based on the straight-line method over the expected useful lives of the nite-lived assets, as follows: • Completed IT development projects are amortized over their useful lives. IT development assets are amortized over a period of3-5 years • Acquired patents, trademarks, licenses and know-how are amortized over their useful lives. The useful lives of patents and trademarks are normally identical to the patent period. Licenses are amortized over the agreement period. Recognized patents, trademarks, licenses and know- how are amortized over a period of 7-15 years Expected useful lives are reassessed regularly. The Group regularly reviews the carrying amounts of its nite-lived intangible assets to determine whether there is an indication of an impairment loss. An impairment loss is recognized to the extent that the asset’s carrying amount exceeds its estimated recoverable amount. Impairment losses are reversed only to the extent of changes in the assumptions and estimates underlying the impairment calculation. Goodwill is tested for impairment annually or whenever there is an indication that the asset may be impaired. ACCOUNTING POLICIES Capitalized interest and pledges Interestof DKK 1 million(2019: DKK 2 million) was capitalized under Additions during the year and included as Investing activities in the statement of cash ows. Capitalization rate: 0.53% (2019: 0.9%). Land and buildings with a carrying amount of DKK 1,516 million (2019: DKK 1,526 million) were pledged as securityto credit institutions. The mortgage loans expire in 2029 and 2039. Impairment No impairment losses on property, plant and equipment were recognized in 2020. 86Novozymes A/S 3.2 Property, plant and equipment Invested capital Recognitionofdepreciation and impairment lossesbyfunction2020 (2019) DKK million • Cost of goods sold 712 (713) • Salesanddistribution 30 (39) • Researchanddevelopment 161 (155) • Administration 79 (65) Accounts and performanceNotes DKK million Land and buildings Plant and machinery Other equipment Assets under construction and prepayments Total Cost at January 1, 2020 7,046 11,176 2,380 662 21,264 Currency translation adjustments (279) (447) (98) (29) (853) Additions from business acquisitions - - 1 - 1 Additions during the year 146 148 131 427 852 Disposals during the year (32) (55) (128) - (215) Transfers to/(from) other items 105 195 78 (378) - Cost at December 31, 2020 6,986 11,017 2,364 682 21,049 Depreciation and impairment losses at January 1, 2020 (2,990) (6,675) (1,387) (11,052) Currency translation adjustments 113 239 58 410 Depreciation for the year (280) (492) (210) (982) Disposals during the year 24 46 117 187 Transfers to/(from) other items - 1 (1) - Depreciation and impairment losses at December 31, 2020 (3,133) (6,881) (1,423) (11,437) Carrying amount at December 31, 2020 B/S 3,853 4,136 941 682 9,612 87Novozymes A/S The implementation of IFRS 16 as of January 1, 2019, resulted in an increase in Property, plant and equipment of DKK 616 million. Refer to Note 3.3 for additional disclosures relating to leases. Depreciation relating to leases in 2019 amounted to DKK 124 million. Impairment An ongoing production-related construction project was abandoned in 2019. This led to an expense of DKK 33 million, which was recognized in Cost of goods sold. Buildings expected to be sold within 12 months were written down to the expected selling price less transaction costs before being transferred to Assets held for sale. Buildings amounting to DKK 62 million were transferred to Assets held for sale. An impairment loss ofDKK 15million wasrecognized in Sales and distribution costs and Administrative costs at DKK 4 million and DKK 11 million respectively. 3.2 Property, plant and equipment (continued) Invested capital Accounts and performanceNotes Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Borrowing costs in respect of construction ofmajor assets are capitalized. Depreciation is based on the straight-line method over the expected useful lives of the assets, as follows: • Buildings: 12-50 years • Plant and machinery: 5-25 years • Other equipment: 3-18 years The residual values and useful lives of the assets are reviewed on an annual basis and adjusted if necessary at each reportingdate. The Group regularly reviews the carrying amounts of its property, plant and equipmentto determine whether there is any indication of impairment in those assets. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of any impairment loss. If the recoverable amount of an asset is estimated to be lower than its carrying amount, the carrying amount is reduced to the recoverable amount. Impairment losses are reversed only to the extent of changes in the assumptions and estimates underlying the impairment calculation. ACCOUNTING POLICIES DKK million Land and buildings Plant and machinery Other equipment Assets under construction and prepayments Total Cost at January 1, 2019 5,694 10,645 1,846 1,848 20,033 Lease assets at January 1, 2019 412 12 192 - 616 Currency translation adjustments 59 99 19 8 185 Additions during the year 127 184 215 383 909 Disposals during the year (41) (71) (61) (33) (206) Transfer to assets held for sale (273) - - - (273) Transfers to/(from) other items 1,068 307 169 (1,544) - Cost at December 31, 2019 7,046 11,176 2,380 662 21,264 Depreciation and impairment losses at January 1, 2019 (2,915) (6,193) (1,227) (10,335) Currency translation adjustments (22) (44) (9) (75) Depreciation for the year (264) (504) (189) (957) Impairment losses (15) - - (15) Disposals during year 15 64 40 119 Transfer to assets held for sale 211 - - 211 Transfers to/(from) other items - 2 (2) - Depreciation and impairment losses at December 31, 2019 (2,990) (6,675) (1,387) (11,052) Carrying amount at December 31, 2019 B/S 4,056 4,501 993 662 10,212 88Novozymes A/S 3.3 Leases Invested capital Accounts and performanceNotes Lease assets Lease assets are ‘right-of-use assets’ from lease agreements. If, at inception, it is assessed that a contract contains a lease, a lease asset is recognized. Lease assets are initially measured at the present value of future lease payments, plus the cost of obligations to refurbish the asset. Payments include xed payments, variable lease payments depending on an index or a rate and the exercise price of purchase options that are reasonably certain to be excercised. The lease assets are depreciated using the straight-line method over the shorter of the expected lease term and the useful life of the underlying asset. The lease assets are tested for impairment whenever there is an indication that the assets may be impaired. Lease assets are depreciated as follows: • Buildings: 1-12 years • Land: 10-90 years • Plant and machinery: 1-10 years • Equipment and company cars: 1-10 years Short-term leases and leases of low value are recognized as expenses in the income statement on a straight-line basis over the lease term. Novozymes’ portfolio of leases covers leases of land, buildings and other equipment such as cars and transportation containers. Lease liabilities Lease liabilities are initially recognized at the present value of future lease payments including payments from extension or purchase options that are considered reasonably certain to be exercised. The lease liability is measured using the implicit borrowing rate in the contracts or, where this is not available, the marginal borrowing rate in the countries in which Novozymes operates. Novozymes applies a single discount rate to portfolios of leases in the countries in which Novozymes operates based on contract currency and loan periods. If a lease contract is modied, the lease liability is remeasured. For building leases, lease terms are estimated taking the size of the building and its strategic importance into consideration. Novozymes has entered into several open-ended building leases and building leases with extension options. Lease terms of such agreements are estimated based on the strategic importance of the buildings and the estimated time frame necessary to vacate the premises. The estimated lease term is reassessed at each reporting date. The estimated lease terms for such contracts do not exceed 12 years. ACCOUNTING POLICIES DKK million 2020 2019 Land and buildings 332 397 Plant and machinery 98 102 Other equipment 114 155 Carrying amount of lease assets 544 654 Additions to the lease assets during 2020 amounted to DKK58 million (2019: DKK 47 million). DKK million 2020 2019 Lease liabilities Less than 1 year 142 165 Between 1 and 5 years 299 307 More than 5 years 180 238 Undiscounted lease liabilities at December 31 621 710 DKK million 2020 2019 Amounts recognized in the income statement Interest on lease liabilities 24 28 Depreciation of lease assets per asset class Land and buildings 67 68 Plant and machinery 5 5 Other equipment 53 51 Depreciation of lease assets 125 124 Amounts recognized in the statement of cash ows Total cash outow for leases 135 136 Dismantling and restoration Dismantling and restoration relates to estimated future costs of environmental restoration. Novozymes aims for its production sitesnot to have a negative environmental impact.Theseliabilities relate to established circumstances, and the costs are expected to be incurred either when concrete measures are implemented or when a site is vacated. The expected costs and timing are inherently uncertain. Legal and other obligations Novozymes is involved in a number of ongoing legal disputes, and provisions are made for the estimated costs of these based on a current evaluation of the outcomes. The ongoing cases are expected to be nalized in 2021-2022. InManagement’s opinion, the outcomes of these cases are not expected togive rise to any signicant losses beyond the amounts provided forat December 31, 2020. In 2019, Novozymes settled a long-standing patent dispute, and as a result Novozymes paid DKK 65 million to the counterpart, of which DKK 31 million was provided for in previous years. Other obligations include other long-term employee benets and other contractual obligations. Other obligations mainly relates to the divestment of the pharma-related royalty, for which part of the selling price received must be repaid if certain patent registrations are not obtained by 2021. A number of registrations were obtained in2020.The amount potentially to be repaid has been reduced by DKK 42 million. Other long-term employee benets account for only a minor amount, asthe majorityof Novozymes’ pension plans are dened contribution plans, covering approximately 99% ofemployees. These obligations are mainly expected to be incurred over a relatively long period of time. In 2019, DKK 40 million in other obligations was utilized as a consequence of the termination of The BioAg Alliance. 89Novozymes A/S 3.4 Provisions Invested capital Accounts and performanceNotes Provisions are recognized where a legal or constructive obligation has beenincurred as a result of past events and it is probable that it will lead to an outow of nancial resources. Provisions are measured at the present value of the expected expenditure required to settle the obligation. ACCOUNTING POLICIES 2020 2019 DKKmillion Dismantlingand restoration Legal and other obligations Total Dismantlingand restoration Legal and other obligations Total Provisions at January 1 83 160 243 82 147 229 Currency translation adjustments (4) (8) (12) 1 1 2 Additions during the year - 43 43 - 168 168 Reversals during the year (15) (48) (63) - (19) (19) Utilization during the year - (6) (6) - (137) (137) Provisions at December 31 64 141 205 83 160 243 Recognized in the balance sheet as follows: Non-current B/S 37 78 115 25 90 115 Current B/S 27 63 90 58 70 128 Provisions at December 31 64 141 205 83 160 243 The following valuation techniques have been applied in the fair value assessment of signicant assets acquired: • Technology; The Multi-period Excess Earnings Method (MEEM) has been applied • Brands; The Relief from Royalty (RfR) method has been applied • Customer relationships; An allowed margin approach has been applied 90Novozymes A/S 3.5 Business acquisitions Invested capital Accounts and performanceNotes On acquisition of companies, the identiable assets acquired and the liabilities and contingent liabilitiesassumed are recognized at their fair values at the acquisition date. The consideration transferred includes the fair value at the acquisition date of any contingent consideration arrangement. Goodwill may subsequently be adjusted for changes in the fair value of the consideration transferred and/or changes in the fair value of the identiable net assets acquired until 12 months aer the acquisition date, to the extent such changes relate to facts and circumstances present at the acquisition date. Acquired companies are consolidated from the date of acquisition. Acquisition-related costs are expensed as incurred. ACCOUNTING POLICIES On June 25, 2020, Novozymes acquired all voting shares in PrecisionBiotics Group Limited. PrecisionBiotics Group holds a leading position within probiotics for human gut health and is well positioned with several clinically-backed products already on the market.PrecisionBiotics Group has strong expertise within clinical development, upscaling and commercialization and is well situated in Cork, Ireland, home to a leading academic society within human gut health. The acquisition of PrecisionBiotics Group will advance Novozymes’ activities in the area of biological solutions for human oral and gut health - one of the growth pillars in the strategy; Better business with biology. Goodwill of DKK 158 million is attributable to expected synergies with Novozymes’ existing business operations and technologies within probiotics and enzymes for human health. The goodwill is not tax deductible. The purchase agreement includes a contingent consideration of up to DKK 298 million. The consideration is contingent on the achievement of sales and EBITDA estimates for 2023 and is recognized at the anticipated fair value of DKK 146 million at the acquisition date. Fair value is assessed by using the earn-out from the most probable sales and EBITDA estimates in 2023 discounted at a 7% discount rate. Net revenue and prot contributed from PrecisionBiotics Group to the consolidated income statement are immaterial for the reporting period. This would also have been the case if the acquisition had been completed on January 1, 2020. The transaction costs amounted to DKK 20 million and are included in Sales and distribution costs. Acquisition in 2020 DKK million PrecisionBiotics Group The assumed fair value of acquired assets and liabilities is as follows: Intangible assets excluding goodwill 639 Property, plant and equipment 1 Inventories 5 Trade and other receivables 37 Cash 64 Deferred tax liabilities (80) Financial and other liabilities (26) Acquired net assets 640 Purchase price: Cash 652 Contingent consideration 146 Total purchase price 798 Goodwill 158 Cash ow for acquisition: Cash payment 652 Less cash and cash equivalents in acquired business (64) Cash outow for acquisition 588 The fair value and allocation of acquired assets and liabilities and contingent consideration are provisional, pending receipt of thenal valuations. The following valuation techniques have been applied in the fair value assessment of signicant assets acquired: • Customer relationships; The Multi-period Excess Earnings Method (MEEM) has been applied • Technology; The Relief from Royalty (RfR) method has been applied • Brands; The Relief from Royalty (RfR) method has been applied 91Novozymes A/S 3.5 Business acquisitions (continued) Invested capital Accounts and performanceNotes Fair value measurement of the acquired assets and liabilities as well as a contingent consideration requires Management to make estimates and use assumptions, as observable market prices are not available. The determined fair values are associated with uncertainty and may be subject to subsequent adjustments. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS On January 7, 2021, Novozymes acquired all voting shares in Microbiome Labs. Microbiome Labs oers a comprehensive suite of proprietary probiotic and microbiome solutions targeting gastrointestinal, immune, metabolic and cognitive health. The solutions are marketed under both the company’sown supplement brands and in private label products. The branded products are sold exclusively through thecompany’s access to an extensive network of healthcare practitioners predominately consisting of medicaldoctors, nutritionists and naturopaths. By acquiring Microbiome Labs, Novozymes adds a broad range of proprietary microbiome solutions to its human health activities. The acquisition also creates an attractive entry point into the North American probiotics marketaccessed through the company’s network of healthcare practitioners. Goodwill of DKK 369 million is attributable to expected synergies with Novozymes’ existingbusiness operations and technologies within probiotics and enzymes for human health. The goodwill is tax deductible. The purchase agreement includes a contingent consideration of up to DKK 825 million. The consideration is contingent on the achievement ofsales targets for 2022 and is recognized at the anticipated fair value of DKK 338 million at the acquisition date. Fair value is assessed by using the earn-out from the most probable sales estimates in 2022 discounted at a discount rate of 8 %. Revenue and prot contributed from Microbiome Labs are not included in the consolidated income statement for 2020.On a pro forma basis, if the acquisition had been eective from January 1, 2020 Microbiome Labs would have contributed DKK ~250 million to revenue and an EBIT margin slightly lower than Novozymes’ EBIT margin. Transaction costs incurred in 2020 amounted to DKK 29 million and are included in Sales and distribution costs. Acquisition aer December 31, 2020 DKK million Microbiome Labs The assumed fair value of acquired assets and liabilities is as follows: Intangible assets excluding goodwill 718 Property, plant and equipment 8 Inventories 19 Trade and other receivables 14 Cash 13 Financial and other liabilities (46) Acquired net assets 726 Purchase price: Cash 757 Contingent consideration 338 Total purchase price 1,095 Goodwill 369 92Novozymes A/S Net working capital 4 ROIC NOPAT EBIT Tax NWC Invested capital excl. NWC Invested capital Net working capital DKK million Note 2020 2019 Inventories 4.1 2,361 2,613 Trade receivables 4.2 2,549 2,864 Contract assets 4.2 6 243 Other receivables 4.3 252 298 Assets held for sale 4.5 23 62 Trade payables (1,100) (1,117) Contract liabilities (67) (74) Other liabilities 4.4 (1,123) (1,411) Net working capital 2,901 3,478 Average net working capital 3,190 3,123 Accounts and performanceNotes 2,361 20.7% 3,190 Inventories reduced from DKK 2,613 million in 2019 to DKK million Net working capital as % of sales Average net working capital in DKK million 93Novozymes A/S 4.1 Inventories Net working capital Accounts and performanceNotes Inventories are measured at the lower of cost determined on a rst-in rst-out basis and net realizable value. The cost of Work in progress and Finished goods comprises direct production costs such as raw materials and consumables, energy and labor directly attributable to production as well as indirect production costs such as employee costs, maintenance and depreciation of plants, etc. If the expected selling price less any completion costs and costs to execute the sale (net realizable value) of inventories is lower than the carrying amount, inventories are written down to net realizable value. Novozymes has entered into a few agreements where Novozymes supplies goods to a customer’s premises but retains title to the inventory until the goods are consumed in the customer’s production. Such goods are derecognized from inventories in the period when they are consumed in the customer’s production. Work in progress and Finished goods are measured at cost, including indirect production costs. Indirect production costs capitalized under inventories amounted to DKK 811 million at December 31, 2020 (2019: DKK 907 million). Indirect production costs are assessed on an ongoing basis to ensure reliable measurement of employee costs, capacity utilization, cost drivers and other relevant factors. Changes in these parameters may have an impact on the gross margin and the overall valuation of Work in progress and Finished goods. ACCOUNTING POLICIES CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS DKK million 2020 2019 Raw materials and consumables 353 365 Work in progress 720 821 Finished goods 1,288 1,427 Inventories at December 31 B/S 2,361 2,613 Cost of materials, included under Cost of goods sold 3,248 3,510 Write-downs expensed during the year 109 110 Reversal of write-downs during the year 48 63 Part of the reversal of write-downs is attributable to written-down inventory being reused in production. Trade receivables Novozymes has collateral of DKK 5 million (2019: DKK 32 million) held as security for trade receivables in selected countries. Contract assets Contract assets amounted to DKK 6 millionat December 31, 2020 (2019: DKK 243 million), and mainly related to theestimated prot split arising from partnerships that Novozymes has entered into. In 2020, changes were made to the BioAg setup and the partnerships Novozymes has entered into within BioAg are no longer based on prot-split agreements. Contract assets related to BioAg at December 31, 2019 was DKK 209 million. The contract assets are initially recognizedas revenue when goods are delivered to the other contracting party. When therealized prot split is invoiced, the contract assets are reclassied to trade receivables. No allowance for expected credit losses had been made for contract assets at December 31, 2020 (2019: no allowance). 94Novozymes A/S 4.2 Trade receivables and contract assets Net working capital Accounts and performanceNotes Trade receivables and contract assets are measured at amortized cost less allowance for lifetime expected credit losses. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and days past due. Furthermore, an allowance for lifetime expected credit losses for trade receivables isrecognized on initial recognition. As the contract assets relate to the partnerships, the credit risk is based on an individual assessment. Trade receivables and contract assets are written o when all possible options have been exhausted and there is no reasonable expectation of recovery. The cost ofallowances for expected credit losses and write-osfor trade receivables andcontract assets are recognized in Sales and distribution costs. Theallowance for expected credit losses for trade receivablesand contract assets is based on historical credit loss experience combined with forward-looking information on macroeconomic factorsaecting the credit risk. The expected loss rates are updated at each reporting date. ACCOUNTING POLICIES CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS DKK million 2020 2019 Trade receivables, gross 2,712 3,022 Allowances (163) (158) Trade receivables at December 31 B/S 2,549 2,864 Aging of trade receivables, gross: Up to 30 days 2,516 2,807 Between 30 and 90 days 42 43 More than 90 days 154 172 Trade receivables, gross, at December 31 2,712 3,022 Changes in allowances for trade receivables: At January 1 158 162 Allowances during the year 19 15 Write-os during the year (3) (4) Reversed allowances (11) (15) Allowances at December 31 163 158 95Novozymes A/S DKK million 2020 2019 Employee costs payable 568 732 Stock-based payment settled in cash 15 16 Deferred income 22 30 Other payables 518 633 Other liabilities at December 31 B/S 1,123 1,411 Recognized in the balance sheet as follows: Current B/S 1,123 1,411 Other liabilities at December 31 1,123 1,411 4.3 Other receivables DKK million 2020 2019 Deposits 29 26 Prepaid expenses 107 102 Other 116 170 Other receivables at December 31 252 298 Recognized in the balance sheet as follows: Non-current B/S 40 29 Current B/S 212 269 Other receivables at December 31 252 298 4.4 Other liabilities Net working capital Accounts and performanceNotes Assets held for sale comprises buildings that are expected to be sold within the next 12 months. One building was sold in 2020, and an agreement to sell another building in 2021 was signed. 96Novozymes A/S 4.5 Assets held for sale Net working capital Accounts and performanceNotes Non-current assets are classied as assets held for sale when their carrying amounts are to be recovered principally through a sale transaction and a sale is considered highly probable. Such assets are stated at the lower of the carrying amount and fair value less costs to sell. ACCOUNTING POLICIES DKK million 2020 2019 Carrying amount of non-current assets held for sale: Land and buildings 23 62 Total B/S 23 62 97Novozymes A/S Capital structure and nancing 5 Capital structure and financing Net interest-bearing debt DKK million Note 2020 2019 Cash and cash equivalents (1,181) (711) Credit institutions 5.3 4,350 4,086 Transitional holiday accrual 5.3 180 58 Non-current lease liabilities 386 453 Current lease liabilities 136 163 Net interest-bearing debt (NIBD) at December 31 3,871 4,049 Accounts and performanceNotes 0.8x 24.9% 1,500 NIBD/EBITDA unchanged at Return on equity down from 27.5% to Novozymes bought back 4.3 million B shares under the stock buyback program at an aggregate transaction value of DKK million 98Novozymes A/S Due to the international nature of Novozymes’ operations, our earnings andnancial positionare exposed to a number of nancial risk factors. Financial risks are managed centrally for the entire Group. The Treasury Policy is approved by the Board of Directors, and sets the limits for the various nancial risks and the derivatives used to hedge risk. The Treasury Policy is adjusted on an ongoing basis to adapt to the market situation, and contains rules on which derivatives can be used for hedging, which counterparties can be used, and the risk prole that is to be applied. Currency risk Currency risk arises due to imbalances between income and costs in each individual currency and because Novozymes has more assets than liabilities in foreign currencies in connection with global operations. Hedging of currency risk is carried out in the currencies in which Novozymes has the largest exposure. Hedging is managed by entering into derivatives such as forward contracts, currency options and swaps. Loans and deposits in foreign currencies are also utilized for hedging purposes. Hedge eectiveness is assessed on a regular basis by comparing changes in the timing and value of the expected exposure in the relevant currencies with the timing and value changes for the designated cash ow hedging transaction. Where deemed appropriate, currency risk related to net investments in foreign subsidiaries is hedged by taking out loans and entering into swaps. Currently, there are noopen transactionsused to hedge equity investments. Foreign exchange sensitivity – 2020 The sensitivity analysis below shows the impact on net prot and other comprehensive income of a 5% change in DKK versus the key currencies to which Novozymes was exposed at December 31, 2020. For other comprehensive income, the analysis shows the impact on currency translation of net investments anddoes not include the impact of cash ow hedges, as these relate tofuture commercial transactions. The sensitivity analysis reects the transaction and translation risk, and assumes that the exchange rates change on December 31, 2020, while all other variables remain constant. The table shows the eect of an increase in exchange rates. A decrease in the exchange rates would have the opposite eect. Foreign exchange sensitivity – 2021 estimate Operating prot (EBIT) is exposed to exchange rate developments, as the eect of hedges is included in nancial income/costs. EBIT is mainly exposed to USD and EUR. A movement of 5% in the USD/DKK exchange rate would result in a change in the expected EBIT for 2021 of around DKK 130-160 million (2020: DKK 130-160 million). A 5% movement in the EUR/DKK exchange rate would result in a change in expected EBIT for 2021 of around DKK 200 million (2020: DKK 200 million). Of the expected USD cash ows for 2021, 88% have been hedged by forward contracts at an average rate of DKK 6.41 at the end of 2020. As a result, the impact on net prot from changes in the USD/DKK exchange rate has been reduced signicantly compared with the impact on EBIT. Foreign exchange analysis 2020 2019 DKKmillion Increase in exchange rates Change in net prot Change in other comprehensive income Change in net prot Change in other comprehensive income CHF 5.0% - 49 - 54 CNY 5.0% (3) 113 (4) 112 USD 5.0% (2) 227 (1) 250 Other 5.0% - 68 7 70 Total (5) 457 2 486 Capital structure and financing 5.1 Financial risk factors and risk management Accounts and performanceNotes 99Novozymes A/S Interest rate risk Interest rate risk arises in relation to interest- bearing assets and liabilities. In accordance with Novozymes’ Treasury Policy, a minimum of 30% of loans must be at xed interest rates. Hedging of the interest rate risk is managed by entering into xed-rate loans and interest rate swaps. With the current hedging of interest rate risk, an increase of one percentage point in the average interest rate on Novozymes’ net interest-bearing debt would have a negative eect on net prot of DKK 2 million (2019: negative eect of DKK 10 million). At December 31, 2020, 69% (2019: 59%) of the loan portfolio carried xed interest rates. No loans, credit facilities or other nancial instruments held by Novozymes are impacted by the IBOR reform. Credit risk Credit risk arises especially for cash and cash equivalents, derivatives, trade receivables and contract assets. The credit risk on trade receivables and contract assets is countered by thorough, regular analysis based on customer type, country and specic conditions. The credit risk on cash and cash equivalents as well as on derivatives is mitigated by the Treasury Policy, which limits exposure solely to counterparties that have an investment-grade credit rating. Credit risk is calculated on the basis of net market values and is governed by the Treasury Policy. Novozymes has entered into netting agreements (ISDA or similar) with all the banks used for trading in nancial instruments, which means that Novozymes’ credit risk is limited to net assets. At December 31, 2020, the Group considered its maximum credit risk to be DKK 4,021 million (2019: DKK 4,051 million), which is the total of the Group’s nancial assets. At December 31, 2020, the maximum credit risk related to a single counterparty was DKK 399 million (2019: DKK 279 million). Liquidity risk In connection with the Group’s ongoing nancing of operations, including renancing, eorts are made to ensure adequate and exible liquidity. This is guaranteed by using committed credit facilities and placing free funds in deposits, government bonds or ultra- liquid mortgage bonds in accordance with the Treasury Policy. At December 31, 2020, Novozymes’ nancial resources amounted to DKK 6,522 million (2019: DKK 4,174 million), consisting of net cash and cash equivalents, overdra facilities and undrawn committed credit facilities of DKK 5,344 million, which expire in 2021-2025. With the exception of debt to credit institutions, the maturity dates are primarily within 12 months. Capital structure Novozymes favors a conservative balance which is reected by a target for net interest- bearing debt of around 1x EBITDA. At December 31, 2020, the ratio was 0.8x and thus the capital structure is in line with the target. The capital structure is mainly managed using two instruments: 1) Dividend payments where Novozymes aims for a payout ratio of around 50%. For 2020, the payout ratio is expected to be 51.9% which is in line with the communicated target. 2) Stock buybacks, where a program of DKK 1,500 million was executed in 2020. A new program of up to DKK 1,500 million is planned for 2021. Capital structure and financing 5.1 Financial risk factors and risk management (continued) Accounts and performanceNotes 100Novozymes A/S 5.2 Financial income and Financial costs DKK million 2020 2019 Interest income 10 90 Gains on cash ow hedges 15 - Gains on fair value hedges 1 22 Financial income I/S 26 112 Interest costs (39) (58) Interest on lease liabilities (24) (28) Losses on cash ow hedges - (164) Other nancial costs (31) (29) Other foreign exchange losses, net (51) (63) Fair value adjustments of cash-settled stock options (8) (5) Financial costs I/S (153) (347) Financial income/(costs), net (127) (235) Capital structure and financing Accounts and performanceNotes Financial income and Financial costs comprise interest income and interest costs, realized and unrealized foreign exchange gains and losses, as well as fair value adjustments of cash-settled stock-based incentive programs, which are oset against Other liabilities and fair value adjustments of Other nancial assets. Total interest income and costs is measured at amortized cost for nancial assets and liabilities. Financial income and Financial costs also include fair value adjustments of derivatives used to hedge assets and liabilities, and income and costs relating to cash ow hedges that are transferred from Other comprehensive income on realization of the hedged item. ACCOUNTING POLICIES 101Novozymes A/S Liabilities arising from nancing activities 2020 2019 DKK million Credit institutions Lease liabilities Total Credit institutions Lease liabilities Total Liabilities from nancing activities at January 1 4,086 616 4,702 3,258 708 3,966 Financing cash ows 272 (111) 161 828 (108) 720 Foreign exchange adjustments (8) (30) (38) - 9 9 Other changes - 47 47 - 7 7 Total liabilities from nancing activities at December 31 4,350 522 4,872 4,086 616 4,702 * Other changes include changes in lease liabilities from new or terminated leases and accrued interest expenses which will be presented as operating cash ows in the statement of cash ows when paid. Credit institutions – currency 2020 (2019) DKK million • EUR 1,658 (1,719) • Other 2,692 (2,367) Creditinstitutions – timetomaturity2020(2019) DKK million • Lessthan1year 1,106 (1,380) • Between1and5years 1,912 (1,477) • Morethan5years 1,332 (1,229) Loan portfolio – xed or oating interest rate 2020 (2019) DKK million • Fixedinterestrate 2,995 (2,396) • Floatinginterestrate1,355 (1,690) 5.3 Other nancial liabilities Capital structure and financing Accounts and performanceNotes DKK million 2020 2019 Credit institutions 4,350 4,086 Derivatives 33 42 Transitional holiday accrual 180 58 Other nancial liabilities at December 31 4,563 4,186 Recognized in the balance sheet as follows: Non-current B/S 3,254 2,775 Current B/S 1,309 1,411 Other nancial liabilities at December 31 4,563 4,186 102Novozymes A/S 5.4 Derivatives – hedge accounting Fair value hedges The table below shows the derivatives the Group has contracted in order to hedge currency exposure on nancial assets and liabilities that give rise to currency adjustments in the income statement. 2020 2019 DKK million Contract amount based on agreed rates Fairvalue Dec.31 Contract amount based on agreed rates Fairvalue Dec.31 Forward exchange contracts CAD (57) - (25) - CHF (1,071) (9) (1,153) 9 USD (649) (13) (333) - INR 364 4 371 - Other (3) (2) (21) (2) Fair value hedges at December 31 (1,416) (20) (1,161) 7 * Positive contract amounts represent a sale of the respective currency, and negative amounts represent a purchase. Capital structure and financing Accounts and performanceNotes The forward exchange contracts fall due in the period January 2021 to July 2021 (2019: January 2020 to June 2020). The fair value hedges were 100% eective, as thegain on forward exchange contracts was DKK 1 million (2019: gain of DKK 22 million), compared with a loss on hedged items of DKK 1 million (2019: loss of DKK 22 million). Hedge accounting consists of positive and negative fair values of derivatives, which are recognizedin the balance sheet under Other nancial assets and Other nancial liabilities respectively. Derivatives used for fair value hedges are measured at fair value on the reportingdate, and value adjustments are recognized as Financial income or Financial costs. Derivatives used for cash ow hedges and hedges of net investments in subsidiaries are measured at fair value at the reporting date, and value adjustments are recognized in Other comprehensive income. Income and costs relating to cash ow hedges and hedges of net investments in subsidiaries are transferred from Other comprehensive income on realization of the hedged item and are recognized as Financial income or Financial costs. Derivatives are recognized at the transaction date. ACCOUNTING POLICIES 103Novozymes A/S 5.4 Derivatives – hedge accounting (continued) Cash ow hedges The table below shows the derivatives that the Group has contracted to hedge currency and interest rate exposure in future cash ows. 2020 2019 DKK million Contract amount based on agreed rates Fair value Dec. 31 Contract amount based on agreed rates Fair value Dec. 31 Forward exchange contracts USD 2,020 114 1,764 (24) 2,020 114 1,764 (24) Interest rate swaps DKK/DKK – pays xed rate of (0.1075%) / earns variable rate of (0.22%) (2019: (0.3933%)) 400 1 400 1 DKK/DKK – pays xed rate of 0.595% / earns variable rate of (0.13%) (2019: (0.27%)) 382 (9) 451 (11) 782 (8) 851 (10) Cash ow hedges at December 31 2,802 106 2,615 (34) * Positive contract amounts represent a sale of the respective currency, and negative amounts represent a purchase. Capital structure and financing Accounts and performanceNotes The forward exchange contracts fall due in the period January 2021 to December 2021 (2019: January 2020 toDecember 2020), and the swaps fall due in May 2026 and December 2026 (2019: May 2026 and December 2026). At the end of 2020, the Group had hedged 88% of expected future cash ows in USD for 2021 at an average rate of DKK 6.41 (2019: 75% of expected future cash ows in USD for 2020 at an average rate of DKK 6.53). 104Novozymes A/S 5.5 Common stock and treasury stock Each A share entitles the holder to 20 votes, while each B share entitles the holder to two votes. Each year, the Board of Directors assesses whether the ownership structure with A and B common stock is optimal. The Board of Directors maintains that this is the best way to safeguard Novozymes’ long-term development to the benet of the company’s shareholders and other stakeholders. Treasury stock is used to reduce the common stock and to hedge employees’ exercise of granted stock awards and stock options. In 2020, Novozymes canceled 6 million treasury shares, reducing the common stock to 285 million shares. 2020 2019 No. Nominal value DKK million No. Nominal value DKK million Common stock A common stock (shares of DKK 2) 53,743,600 107 53,743,600 107 B common stock (shares of DKK 2) 231,256,400 463 237,256,400 475 Common stock at December 31 B/S 285,000,000 570 291,000,000 582 Treasury stock - B stock Treasury stock at January 1 9,663,317 19 9,405,806 19 Additions during the year 4,278,090 9 6,591,413 13 Disposals during the year (2,266,809) (5) (333,902) (1) Cancellation of common stock (6,000,000) (12) (6,000,000) (12) Treasury stock at December 31 5,674,598 11 9,663,317 19 No. 2020 2019 Shares of common stock in circulation Shares of stock at January 1 281,336,683 287,594,194 Purchase of treasury stock (4,278,090) (6,591,413) Sale of treasury stock 2,266,809 333,902 Shares of common stock in circulation at December 31 279,325,402 281,336,683 Treasurystock2019 % of common stock Treasurystock2020 % of common stock Capital structure and financing Accounts and performanceNotes 105Novozymes A/S 5.6 Financial assets and liabilities by category The table below shows the Group’s nancial assets and nancial liabilities at December 31 by category. DKK million Note 2020 2019 Trade receivables 4.2 2,549 2,864 Contract assets 4.2 6 243 Other receivables, excl. prepaid expenses 4.3 145 196 Cash and cash equivalents 1,181 711 Financial assets at amortized cost 3,881 4,014 Other nancial assets 21 22 Fair value through prot and loss 21 22 Derivatives 119 15 Fair value through other comprehensive income 119 15 Financial assets 4,021 4,051 Lease liabilities 5.3 (522) (616) Credit institutions 5.3 (4,350) (4,086) Trade payables (1,100) (1,117) Transitional holiday accrual 5.3 (180) (58) Other payables 4.4 (518) (633) Financial liabilities at amortized cost (6,670) (6,510) Contingent consideration 3.5 (146) - Fair value through prot and loss (146) - Derivatives 5.3 (33) (42) Fair value through other comprehensive income (33) (42) Financial liabilities (6,849) (6,552) Capital structure and financing Accounts and performanceNotes Measurement and fair value hierarchy All nancial assets and liabilities, except for derivatives and other nancial assets, are measured at amortizedcost. The carrying amounts for these approximate fair value. Derivatives are measured at fair value based on observable data (level 2 input) according to the fair valuehierarchy. The derivatives are nottraded on an active market based on quoted prices, but areindividual contracts. The fair value of these assets is determinedusing valuation techniques that utilize market-based data such asexchange rates, interest rates, credit risk and volatilities.Other nancial assets and contingent considerations are measured at fair value based on non- observable data (level 3 input).There are no nancial instruments measured at fair value on the basis of quoted prices (level 1 input). 106Novozymes A/S Other nancial notes This section contains other statutory disclosures not related to the previous sections. 6 Other financial notes Accounts and performanceNotes 46 1.0 83 No. of Danish and foreign subsidiaries in the Group following the acquisition of PrecisionBiotics Group Realized Group audit fee ratio during 2020 Grant date fair value of options granted in 2020 in DKK million 107Novozymes A/S 6.1 Management remuneration General guidelines for the remuneration of the Board of Directors and the Executive Leadership Team of Novozymes A/S, as assessed by the Board of Directors in accordance with the recommendations of the Nomination and Remuneration Committee, are approved at the Annual Shareholders’ Meeting. A summary of the Management remuneration can be found in the Governance section of the annual report. Executive Leadership Team Remuneration of the Executive Leadership Team comprises a base salary, pension contribution, a cash bonus (short-term incentive program), stock-based incentive programs (long-term incentive programs) and other benets (car, telephone, etc.). The variable components of the total remuneration (cash bonus and stock-based incentive programs) are relatively high compared with the base salary and is subject to the achievement of individual targets and Novozymes’ targets for nancial, social and environmental performance. The annual cash bonus cannot exceed 9.5 months’ xed base salary, of which 65% is expected to be payable at target performance. The stock-based incentive programs are described in Note 6.2. Members of the Executive Leadership Team have contracts ofemployment containing standard conditions for executive ocers of Danish listed companies, including the periods of notice that both parties are required to give and noncompetition clauses. If an executive ocer’s contract of employment is terminated by the company without any misconduct on the part of the executive ocer, the executive ocer has a notice period of 12 months. In addition to the notice period, the executive ocer has a right to termination compensation of 12 months’ base salary and pension contributions. However, executive ocers appointed before 2016 had a right to compensation of up to two years’ base salary and pension contributions. Board of Directors The remuneration of the Board of Directors comprises a xed fee and is not based on incentives. Changes to the Executive Leadership Team On February 1, 2020, Ester Baiget joined Novozymes as new Chief Executive Ocer. Ester Baiget replaced CEO Peder Holk Nielsen, who le Novozymes at the end of January 2020. Peder Holk Nielsen’s severance package was fully expensed in 2019. In September 2020, Novozymes announced a change to the organizational structure. As part of the re-organization, Graziela Chaluppe dos Santos Malucelli and Claus Crone Fuglsang joined the Executive Leadership Team, whileAndrew Fordyce, former Executive Vice President, Food & Beverages le Novozymes, and Thomas Videbæk, Executive Vice President and COO, will leave the company during 2021. Thomas Videbæk will act as interim EVP for People & Organization, Sustainability and Branding, as well as EVP Strategy & Business Transformation. The severance packages of Andrew Fordyce and Thomas Videbæk, totaling DKK 61 million, were fully expensed in 2020. The severance packages consist of salary and bonuses during the notice period (12 months) as well as termination compensation (18 and 24 months respectively), and compensation for not being part of a stock-based incentive program in 2020-21. Furthermore, the remaining value of awarded stock and stock options (DKK 4 million) has been expensed. Other financial notes Accounts and performanceNotes 2020 2019 Executive Leadership Team Executive Leadership Team DKK million Board of Directors Registered Non-registered Total Board of Directors Registered Non-registered Total Salaries and other short-term benets 8 21 18 47 7 20 14 41 Dened contribution plans - 2 2 4 - 5 3 8 Cash bonus - 12 7 19 - 2 1 3 Expensed stock-based incentive programs - 6 9 15 - 7 4 11 Total remuneration 8 41 36 85 7 34 22 63 Compensation for lost incentives 5 - 5 - - - Severance cost 37 28 65 58 - 58 Additional payments 42 28 70 58 - 58 No. of members at December 31 10 3 4 8 3 3 108Novozymes A/S Novozymes has established stock-based incentive programs for the Executive Leadership Team, vice presidents, directors, and other employees. The purpose of these programs is to ensure an alignment of interests of the Management, employees and shareholders. Allocation of programs has been, and remains, dependent on prot, value- creation and, in some cases, sustainability targets being achieved. The exercise price and the share price of a stock option are identical at the date of grant. A new incentive program for the Executive Leadership Team was established in 2020, covering the performance period 2020-2022. The program is a combination of stock options and stock, with half of the incentive program allocated in stock options and half in stock. The total number of stock options and stock achievable is divided into two categories: ‘target stock options and target stock’ and ‘extra stock options and extra stock’. The target stock options, and target stock correspond to 65% of the maximum stock options and stock, and extra stock options and extra stock correspond to 35% of the maximum stock options and stock. Compared to previous programs the targets reect an increased weight on organic sales growth (40%), an explicit and increased weight on sustainability targets (20%) and a reduced but still prominent weight on Economic Prot (40%). The targets are aligned with the updated strategy and the business measures for the period 2020-2022. • If Novozymes reaches the mid-term targets for 2020-2022 for sales growth and economic prot and on all four measures for the sustainability targets, then the target stock options and the target stock will be granted. Extra stock options and extra stocks will not be granted. • If Novozymes manages to outperform compared to the mid-term targets, some or all of the extra stock options and extra stock may be granted. • If Novozymes does not meet the mid-term targets for 2020-2022, then none or only part of the target stock options and target stock will be granted. The program contains a maximum-value clause, allowing the Board of Directors to choose to limit the total allocation of stock options and stock if the intrinsic value of the program exceeds twice the annual conditional grant. The total target-level fair value of the program at the date of grant was approximately DKK 40 million. The value of the stock will be expensed over the three-year qualifying period (2020- 2022) and will be released in 2023. The stock options have a vesting period of four years, followed by an exercise period of ve years. The fair value of the stock options will be expensed over the four-year vesting period. Furthermore, a new program was established in 2020 for vice presidents and directors covering the performance period 2020-2022 (195 vice presidents and directors). The total target level fair value at grant date was DKK 55 million and based on the same requirements and targets as for the Executive Leadership Team. The program is a combination of stock options and stock, with half of the incentive program allocated in stock and half in stock options. The stock options have a four-year vesting period, while the stock will be released in 2023. The program contains a maximum-value clause, allowing the Executive Leadership Team to choose to limit the total allocation of stock and stock options if the intrinsic value of the program exceeds twice the annual conditional grant. For other employees, a new stock option-based incentive program was established in 2020 covering the performance period 2020-2022. The employee program follows the same requirements and targets as the program for the Executive Leadership Team and the program for vice presidents and directors. The Executive Leadership Team and other senior management, who are already included in an existing incentive program, are excluded from this new program. In total, approximately 5,700 employees will be covered by the program. The awarded stock options have a vesting period of four years, aer which there is an exercise period of ve years. The target level value of the program is approximately DKK 40 million. In previous years, stock option programs were established for all or selected groups of employees, conferring the right to purchase one share per stock option. Allocations were made based on each individual employee’s base salary and the achievement of a series of business targets – both nancial and nonnancial – set by the Board of Directors for each year. The stock options have a vesting period of three to four years, followed by an exercise period of ve years. In order to exercise the options, the employee must still be employed at the exercise date. This does not apply to persons who have retired, taken voluntary early retirement or been given notice. Other financial notes 6.2 Stock-based payment Accounts and performanceNotes 109Novozymes A/S 6.2 Stock-based payment (continued) Stock options The number of outstanding options (excl. stock awards) has developed as follows: Number of options DKK DKK million Executive Leadership Team Vice presidents and directors Other employees Total Avg. exercise price per option Grant date fair value per option Grant date fair value total OutstandingatJanuary1, 2020 1,882,907 3,902,302 1,756,819 7,542,028 267 Change in Management (874,904) 874,904 - - Granted 1 269,942 553,482 877,336 1,700,760 351 49 83 Exercised 2 (280,434) (1,218,182) (568,307) (2,066,923) 260 Forfeited - (21,400) (1,948) (23,348) 276 Expired - - (9,246) (9,246) 279 OutstandingatDecember31, 2020 997,511 4,091,106 2,054,654 7,143,271 289 OutstandingatJanuary1, 2019 1,934,249 4,165,211 1,871,253 7,970,713 266 Granted (62,626) 62,626 - - Allocation adjustment 602,535 1,102,730 - 1,705,265 275 40 69 Exercised (591,251) (1,131,136) - (1,722,387) 275 Forfeited - (269,842) (78,703) (348,545) 227 Expired - (27,287) (35,731) (63,018) 277 OutstandingatDecember31, 2019 1,882,907 3,902,302 1,756,819 7,542,028 267 Number of exercisable options at December 31, 2020 2,936,359 266 Number of exercisable options at December 31, 2019 3,215,513 258 1. The allocation of stock options for 2020-2022 will be adjusted in January 2023 based on the cumulative level of target achievement for the period. 2. The weighted average share price for stock options exercised during 2020 was DKK369 (2019: DKK 316). Other financial notes Accounts and performanceNotes 2020 2019 Remaining term to maturity of up to ve years Remaining term to maturity of over ve years Total Remaining term to maturity of up to ve years Remaining term to maturity of over ve years Total Stock options outstanding No. 3,727,217 3,416,054 7,143,271 5,015,210 2,526,818 7,542,028 Weighted average term to maturity Years 3 7 5 4 7 5 Range of exercise prices DKK 178-317 275-351 178-351 160-317 249-335 160-335 Average exercise price DKK 263 318 289 264 275 267 110Novozymes A/S 6.2 Stock-based payment (continued) During 2020, DKK 54 million arising from stock-based payment was recognized in the income statement (2019: DKK 46 million), DKK 53 million of which was from equity-settled programs (2019: DKK 45 million) and DKK 1 million was from cash-settled programs (2019: DKK 1 million). Most programs are equity settled, and no liability is recognized for these. If allocations under the programs are made in countries where ownership of foreign stock is not permitted, the value of stock options is settled in cash instead, and a liability of DKK 15 million was recognized for this in 2020 (2019: DKK 16 million). The intrinsic value of exercisable cash-settled programs in 2020 was DKK 13 million (2019: DKK 14 million). The fair value of employee services received is measured with reference to the fair value of the equity instruments granted. Fair value at grant date is measured in accordance with the Black–Scholes model, using the average exercise price, the option term and the following signicant assumptions: 2020 2019 Expected future dividends per share DKK 39.6 37.4 Volatility % 22.1 23.2 Annual risk-free interest rate % (0.6) 0.0 Weighted average share price at grant date DKK 351 275 Other financial notes Accounts and performanceNotes Furthermore, the options are assumed to be exercised two years aer the vesting period, on average, or at the option’s expiry date if this is within one year. Volatility is estimated using the historical volatility over the last three years. The risk-free interest rate is based on Danish government bonds with a maturity equivalent to the option’s term to maturity. Stock awards The stock allocated under the three-year programs is stock awards. The majority of the stocks was allocated in 2017. In 2020, 108,242 stock awards with a fair value of DKK 38 million were granted to new employees enrolled in the programs (2019: DKK 3 million). The total number of outstanding stock awards at December 31, 2020 was 108,242 (2019: 307,262). The fair value of these at December 31, 2020 was DKK 38 million (2019: DKK 100 million), which will be expensed over the three- year period (2020-2022). The Group has established stock-based incentive programs comprising equity- settled and cash-settled programs. The fair value of the employee services received in exchange for the grant of stock options and stock awards is measured with reference to the fair value of the stock options and stock awards granted. The fair value is measured using the Black–Scholes option-pricing model. The fair value of stock-based payment at the grant date is recognized as an employee cost over the period in which the stock optionsvest. In measuring the fair value, account is taken of the number of employees expected to gain entitlement to the options as well as the number of options the employees are expected to gain. This estimate is adjusted at the end of each reporting period such that only the number of options to which employees are entitled or expected to be entitled is recognized. The value of equity-settled programs is recognized in Shareholders’ equity. The value of cash-settled programs, which are recognized as Other liabilities, is adjusted to fair value at the end of each reporting period, and the subsequent adjustment is recognized in the income statement under Financial income or Financial costs. ACCOUNTING POLICIES 111Novozymes A/S 6.3 Commitments and contingencies Pending litigation and arbitration Novozymes is engaged in certain legal cases. The Board of Directors and Management believe that settlement or continuation of these cases will not have a signicant eect on the Group’s nancial position. A liability is recognized under Provisions where the risk of a loss on a legal case is considered more likely than not. Contract conditions Several of the partnership contracts to which Novozymes is a party may be terminated by the other party in the event of signicant changes in ownership or control of Novozymes. Furthermore, a few contracts contain provisions that restrict Novozymes’ licenses from using specic forms of technology in such situations. Novozymes is committed to increasing production capacity in Latin America if a specic customer reaches certain milestones. The amount required to meet this commitment cannot be estimated reliably at the moment. DKKmillion 2020 2019 Other commitments Contractual obligations to third parties relating to property, plant and equipment 272 200 Other guarantees Other guarantees and commitments to related companies 21 27 Other guarantees and commitments 293 242 Other financial notes Accounts and performanceNotes Novozymes A/S is controlled by Novo Holdings A/S, domiciled in Hellerup, Denmark, which holds 72.4% of the votes in Novozymes A/S. The remaining stock is widely held. The ultimate parent of the Group is the Novo Nordisk Foundation (incorporated in Denmark). In 2020, Novozymes purchased from Novo Holding 1,530,000 of its own B shares with the approval of the Board of Directors, at a price Related parties are considered to be Novo Holdings A/S and the Novo Nordisk Foundation, and the Board of Directors and Executive Management of these entities together with their immediate families. Other related parties are considered to be the Novo Nordisk Foundation’s subsidiaries and associates, such as the Novo Nordisk of DKK 537 million (2019: 1,530,000 B shares at a price of DKK 475 million). The transactions were based on the market price. Group, the NNIT Group and the Chr. Hansen Group, associates of Novozymes A/S, such as Microbiogen Pty. Ltd., as well as the Board of Directors and Executive Leadership Team of Novozymes A/S together with their immediate families. Related parties also include companies where the above persons have control or joint control. There were no transactions with related parties other than the transactions described and normal remuneration of the Board of Directors and Executive Leadership Team, which is presented in Note 6.1. All agreements relating to these transactions are based on market price (arm’s length). The majority of the agreements are renegotiated regularly. The Group had the following transactions with related parties: Rental commitments to related parties at December 31, 2020 amounted to DKK 13 million, compared with DKK 14 million at December 31, 2019. 112Novozymes A/S 6.4 Related party transactions Other financial notes Accounts and performanceNotes DKK million 2020 2019 DKK million 2020 2019 Novo Holdings A/S Novo Holdings A/S Sale of services 1 - Receivables - - The Novo Nordisk Group The Novo Nordisk Group Sale of goods and materials - 26 Receivables 8 9 Sale of services 72 77 Payables (85) (98) Purchase of goods and materials (79) (64) Purchase of services (35) (68) The NNIT Group The NNIT Group Purchase of services (43) (27) Payables (14) (7) The Chr. Hansen Group The Chr. Hansen Group Sale of goods and materials 69 53 Receivables - 11 Purchase of services (3) (9) Microbiogen Pty. Ltd. Microbiogen Pty. Ltd. Purchase of services (30) (15) Payables (7) (4) 113Novozymes A/S 6.5 Fees to statutory auditors Audit fee policy It is Novozymes’ policy that the annual fee for nonaudit servicesprovided by the statutory auditors should not exceed the annual fee for statutory audit services measured at Group level. The Group audit fee ratio may onlyexceed 1withthe approval of the Audit Committee. No such approvals were given in 2020 or 2019. Implementation of the EU audit reform has led to restrictions on the nonaudit services that the auditors elected at the Annual Shareholders’ Meeting may perform. The fee for nonaudit services performed for Novozymes by PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab is DKK 3 million (2019: DKK 2 million) and does not exceed the 70% CAP. The services comprise audit of project accounts, tax advisory services concerning transfer pricing, M&A support and other general nancial reporting and tax consultancy. An insignicant service were performed in relation to local reporting assistance in a subsidiary. DKK million 2020 2019 Statutory audit 9 8 Other assurance engagements - - Tax assurance services 6 4 Other services 3 1 Fees to statutory auditors 18 13 Group audit fee ratio 1.0 0.6 Other financial notes Accounts and performanceNotes 114Novozymes A/S 6.6 Cash ow DKK million Note 2020 2019 Non-cash items Accrued interest income and interest costs 53 (3) (Gain)/loss on nancial assets, etc., net 9 5 Depreciation, amortization and impairment losses 3.1, 3.2 1,266 1,182 Realized loss and allowances for doubtful trade receivables 20 (1) Financial (gain)/loss on sale and disposal of assets - 50 Unrealized foreign exchange (gain)/loss 31 10 Tax 2.6 695 644 Stock-based payment 6.2 54 46 Change in provisions 8 (88) Termination of The BioAg Alliance - (335) Divestment of the pharma-related royalty (42) (194) Transitional holiday accrual 122 - Prot/loss in associates 4 5 Non-cash items 2,220 1,321 Business acquisitions, divestments and purchases of nancial assets Acquisition of PrecisionBiotics Group 3.5 (588) - Divestment of the pharma-related royalty - 430 Cash ow from acquisitions, net (588) 430 Additions of intangible assets 3.1 146 230 Intellectual property transferred from The BioAg Alliance 3.1 - (95) Purchase of intangible assets 146 135 Additions of property, plant and equipment 3.2 852 909 Less additions to lease assets 3.3 (58) (47) Purchase of property, plant and equipment 794 862 Undrawn committed credit facilities were DKK 5,344 million at December 31, 2020 (2019: DKK 3,758 million), all of which expire in 2021-2025. Other financial notes Accounts and performanceNotes The consolidated statement of cash ows, which is compiled using the indirect method, shows cash ows from operating, investing and nancing activities, and the Group’s cash and cashequivalents at the beginning and end of the year. Cash ow from operating activities comprises net prot adjustedfor non- cash items, paid nancial items, corporate income tax paid and change in working capital. Cash ow from investingactivities comprises payments relating to the acquisition andsale of companies and non- controlling interests, intangibleassets, and property, plant and equipment. Cash ow from nancing activities comprises proceeds fromborrowings, repayment of principal on interest-bearing debt, repayment of lease liabilities, payment of dividends, proceeds from stock issues, and the sale of treasury stock and other securities. Cash and cash equivalents comprises cash at bank and in handless current bank loans due on demand. ACCOUNTING POLICIES 115Novozymes A/S 6.8 Group companies On January 7, 2021, Novozymes acquired all voting shares in Microbiome Labs. Reference is made to Note 3.5 for more details. No other events have occurred aer the reporting date of importance to the consolidated nancial statements. ISO 14001-certied sites. All major companies are also ISO 9001 certied. Production Sales and marketing Research and development Holding companies, etc. Activity Percentage of shares owned Activity Percentage of shares owned Parent Company Novozymes Deutschland GmbH, Germany 100 Novozymes A/S, Denmark Novozymes Hong Kong Ltd., Hong Kong 100 Novozymes South Asia Pvt. Ltd., India 100 Subsidiaries PrecisionBiotics Group Ltd., Ireland 100 Novozymes BioAg S.A., Argentina 100 PrecisionBiotics Ltd., Ireland 100 Novozymes Australia Pty. Ltd., Australia 100 Novozymes Italia S.r.l., Italy 100 Novozymes Belgium BV, Belgium 100 Novozymes Japan Ltd., Japan 100 Novozymes Latin America Ltda., Brazil 100 Novozymes Kenya Ltd., Kenya 100 Novozymes BioAg Productos Para Agricultura Ltda., Brazil 100 Novozymes Malaysia Sdn. Bhd., Malaysia 100 6.7 Events aer the reporting date Other financial notes Accounts and performanceNotes 116Novozymes A/S Activity Percentage of shares owned Activity Percentage of shares owned Novozymes BioAg Limited, Canada 100 Novozymes Mexicana, S.A. de C.V., Mexico 100 Novozymes Canada Limited, Canada 100 Novozymes Mexico, S.A. de C.V., Mexico 100 Novozymes (China) Biotechnology Co. Ltd., China 100 Novozymes Nederland B.V., Netherlands 100 Novozymes (China) Investment Co. Ltd., China 100 Novozymes RUS LLC, Russia 100 Novozymes (Shenyang) Biologicals Co. Ltd., China 100 Novozymes Singapore Pte. Ltd., Singapore 100 Suzhou Hongda Enzyme Co. Ltd., China 96 Novozymes South Africa (Pty) Ltd., South Africa 100 Novozymes Bioindustrial A/S, Denmark 100 Novozymes Korea Limited, South Korea 100 Novozymes Bioindustrial China A/S, Denmark 100 Novozymes Spain S.A., Spain 100 Novozymes Biopharma DK A/S, Denmark 100 Novozymes Sweden AB, Sweden 100 Novozymes BioAg A/S, Denmark 100 Novozymes Switzerland AG, Switzerland 100 Novozymes France S.A.S., France 100 Novozymes Switzerland Holding AG, Switzerland 100 Novozymes Berlin GmbH, Germany 100 Novozymes (Thailand) Ltd., Thailand 100 Novozymes EnzimDis Ticaret Ltd. Sirketi, Turkey 100 Novozymes UK Ltd.,, UK 100 Joint operations/associates Novozymes BioAg, Inc., USA 100 Grundejerforeningen Smørmosen, Denmark Novozymes Biologicals, Inc., USA 100 Grundejerforeningen Hallas Park, Denmark Novozymes Blair, Inc., USA 100 Microbiogen PTY Ltd., Australia 23.10 Novozymes, Inc., USA 100 Tecnol s.r.l. in liqudiazione (formerly Beta Renewables S.p.A.), Italy 9.95 Novozymes North America, Inc., USA 100 MagnaBioAnalytics LLC, USA 19.35 Novozymes US, Inc., USA 100 * Owned directly by Novozymes A/S. ** Novozymes A/S has guaranteed the liabilities of Novozymes UK Limited (company number: 1328873) in order that it qualify for the exemption from preparing individual nancial statements under Section 479A of the Companies Act 2006 in respect of the year ended December 31, 2020. 6.8 Group companies (continued) Other financial notes Accounts and performanceNotes 117Novozymes A/S Environmental data We measure our performance in areas where we believe we have signicant impact on the environment. Monitoring our environmental data is key to measuring progress against the ambitious goals we have adopted. We have a high focus on reducing CO2 emissions from our own operations and on being more circular in the use of natural resources by reducing our footprint in other environmental areas like water, energy, waste and biodiversity. 7 Environmental data Accounts and performanceNotes 97% 45,000 43% Percentage of biomass waste handled in a circular set-up m 3 of water saved due to water eciency projects Renewable energy share of total energy consumption 118Novozymes A/S Novozymes’ solutions enable our customers and end users to reduce their CO 2 emissions through the application of our products, and climate action is an integral part of our business strategy. Climate change also impacts Novozymes’ supply chain as well as operations, and it is important we address related risks through appropriate measures. Our approach Novozymes has established an ambitious climate strategy that drives our approach to addressing climate-change-related impacts across our value chain. The Operations, Supply & Quality function and the Global Sustainability department are responsible for driving the climate change action agenda both within and outside Novozymes. Climate change poses multiple risks, transitional as well as physical, to our business and we have set up an internal process to manage key climate-related risks. In addition to our full disclosure to CDP climate change, we strongly support the recommendations of the Task Force on Climate Related Financial Disclosures (TCFD) and are in the process of its implementation. Novozymes’ approach to making its operations less carbon intensive is based on two levers: implementing various energy eciency projects and increasing the share of renewable energy consumption. Our eorts to reduce operational CO 2 emissions are driven by our science-based targets. We have committed to reduce our absolute Scope 1 & 2 CO 2 emissions by 50% by 2030 (relative to 2018) on our way to becoming carbon neutral by 2050. We have also committed to reduce absolute Scope 3 CO 2 emissions from the purchased goods and services category by 15% by 2030 (relative to 2018). To drive performance towards these commitments, we have set mid-term targets (2020-2022) for reducing absolute CO 2 emissions from operations by 40% by 2022 (relative to 2018). We have also dened annual internal targets to guide implementation. Many Novozymes solutions enable our customers to reduce CO 2 emissions from their products. Novozymes has committed to help the world limit global warming increase to 1.5 o C by saving 60 million tons of CO 2 by enabling low-carbon fuels in the transport sector in 2022. Novozymes conducts peer-reviewed cradle- to-grave life cycle assessment (LCA) studies to document the environmental impact of our solutions. These studies are used to keep our stakeholders informed and to demonstrate to our customers ways to reduce their CO 2 emissions and leverage the positive impact on climate change made possible by Novozymes’ solutions. To learn more, please nd our approach to LCA at Novozymes.com. Also, Novozymes continues to support global climate action, including through responsible public advocacy and partnerships. In many geographies, Novozymes actively supports policies to promote the use of sustainable, low- carbon fuels. See our position paper on climate change at Novozymes.com Environmental data 7.1 Climate change Accounts and performanceNotes Reported CO 2 emissions comprise scope 1, scope 2 and emissions from outbound transport of products. CO 2 from internally generated energy (scope 1) is calculated based on the amount of fuel consumed, using local emission factors. CO 2 from externally generated energy (scope 2) is reported in accordance with both the market-based and the location-based methods, as dened by the Greenhouse Gas (GHG) Protocol. The location-based method assumes zero CO 2 emissions from sourced renewable energy and uses CO 2 factors from International Energy Agency (IEA) for non-renewable energy. The market-based method uses CO 2 factors from IEA. Transport-related CO 2 emissions (scope 3) are calculated based on principles described in the GHG Protocol. Reported quantities comprise CO 2 emissions related to transport from all primary enzyme production sites to customers where Novozymes pays for the freight. Transport between production sites is also included. Transport of raw materials to a production site is not included. CO 2 emissions generated at external warehouses are not included. Emissions data are calculated based on distance and emission factors from the GHG Protocol. The environmental impact potentials for global warming and ozone layer depletion are calculated on the basis of data published by the US Environmental Protection Agency (EPA) and the Montreal Protocol published by the United Nations Environment Programme (UNEP). ACCOUNTING POLICIES 119Novozymes A/S 2020 highlights In 2020, CO 2 emissions (scope 1 + 2 only) from our operations decreased by 29% to 234,000 tons from 330,000 tons in 2019. We also achieved a 46% reduction of our absolute emissions (scope 1 + 2) compared to our 2018 baseline, allowing us to achieve our 2022 target well in advance. Apart from the transition to renewable electricity and green steam at some of our sites, this reduction was also inuenced by lower capacity utilization of our high impact sites in China and North America, as a result of the COVID-19 pandemic. We have decided not to revise our 2022 target yet as we expect production levels to normalize. A breakdown of the operational emissions is provided in the table. We began to implement our scope 3 target to reduce our absolute CO 2 emissions from purchased goods and services. We are exploring multiple levers to achieve our target such as substitution to less CO 2 intensive materials, and engaging with our suppliers to drive emission reduction. In 2020, we developed an accounting methodology for our scope 3 target, and have also begun to engage with key suppliers on this. Novozymes solutions in bioenergy helped the transport sector save 49 million tons of CO 2 in 2020 by enabling the production of low carbon fuels. Going forward, we will continue to explore renewable energy opportunities for our larger sites in North America and China. We will also work on our scope 3 target by driving supplier engagement and developing emission reduction plans. Finally, we will continue to invest in energy eciency and waste-to-energy opportunities. Environmental data Five -yearoperational emissions(CO 2 -eqv.) 1,000 tons • Scope 2 • Scope 1 7.1 Climate change (continued) Accounts and performanceNotes CO 2 -equivalent emissions 1,000 tons 2020 2019 Natural gas 33 35 Gas oil, light fuel oil and diesel oil 4 4 HCFCs 0 1 Scope 1 37 40 District heat 2 11 Electricity 148 203 Steam 47 76 Scope 2 (market-based) 197 290 Scope 1 and 2, Total 234 330 Ship 4 6 Truck 20 17 Air freight 10 12 Scope 3 34 35 Emissions, total ESG 268 365 Market-based vs. location-based scope 2 emissions 1,000 tons 2020 2019 Scope 2 CO 2 emissions (market-based) 197 290 Scope 2 CO 2 emissions (location-based) 445 415 120Novozymes A/S Energy is material to Novozymes across the value chain, as our operations depend on steam and electricity, while many of our biosolutions enable downstream users to save energy in certain applications (e.g. in laundry and dishwashing detergents and textile applications) compared with conventional methods. Furthermore, our bioenergy solutions enable the development of low-carbon fuels for transportation, which represents a signicant share of the global energy mix. Our approach We manage energy in our operations through a two-pronged approach: reducing energy use in production by implementing optimization or energy-saving projects and increasing the sourcing of renewable energy. Relevant targets drive our performance in these areas. Novozymes’ Supply Operations and Sourcing departments manage and monitor all energy eciency and renewable energy-sourcing eorts, and through the RE100 initiative have committed to source 100% renewable electricity by 2030. We also have internal annual targets that guide our progress towards our 2030 target. 2020 highlights In 2020, projects driving process optimization and energy eciency undertaken at our sites throughout the year resulted in energy savings of 33,000 GJ. The savings originated from many projects, including the replacement of pumps, optimization of ventilation, improved monitoring enabling optimization of energy consumption, etc. On top of the internal energy savings, Novozymes also has a strategy to produce energy from waste to local communities. In 2020, we installed a large heat pump at our Fuglebakken site in Denmark that will generate 80,000 GJ annually from excess heat from our production and to be distributed as district heating to the city of Copenhagen. This corresponds to the annual consumption of more than 2,000 Danish households. The table provides details of energy consumed by primary source. Five-year energy consumption 1,000 GJ Environmental data 7.2 Energy Accounts and performanceNotes Energy consumption by primary source 1,000 GJ 2020 2019 Natural gas 644 656 Biogas 63 70 Gas oil, light fuel oil and diesel oil 39 46 Internally generated energy, total 746 772 Electricity – conventional 806 1,347 Electricity – renewable 1,758 1,315 District heat - conventional 89 187 District heat - renewable 112 - Steam 964 953 Externally purchased energy, total 3,729 3,802 Energy consumption, total ESG 4,475 4,574 Energy production from waste 89 86 121Novozymes A/S This year, we sourced 69% of our electricity from renewable sources, making progress towards our 2030 goal. We recognize that in order to meet our 2050 ambition of becoming carbon neutral, we will need to also explore renewable options for energy sources other than electricity. In 2020, the share of renewables in our energy mix increased to 43% from 30% in 2019. This was possible because we started procuring renewable electricity at our site in Franklinton as well as district heat from renewable sources at our site in Kalundborg. Going forward, Novozymes will continue to seek renewable energy opportunities for all sites in order to reduce its operational CO 2 footprint and deliver on the 100% renewable electricity commitment. Novozymes will also continue to explore energy saving opportunities at all sites and has allocated specic budgets for energy eciency and waste-to-energy initiatives. Renewable energy sources2020(2019) • Wind power 51% (70%) • Solar 26% (0%) • Hydro 4% (5%) • Biomass 19% (25%) Environmental data 7.2 Energy (continued) Accounts and performanceNotes Energy consumption includes quantities consumed both in the production process and in other areas. Internally-generated energy is measured as fuel consumption converted to energy based on the lower combustion value and weight by volume, except in the US, where legal requirements for reporting of CO 2 state that the higher combustion value is to be applied. Fuel consumption comprises all types of fuel used to produce electricity, heat and steam on site and converted to energy using factors supplied by utility providers or local authorities. Fuel for transportation is not included. Externally generated energy is the input to Novozymes of externally generated electricity, heat and steam. Energy produced from waste or wastewater is renewable and corresponds to the total energy (heat, electricity or steam) produced by an internal or external utility provider. An example is energy produced from biomass waste or biogas. Reported quantities are based on meter readings, with the exception of steam, which may be subject to calculation. The renewable energy percentage is calculated by dividing renewable energy consumed by total energy consumption. Renewable energy used at Novozymes sites comprises energy generated from natural processes and continuously replenished. Sources include solar, wind and hydropower- based electricity and energy from biogas and biomass. District heat - renewable is based on biomass. ACCOUNTING POLICIES 122Novozymes A/S The production of Novozymes’ solutions are based on the use of freshwater, at dilution and recovery stages,for example, and results in wastewater generation. Many of the raw materials required in our operations are agriculture-based and need water for production. At the same time, some of Novozymes’ existing solutions, specically in textile and laundry, enable our customers to reduce water consumption compared with conventional methods, and improve wastewater quality by replacing chemicals. Further, our solutions improve processes in the wastewater treatment industry. Therefore, water remains one of our priority focus areas as it presents both risks and opportunities across our value chain. Our approach Novozymes is committed to ensure water use that is clean, ecient and respects the capacity of the planet thereby contributing to long-term water security for all. Our 2030 ambition on water is to manage water in balance with local conditions. We have a short-term target to develop contextual water management programs for all our key sites by 2022, which will help us focus our eorts in the regions where it is needed the most and where we can make the maximum impact. We also recognize that internal water-related risks are oen a result of water challenges that exist in the local water basin and it requires collective action and eorts beyond our own boundary to address them eectively. Read more about our water stewardship approach in our position paper on water. In our operations, we focus on improving water eciency and ensuring compliance with wastewater discharge regulations at all our sites to reduce our freshwater consumption and improve the quality of water that leaves our boundary. The wastewater and biomass treatment at our production sites are given high priority and our wastewater is treated internally or externally in biological wastewater treatment systems before being discharged to a nal destination point or used in agriculture for irrigation. All water eciency and wastewater management eorts are managed by Novozymes’ Operations, Supply and Quality function. The table provides a breakdown of total water consumed. Five-yearwaterconsumption 1,000 m 3 Water by primary source 1,000 m 3 2020 2019 Drinking water 5,473 5,288 Industrial water 2,177 2,214 Steam 348 343 Water, total ESG 7,998 7,845 Environmental data 7.3 Water Accounts and performanceNotes Water includes drinking water, industrial water and externally supplied steam.Drinking water is water of drinking- water quality. Industrial water is not of drinking-water quality, but is suitable for certain industrial processes, for example for use in cooling towers. Industrial watermay come from lakes or wells. The reported quantities are stated based on the metered intake of water to Novozymes and include quantities consumed both in the production process and in other areas. The reported quantities of steam are converted to volumes of running water and are therefore subject to calculation. Wastewater is measured as the volume discharged by Novozymes or calculated based on water consumption. ACCOUNTING POLICIES 123Novozymes A/S 7.3 Water (continued) 2020 highlights In 2020, we established strong internal and external engagement to secure successful results from our long-term water strategy. We became a proud signatory to the UN Global Compact’s CEO Water Mandate and established a partnership with the World Wide Fund for Nature (WWF). WWF will help us to develop contextual water programs for our key sites that will ensure our eorts are focused on addressing the priority operational and basin water challenges. This year, we developed contextual water management programs for two of our sites in China and have identied water targets that will help us address water challenges in and around these sites. Novozymes has also joined the Science Based Targets Network’s (SBTN) Freshwater Hub working group driving the development of methodology for science-based targets for water. The table provides a breakdown of total wastewater generated in 2020. Within our operations, we achieved water- savings of 45,000 m 3 for the year through water reduction and re-use projects. This year, we also initiated a large water savings project at our Tianjin site in China which when completed will contribute to estimated water savings of around 150,000 m 3 annually through the re-use of water for cooling towers and our internal processes, among other things. To further expand our water stewardship eorts in India, Novozymes initiated work on the ambitious water project ‘NOWO – Novozymes Water Opulence’ to address water-scarcity situation in the neighboring villages near our production site in Patalganga near Mumbai. The project, which is being implemented in close collaboration with, Anarde, a local NGO that aims to raise the underground water table in the area, empowers villagers to be self-reliant for water, and educates them on its ecient and appropriate use. Going forward, we will focus on completing the development of contextual water management programs for all our key sites and further expand our water stewardship eorts. At the same time, we will continue our eorts to increase water eciency and wastewater recycling internally to reduce our dependence on freshwater. Wastewater by treatment method 1,000 m 3 • Novozymes-treated to external water recipient • Novozymes-treated to external treatment • Novozymes-treated to irrigation • Untreated to external treatment Environmental data Accounts and performanceNotes Wastewater treatment 1,000 m 3 2020 2019 Wastewater used for irrigation 662 774 Wastewater discharged 5,809 5,373 Wastewater volume, total ESG 6,471 6,147 124Novozymes A/S 7.4 Waste Novozymes supports the transition to a circular economy through biological solutions which enable our customers to adopt sustainable production and consumption practices. At the same time, we are committed to driving our own business towards more circularity by focusing on the reduction, reuse and recycling of the planet’s limited natural resources. Circular waste management is a key enabler for a sustainable future and we are committed to doing our part. Our approach Waste management at Novozymes is managed through the ‘Production and consumption’ pillar of our strategy, which includes ambitions and targets on circular waste management. We aim to have all key materials and waste managed in circular systems by 2030. Novozymes has 17 major sites. As waste management is a complex issue subject to a diverse set of local regulations and involving several external service providers, we have adopted a site-specic management approach. 2020 highlights Novozymes generated 480,000 tons of total waste in 2020, of which 465,000 tons was biomass, compared with 526,000 tons of total waste in 2019, of which 513,000 tons was biomass. The majority of the waste was recovered, and only 5% was sent to landll. Wasteandby -products2020(2019) • Recoveredbiomass 93.4% (94.5%) • Recovered(recycled)non-biomasswaste 1.5% (1.3%) • Biomasssentforlandll 3.4% (3.0%) • Non-biomasswastesentforlandll/incineration 1.7% (1.2%) Biomass The biomass generated during production makes up 97% of Novozymes’ total waste. The biomass is rich in nitrogen and phosphorus, and the energy can be recovered in biogas facilities. As part of our strategy, we have a target of achieving 100% circular management of our biomass by 2022. In 2020, 97% of our biomass volume was handled in a circular set-up with nutrients, such as nitrogen and phosphorus, being used in agriculture. The biomass is distributed to local farmers or used as a raw material for fertilizer production. A part of the biomass is also sent through biogas plants to produce biogas on its organic content prior to being used in agriculture. In 2020, we secured a new contract to increase the amount of biomass to be recovered by local farmers for land applications. A breakdown of the total biomass generated is provided in the table. Biomass Biomass wet (actual) Biomass dry matter (excl. water) 1,000 tons 2020 2019 2020 2019 Used in Agriculture 449 497 47 52 Landll 16 16 10 9 Biomass, total ESG 465 513 57 61 Environmental data Accounts and performanceNotes Biomass is measured or calculated based on volume or weight produced. At each site, biomass is produced with dierent dry- matter-to-water ratio. The consolidated dry matter gure is calculated by measuring of dry matter content in biomass from each site multiplied by volume produced at the same site. Biomass is distributed to local farmers, biogas plants or supplied as raw material for fertilizer production by third parties. Non-biomass waste is the registered volume of waste broken down into hazardous and nonhazardous waste, and by disposal method. The amount recycled is the quantity recycled internally or sent to an external service provider for recycling. Biomass is not included in the reported amounts of solid waste. ACCOUNTING POLICIES 125Novozymes A/S Non-biomass waste Our non-biomass waste accounts for 3% of Novozymes’ total waste and it is further classied into nonhazardous and hazardous waste. In 2020, the recycling rate of non- biomass waste was 48% compared with 52% in 2019. The remaining 52% of the waste was sent for landll or incineration. A breakdown of the total waste generated is provided in the table. To pave the way for our long-term circular ambition, we have a target that, by 2022, all sites should have programs to reach zero waste by 2030. To develop local solutions, we are working actively with local experts and service providers to explore site-specic opportunities. In 2020, we developed zero waste programs for three of our major sites, located in Denmark. Specically on hazardous waste, in 2020, we introduced several measures to reduce both its generation and environmental impact. They include expansion of our internal recycling capability, local process improvements and engagement with local organizations to safely reuse or recycle specic types of hazardous waste. In 2020, we increased our hazardous waste recycling capacity at two of our major sites. Due to the planned expansion, we safely diverted some of the hazardous waste from incineration in 2019 and we recycled it in 2020 – this explains the increase in the reported hazardous waste for 2020. Circular packaging We are committed to minimizing the impact of the waste generated by our packaging. Therefore, by 2022 we will have circular plans for all our key packaging materials in key markets. We are working to minimize our packaging footprint by making our packaging recyclable, reusable or compostable. Environmental data 7.4 Waste (continued) Accounts and performanceNotes Waste 1,000 tons 2020 2019 Nonhazardous waste Incineration 2.5 2.3 Landll 4.5 3.1 Recycling (external) 4.2 4.3 Nonhazardous waste, total 11.2 9.7 Hazardous waste Incineration 0.8 1.0 Landll 0.2 - Recycling (external) 0.4 0.2 Recycling (internal) 2.7 2.4 Hazardous waste, total 4.1 3.6 Waste, total ESG 15.3 13.3 126Novozymes A/S Novozymes’ research and business are based on bio-innovation. To develop sustainable solutions and applications for our customers, we explore nature and take samples of fungi, bacteria and enzymes among the available biodiversity. Next, we assess the samples and optimize applications by means of biotechnological research. Our approach Novozymes’ position paper on industrial biotechnology describes how industrial biotechnology and gene technology can contribute to sustainable development. Novozymes is committed to sharing its knowledge about the potential of biology and industrial biotechnology with the public and other stakeholders outside of Novozymes. Novozymes supports a science-based regulatory framework for products involving gene editing, operating in compliance with legislation and following any guidance and requirements from regulatory authorities on biotech innovation classication. We are committed to using scientically-sound tools in a way that is safe to humans, animals and the environment. When we take biological samples in nature, it is important that we always follow the local laws of the countries where we operate as well as complying with globally recognized principles on the utilization of genetic resources. We continuously discover new microbes that are valuable solutions for more environmentally-friendly industrial processes. Novozymes’ position paper on biodiversity articulates how we endorse, acknowledge and respect the principles of the United Nations Convention on Biological Diversity and the complementary Nagoya Protocol on Access and Benets Sharing. Internal procedures in our management system ensure that we live up to our commitments. As an example, we have established a Nagoya Protocol steering group which ensures compliance with the protocol and that internal guidelines are maintained. We also continuously monitor the global dialogue and development on biodiversity. Compliance with environmental norms and regulations is a high priority for Novozymes so as to maintain business continuity and the day-to-day running of operations. Novozymes is committed to complying with all environmental regulations at all our sites and maintaining high standards of environmental management on various aspects, including pollution prevention, resource conservation and waste reduction. Our approach Our commitment to environmental compliance is outlined in Novozymes’ Sustainability Policy. All activities to ensure environmental compliance are anchored in the Quality, Environment & Safety function. Our Environmental Management System is based on ISO 14001 certication, and we strive to minimize instances of non-compliance and neighbor complaints. 2020 highlights In 2020, 20 environmental incidents were registered across our facilities, compared with 17 in 2019. Most of these were related to wastewater treatment. Plans for preventive action for these incidents have been agreed with the relevant authorities. Novozymes received ten neighbor complaints in 2020 compared to seven complaints in 2019. 7.6 Bioethics & biodiversity Environmental data 7.5 Environmental compliance Accounts and performanceNotes Breaches of environmental regulatory limitsare measured as the number of incidents in the reporting year considered not to be in conformity with environmental permits or requirements under environmental law. Breaches related to annual control measurements of spills reported in previous years are not included, as they are not indicative of performance during the reporting year. Neighbor complaints refers to the number of registered environmental complaints, primarily odor and noise related. ACCOUNTING POLICIES 127Novozymes A/S Novozymes is committed to ensuring product safety and stewardship in our operations and across our value chain. Many of our biological solutions serve as ingredients in consumer goods (e.g. in laundry detergents) or are used for manufacturing consumer products such as food, textile and paper. Novozymes’ ambition is tocontinue supplying safe products and substitute hazardous substances in its operations using safer and more sustainable alternatives wherever possible. Novozymes strives to reduce the risk of enzyme allergies among employees and downstream users by promoting adherence to enzyme safety standards. Our approach Product stewardship is an integral part of Novozymes’ Quality Management System, and our approach is outlined in the Quality and Product Safety Policy. Novozymes constantly strives to reduce the risk of potential harm to both human health and the environment during the manufacture, handling and use of its products. This approach is implemented by means of many cross-functional teams, and the primary responsibility rests with Regulatory Aairs & Product Safety functions. Procedures ensuring product stewardship are enforced globally and audited by the independent external body Bureau Veritas. Novozymes measures performance in product stewardship, through internal targets that guide our progress, particularly in the areas of product safety and hazardous substance management. We have also developed a position on and approach to related topics such as product information and labeling, traceability, industrial biotechnology, animal testing, REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) and FIAP (Food Improvement Agents Package). Our position papers on animal testing and industrial biotechnology are available at Novozymes.com. Novozymes chairs the Enzyme Safety Working Group, which plays a coordinating role within The Association of Manufacturers and Formulators of Enzyme Products (AMFEP) in the EU. In addition, Novozymes is a co-chair of the Safety and Sustainability Committee in Enzyme Trade Association (ETA) in the US. Through both of these groups, Novozymes has developed advanced safety standards for enzyme use. An annual cross-functional process has recently been established to explore the potential phase-out and substitution of hazardous substances and materials. Every year, new and existing chemicals are screened for environmental, health and safety impacts, followed by risk and feasibility assessments to determine candidates for potential phase-out. 2020 highlights Novozymes remains rmly committed to maintaining high-quality dossiers that document product safety and transparency under relevant regulatory schemes such as REACH and FIAP. With its extensive experience in responding to increasing global regulatory requirements, Novozymes worked in 2020 on developing compliance with new REACH-like regulations in South Korea, Turkey, UK, India and other countries. Novozymes also strongly supports and complies with regulation on the reduction of chemicals of concern such as microplastics and 1.4-dioxane. In 2020, Novozymes established an internal governance committee to guide implementation and decisions in the phase-out of hazardous substances. Within our annual process cycle, we also identied top candidates to explore potential phase-outs in 2021. In 2020, through the AMFEP, Novozymes published an industry guideline on the ‘Safe Handling of Enzymes in Pulp and Paper Manufacturing’ in collaboration with the Confederation of European Paper Industries. Furthermore, as a member of the American Cleaning Institute (ACI), Novozymes took part in the update of the guideline for ‘Risk Assessment of Enzyme-Containing Consumer Products’. In 2021, we will continue to prioritize product stewardship practices at Novozymes. One example is, we will focus on establishing a systematic follow up on the identied hazardous substance candidates to explore the feasibility of phasing them out and developing appropriate substitution strategies. Another example of a new initiative in 2021 will be the development of safety guidelines for the feed industry in collaboration with the EU Association of Specialty Feed Ingredients and their Mixtures (Fefana). Environmental data 7.7 Product stewardship Accounts and performanceNotes 128Novozymes A/S Social and governance data We measure our social performance using a number of indicators in the areas of labor practices & human rights, occupational health & safety, business ethics, customer engagement and community engagement. These indicators enable us to track our progress and respond to risks and opportunities related to both talent attraction and retention, and business development. 8 Social and governance data Accounts and performanceNotes 99% 33% 1.3 Completion of business integrity training for employees Women in senior management Lost-Time Injury frequency (per million working hours) 129Novozymes A/S Employees are vital for Novozymes’ growth and the successful execution of our strategies. Therefore, it is important for Novozymes to focus on employee development and diversity in all operations. Novozymes is responsible for ensuring that human rights are respected throughout its value chain. Our approach We have adopted a common management approach and reporting structure for labor practices and human rights. Our People and Organization (P&O) function, together with leaders across Novozymes are responsible for ensuring equal rights for all employees and for promoting diversity. We are committed to ensuring equal opportunities and avoiding discrimination based on race, religion, gender or age in our global organization. In Novozymes, we have a policy for diversity and equal opportunities, which covers the entire workforce. Accordingly, the monitoring and the measures implemented to improve diversity in Novozymes cover all layers of management. One of Novozymes’ primary priorities on the diversity agenda has been to increase the number of women in senior management. Novozymes is committed to providing a work environment where all individuals can work together comfortably and productively, free of any kind of harassment and discrimination. Novozymes recognizes and respects the right to form and join associations and to bargain collectively. Our P&O function works together with local leadership to facilitate the fulllment of these fundamental rights in countries with limited labor legislation. Novozymes respects human rights as dened by the UN Guiding Principles on Business and Human Rights and has implemented them in our operational policies and procedures. We respect the International Bill of Human Rights, the International Labor Organization’s Declaration on Fundamental Principles and Rights at Work, and, since 2001, we have been a signatory to the United Nations Global Compact. Novozymes is also a signatory to the Women’s Empowerment Principles. We publish an annual statement under the UK Modern Slavery Act. In 2019, we dened targets for 2020-2022 focused on building a culture where our employees can thrive, grow and perform to bring out their best. Novozymes aims to nurture diversity, and to achieve a score of 86 on our diversity index by 2022. The diversity index is calculated based on gender and national representation at management and other job levels. By 2022, we aim to achieve an 80-point rating on Enable learning in our employee survey. For the Zymer spirit index, our target is to achieve a score of 81 by 2022. 2020 highlights Labor practices The Enable learning target and excite zymers target are based on our annual employee survey. In 2020, in our employee survey, we achieved a score of 78 points on Enable learning, and a score of 81 on our Zymer spirit index. The employee survey is an important tool that enables us to not only track the organizational mood but also to make room for better and more relevant team talks focusing on how we work together at Novozymes. These tools are critical to ensuring our success as a business and for sustaining our reputation as a great place to work. We also believe in promoting diversity at work and this year, for our nurture diversity target, we achieved 83 on our diversity index, which is based on gender and nationality. We are on track to achieving our 2022 targets. Social and governance data 8.1 Labor practices & human rights Accounts and performanceNotes Employee statistics 2020 2019 Rate of employee turnover – retirement % 1.2 1.0 Rate of employee turnover – dismissal % 3.0 5.7 Rate of employee turnover – voluntary % 4.5 6.0 Rate of employee turnover, total % 8.7 12.7 Rate of absence Senior management, management, professional and administrative % 1.1 1.2 Skilled workers, laboratory technicians, other technicians and process operators % 2.8 2.6 All employees ESG % 1.9 1.9 Other employee statistics Average age Years 42.0 42.0 Average seniority Years 10.0 10.1 Number of expatriates No. 19 22 Average training cost spent per employee DKK 3,871 3,351 Costs as percentage of total employee costs % 0.7 0.5 130Novozymes A/S 8.1 Labor practices & human rights (continued) In 2020, we converted our policy for diversity and equal opportunities into action by ensuring that diversity became a design criterion in our 2020 reorganization. To increase diversity following our reorganization, we have initiatives targeting the recruitment process where we held bias training for recruiters and developed relevant material for hiring managers. Further, our local oces partner with organizations to support diverse long lists of candidates. Novozymes engages in forums to learn about and promote gender equality and this year we focused on the challenges caused by COVID-19. For example, we are active in the ‘UN Women’ and ‘Advancing Women in Agriculture Conference’. Novozymes’ President and CEO Ester Baiget was invited to ring the bell for Gender Equality together with UNGC Denmark, Nasdaq Copenhagen, UN Women and other leaders. We are continuously tracking the impact of our initiatives, for example, gender diversity of new hires and internal transfers, and overall, we have made progress to ensure gender diversity in management levels. In 2020, 33% of our senior management were female. Novozymes believes that respectful, professional conduct furthers Novozymes’ mission and is fundamental to a good workplace. This year, we launched a global non-discrimination and anti-harassment policy and company-wide global training for all employees on these topics. In 2020, the enrollment of leaders in our leadership development program ‘‘Lead the Way’ increased to ~70% from ~57% in 2019. The program was impacted by COVID-19 as trainings were cancelled, postponed or changed to virtual sessions, which did not suit all participants. The rate of employee turnover decreased to 8.7% from 12.7% in 2019. We recorded a 1.9% rate of absence, which is in line with last year. The rate of absence has been broken down into grouped job categories, based on whether the work carried out is primarily oce-based. Human rights We conduct regionally focused human rights impact assessments to identify and assess human rights risks and impacts in our business and supplier base. As human rights risks vary from region to region, this approach enables us to gain a more comprehensive understanding of human rights risks, our positioning and the associated gaps within the respective regions. In 2020, we conducted the human rights impact assessment for The Americas. In the past two years, we have completed assessments for Europe, Middle East and Africa (EMEA) region and India. Through these assessments, we identied the most salient human rights, and are taking appropriate measures to mitigate the identied risks and gaps. Our aim is to complete the assessment for China in 2021. Accounts and performanceNotes Social and governance data Absence is dened as time lost due toan employee’s illness, including sick leave, and occupational injuries and diseases. The rate of absence is calculated as the number of registered days of absence as a percentage of the total number of normal working days in one year, less vacation and public holidays. The rate of employee turnover is calculated as employee turnover divided by the average number of permanent employees. Employee turnover is measured as the number of permanent employeesleaving the Group during thepreceding year (excluding employees at divested entities transferred to the acquiring company). Average age and seniority are calculated as the sum of employees’ total age/seniority in whole years at the reporting date, divided by the number of employees. Expatriation refers to Novozymes employees temporarily reassigned within Novozymes from the country of original employment for periods of more than six months. Training costs expressthe cost of external training courses and seminars, translated into Danish kroner at average exchange rates. Training costsare also shown as a percentage of total employee costs. Women in senior management measures the percentage of women in director positions or higher (i.e. director, vice president or executive vice president). Nurture Diversity index measures the ratio of women and international employees at both Senior management and Management level. If women and international employees are represented at the same ratio in all management layers as in the academic population in Novozymes as such, the index would be 100. The Zymer spirit and Enable learning are derived from specic questions in the annual employee survey questionnaire. The resulting score is a value between 0 and 100. The ‘Lead the Way’ program indicates the number of leaders globally who have been registered for the leadership development program ‘Lead the Way’. It is shown as a percentage of total number of leaders in Novozymes. ACCOUNTING POLICIES 131Novozymes A/S 8.2 Occupational health & safety The health and safety of all our employees is of paramount importance to Novozymes, and therefore forms a fundamental part of our business strategy. The aim is to ensure that robust safety processes, equipment, standards, tools and training are fully integrated into the way we work. We take appropriate measures to ensure focus on occupational health and safety across the organization, by means of initiatives owned and driven locally under a global framework. Our approach Novozymes’ Quality, Environment and Safety function is responsible for supporting the organization in ensuring a safe and healthy work environment. To reinforce our safety culture, we have a global Health and Safety Policy, along with internal standards and procedures. We monitor our performance and ensure continuous improvement through benchmarking of both internal and external key performance indicators. We dene annual targets to ensure we continue to improve our performance on health and safety. In 2019, as part of our strategy update, we increased our focus on health and wellbeing and dened new ambitions and programs on these topics. Our main target is to drive down the three-year rolling average of lost-time injury frequency rate to 1.5 per million working hours by 2022 relative to a 2017-19 baseline of 1.6 per million working hours. 2020 highlights As for most companies, the COVID-19 pandemic posed a huge challenge to Novozymes in 2020 and our regional leadership teams and OHS professionals were instrumental in handling the situation and keeping employees safe and production running. We are successfully addressing the dierent challenges across the world through our regional task force teams that are led by our regional senior leadership. In 2020, we met our target to drive down the three-year rolling average of lost-time injury frequency rate to 1.5. The performance this year was recorded at 1.3 compared with 0.9 in 2019. This year, in occupational health and safety, we followed a risk and data-based strategy when dening clear category themes such as trac in outdoor areas, exposure to chemicals, struck by object (e.g. falling items) and maintenance hazards. Social and governance data Accounts and performanceNotes Occupational injuries are dened as the reported number of occurrences arising out of or in the course of work that result in fatal or nonfatal injury with at least one day of absence from work other than the day of injury. Occupational diseases are dened as the number of diseases contracted as a result of exposure to risk factors arising from work activity and notied as work related in accordance with local legislation. The consequences of occupational injuries with absence and occupational diseases are measured by recording the work situation once the situation resulting from an incident has stabilized, for example whether the employees have returned to their original jobs, and the total number of calendar days of absence. Frequencies of occupational injuries with absence are stated per million working hours. The injury severity rate is calculated by dividing total days of absence related to injuries registered in the same year by the number of occupational injuries. ACCOUNTING POLICIES Consequences of occupational injuries No. 2020 2019 Return to original job 13 10 Return to a dierent job in the same department - - Out of work or early retirement - - Case pending 1 - Occupational injuries with absence, total 14 10 Total days of absence related to injuries registered in the same year 400 351 Injury severity rate 29 35 132Novozymes A/S 8.2 Occupational health & safety (continued) Social and governance data Consequences of occupational diseases No. 2020 2019 Return to original job 2 1 Return to a dierent job in the same department - - Out of work or early retirement - - Case pending 2 - Occupational diseases, total 4 1 Total days of absence related to diseases registered in the same year - - Types of occupational diseases No. 2020 2019 Skin disease 2 - Enzyme allergy 2 - Other - 1 Occupational diseases, total 4 1 Accounts and performanceNotes Injury prevention is key to our safety strategy. Our global incident handling system CAPTURE has since 2018 enabled us to implement targeted, data and theme- based safety initiatives. In 2020, we took CAPTURE a step further by introducing a medical application which allows EU GDPR (General Data Protection Regulation) compliant management of all medical cases. Enzyme & biological safety is a top priority for Novozymes. In January 2020, we published a scientic study, which concluded that our preventive program for enzyme safety works eectively. Our learnings enable us to further improve the enzyme safety program ZEAL (Zero Enzyme Allergy) and gives inspiration for our biological safety program ZEBRA (Zero Biological Reactions) for the benet of both employees and customers. We continuously promote a culture of product safety across the Novozymes organization through our corporate safety culture and awareness activities that promote safe behavior. Focus on mental wellbeing is an ongoing activity that aims to help and inspire our leaders and employees. One example is our global initiative called BrainSpace. Moving forward, we will focus on further implementing our strategy, aiming to improve safety in relation to our workplace and products and assure the continued wellbeing of all our employees. 133Novozymes A/S 8.3 Business ethics Novozymes is committed to conducting business in a responsible, ethical, and transparent manner, and to meeting stakeholders’ expectations of high business integrity standards across our operations. Our approach Novozymes’ approach to business integrity is embedded in our corporate values, policies and procedures. Novozymes has adopted seven business integrity principles that lay the ground rules for engaging with third parties and apply to all employees across the world. The business integrity principles underline Novozymes’ zero tolerance approach to bribery and dene clear rules for gis and donations. They act as Novozymes’ code of conduct in business integrity matters and form the basis of our eorts to eliminate all forms of corruption. See our position paper on business integrity at Novozymes.com. A dedicated legal compliance function, headed by the Chief Legal Compliance Ocer, handles business integrity-related matters and training of our employees. All employees have access to relevant guidance on our intranet and are encouraged to raise any concerns about business integrity to the designated business integrity contacts or through other relevant grievance channels. Novozymes also has a whistleblower system which allows employees and others to report their concerns relating to business integrity and corruption, fraud and other serious matters. We oer mandatory business integrity training annually for our employees in scope. This training is designed and rolled out by the Chief Legal Compliance Ocer, based on input from regional lines of business and questions raised during the year to ensure relevance and applicability. This training includes real- life case studies and reinforces employee commitment to business integrity principles. Novozymes’ recurring antitrust training provides general guidance on competition law and is completed by relevant employees in commercial roles across all regions. Novozymes works proactively to prevent, detect and respond to fraud, corruption and other violations of our business integrity principles, and we continuously promote internal awareness and develop relevant programs or initiatives as required. An internal control system enables identication of potential violations and addresses concerns raised, e.g. through our whistleblower system. All whistleblower reports and all cases on fraud and corruption are reported to the Audit Committee on a quarterly basis. All allegations of fraud, corruption and other business integrity violations are appropriately investigated in accordance with internal policies and procedures. Substantiated violations will lead to proportionate disciplinary sanctions for the parties involved. Accounts and performanceNotes Social and governance data Completion of business integrity training refers to the percentage of employees in scope who have undergone business integrity training in the latest training period. New entities are included within six months of acquisition. Business integrity training is conducted for employees who can potentially inuence third-party interactions or decisions as part of their job role. This comprises employees in professional, managerial or administrative positions. The reporting criteria for competition law violations are whether it has been established by an authority member of the International Competition Network or by a competent court anywhere in the world that a company in the Novozymes Group has violated applicable anti-trust regulations. Novozymes denes fraud and corruption as deliberate misconduct with the intent to gain a direct or indirect personal advantage while exposing Novozymes to a nancial or reputational loss. ACCOUNTING POLICIES 134Novozymes A/S General concerns and violations of our business integrity principles are reported to Novozymes’ Corporate Business Integrity Committee, which oversees business integrity matters across the company and our business partners. Novozymes’ responsibility for ensuring ethical business practices also extends to our business partners. Our third-party due diligence processes include monitoring and ensuring that our commercial partners conduct business with integrity and share our values regarding legal compliance. Novozymes’ whistleblower system allows employees and others to report their concerns relating to fraud, corruption and other violations of Novozymes’ business integrity principles as well as other serious violations of law. Concerns reported are handled by the Chief Legal Compliance Ocer and all concerns from the system are reported to the Audit Committee. 2020 highlights In 2020, the business integrity training was completed by 99% of our employees in scope and focused on risks relating to conicts of interest. The competition law compliance training this year provided a general reminder on competition law restrictions. During the year, we released a new conict of interest policy that provides better guidance to employees on identication and proper management of potential conicts of interests and related risks with respect to business integrity. In 2020, a new dedicated fraud detection e-learning was rolled out to select functions. Consistent with previous years, there were no violations of competition law in 2020. The number of potential fraud and corruption cases investigated increased in 2020 due to extended use of data mining in internal controls and proactive detection. The nominal number of substantiated cases increased slightly compared to 2019. The substantiated cases had no material business or nancial impact. The charts below provide further details of the reporting channels and consequences for fraud and corruption cases. Social and governance data Consequences of substantiated fraud and corruption cases 2020 (2019) • Dismissal 29% (25%) • Other disciplinary sanctions 25% (30%) • Unknown perpetrator 46% (45%) Reporting channels for potential fraud and corruption 2020 (2019) • Whistleblower/tip-o 13% (66%) • Internal controls and proactive detection 87% (34%) 8.3 Business ethics (continued) Accounts and performanceNotes 135Novozymes A/S 8.4 Customer engagement As part of our strategy Better business with biology, we want to give the voice of the customer a stronger presence at Novozymes and convert customer needs and demands into biological solutions. We believe that our customers’ feedback on our solutions and services is of great importance to determining the success and performance of our business. Therefore, customer engagement and value of our partnership is measured across our commercial divisions and across regions. Our approach Each year, we conduct a customer satisfaction survey. This is to monitor customer perceptions of our solutions and services and learn where we can improve. We use the survey as a dialogue tool with our customers. Overall customer perceptions are measured via four key performance indicators: Net Promoter Score (NPS), Loyalty Index, Value of Partnership, and Customer Satisfaction Score. Responsibility for measuring, analyzing and addressing customer satisfaction and performance is anchored with our commercial functions. 2020 highlights In 2020, Novozymes invited 1,063 customers across 100 countries to participate in the survey with a response rate of 58%. We achieved an NPS of 50. The results conrm our strong relationships with our customers both large and small, new and old and across emerging and developed markets. The COVID-19 pandemic does not seem to have aected customer perceptions of Novozymes in 2020 compared to previous years. Responding customers pointed out that it is essential that we continue to deliver innovation to help them become more competitive and within their detailed responses are a number of insights that relate to how we can improve our performance within certain industries and with certain accounts. Going forward, we will strive to maintain close relationships with our customers and proactively work on the areas where we can improve. Social and governance data Accounts and performanceNotes The Net Promoter Score (NPS) is derived from an annual questionnaire measuring on a scale from 1-10 how likely the customer is to recommend Novozymes to others. The NPS is calculated as the share of promoters (rating us 9 or 10) less the share of detractors (rating us 1-6). The resulting score is a value between -100 and +100. ACCOUNTING POLICIES 136Novozymes A/S We believe that businesses have an obligation to engage with the communities in which they operate and to invest strategically in programs that create value for society. We are passionate about delivering on our promise of better lives in a growing world, both inside and outside the workplace. Our approach Novozymes has committed to contribute to our local communities and inspire people about the potential of biology. As part of this commitment, Novozymes has set a target to “Pledge 1% of our time to local outreach activities by 2022”. Our community engagement initiatives are driven through our Inspire-related initiatives. The Inspire program is governed by strong guardrails to guide implementation and determine eligibility, and is led by a cross- functional team. The Inspire initiatives are regionally owned and driven by grassroot employee-led initiatives. The Executive Leadership encourages all employees to spend up to 1% of work time in local outreach and workplace sustainability initiatives. 2020 highlights Inspire is about helping our communities respond to local challenges. In 2020, the biggest crisis we all faced was the COVID-19 pandemic. Our employees in all regions stepped up, contributing with their resources, time, and creativity to help their communities respond to the pandemic and other pressing local issues. In China, we donated RMB 1 million via the Red Cross to help build hospitals in Huoshenshan and Leishenshan, procure supplies, and provide support for frontline workers. In Denmark, one of our employees, a trained nurse, spent a number of working days to help with COVID-19 testing at Holbæk Hospital. Another employee, an operator from Kalundborg, was seconded to his former employer who started a large production of hand sanitizer and needed his expertise to keep up with the high demand. In India, around 140 Zymers participated in a virtual tness challenge to raise money for daily-wage earners, whose lives had come to a standstill due to COVID-19. Observing local rules and guidelines, our employees walked an estimated 2.3 million steps in a day raising INR 1.7 million. The sum was donated towards state funds, and organizations involved with disaster management and eradication of hunger. In Kenya, Novozymes was awarded by the Marketing Society of Kenya (MSK) for driving Biology amongst the disadvantaged and future generations for funding the upgrade of the Starehe Boys Bio-Lab. Starehe Boy’s Centre & School is a charitable institution that runs a high school and a technical training institution for exceptionally talented students with nancial constraints. In Latin America, to promote digital inclusion especially among underprivileged students, we provided 100 computers with internet access for students of Marista Escola Social Ecológica. In North America, our employees helped educators create meaningful content for students learning from home due to COVID-19 restrictions. We worked with local schools to organize virtual chats to discuss career opportunities in the sciences and hosted virtual tours of our site for teachers’ professional development. Our North American sites have also supported COVID-19 response of local non-prot organizations. Through in-kind and nancial charitable donations, we have helped local food banks, provided protective equipment and sanitizers to local hospitals, and given internet access to students in remote areas so that they can learn online. Social and governance data 8.5 Community engagement Accounts and performanceNotes 137Novozymes A/S Novozymes always strives for responsible sourcing and we focus on environment, social and governance (ESG) issues across our value chain. Agricultural raw materials are a major component of our production processes and a secure supply of sustainable raw materials is crucial to Novozymes’ production. Our approach Novozymes’ sourcing department drives our supplier management and responsible sourcing program and is anchored within Novozymes Operations, Supply and Quality function. Our approach to responsible sourcing is dened by our Responsible Purchasing Standards (RPS) and managed through our Supplier Performance Management (SPM) process and SEDEX platform. Through the SPM process, Novozymes screens suppliers and classies their risk based on spend, country and category. In case a supplier does not meet our assessment criteria, either an action plan is established, or an alternate supplier is identied. Furthermore, we aim to use SEDEX to enhance the sustainability aspects of our SPM evaluation going forward. We have started onboarding our key suppliers, with due consideration for risk and spend, to the platform to increase the level of transparency in our supply chain. Novozymes requires all contracted suppliers to comply with our RPS, as well as, when requested, to complete questionnaires and to accept visits and audits relevant for conrmation of compliance with the standards. These standards cover various ESG criteria including respect for human and labor rights, business ethics, employee health and safety and environmental stewardship. All our suppliers of directly sourced agricultural raw materials are required to adhere to our deforestation requirements by not contributing to further deforestation and to have zero tolerance for land grabbing. To know more, see our position paper on Responsible Purchasing, and our annual statement on Modern Slavery at Novozymes. com. We will continue to focus on our long-term commitment of securing 100% renewable electricity, reducing Scope 3 CO 2 emissions from key raw materials and developing plans to manage 100% key materials and waste in circular systems. 2020 highlights Novozymes continued to expand the use of the SEDEX platform, a sustainability platform, to enhance the transparency of our supply chain. Aer onboarding high-risk suppliers in 2019, this year our focus has been to onboard high-spend suppliers across Novozymes onto SEDEX, a process which will continue over time. As part of Novozymes’ journey towards becoming carbon neutral, we are taking various steps to reduce emissions. During 2020, Novozymes initiated additional means to increase the level of renewable electricity sourced. In 2020, the entire electricity consumption at Novozymes’ Franklinton site was covered by renewable electricity through the purchase of Renewable Energy Certicates (REC), deriving from a nearby solar energy plant. Novozymes and Novo Nordisk have jointly engaged in a power purchasing agreement with Swedish energy provider Vattenfall AB, to supply the two Danish companies with renewable electricity for the coming decade. As part of our climate target we have also set a science-based Scope 3 target focused on purchased goods and services. For 2020, the target internally has been to identify relevant key suppliers with whom to engage with and to establish supplier engagement plans. For more details, read Note 7.1 Climate change. During 2020, a sustainability hotspot analysis was conducted for all categories of direct sourcing of raw materials across dierent regions. The results of this exercise will be used to identify key sustainability issues and will serve as input to future sustainable sourcing strategies. As a member of the Roundtable on Sustainable Palm Oil (RSPO), 100% of the palm oil we sourced in 2020 was RSPO-certied. Novozymes has further increased its focus on sustainability when sourcing products and services other than raw materials, by including sustainability criteria in the tender supplier evaluations and implementing initiatives to improve sustainability performance within categories prioritized in risk assessments, e.g. waste and internal logistics. Furthermore, we also completed a Human Rights & Impact assessment of our operations and supplier base in North America and Latin America. Read more about these assessments in Note 8.1 Labor Practices & Human Rights. Social and governance data 8.6 Responsible sourcing Accounts and performanceNotes 138Accounts and performane StatementsNovozymes A/S Statement of the Board of Directors and Executive Management The Board of Directors and the Executive Management have today considered and approved the Annual Report of Novozymes A/S for the nancial year January 1 – December 31, 2020. The Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act, and the Parent Company Financial Statements have been prepared in accordance with the Danish Financial Statements Act. Management’s Review has been prepared in accordance with the Danish Financial Statements Act. In our opinion, the accounting policies used are appropriate, and the Group’s internal controls relevant to preparation and presentation of the Annual Report are adequate. The Consolidated Financial Statements and the Parent Company Financial Statements give a true and fair view of the nancial position at December 31, 2020 of the Group and the Parent Company and of the results of the Group and the Parent Company operations and consolidated cash ows for the nancial year January 1 – December 31, 2020. In our opinion, Management’s Review includes a true and fair account of the development in the operations and nancial circumstances of the Group and the Parent Company, of the results for the year, and of the nancial position of the Group and the Parent Company as well as a description of the most signicant risks and elements of uncertainty facing the Group and the Parent Company. Novozymes’ Consolidated environmental data and the Consolidated social and governance data and the related notes, have been prepared in accordance with the reporting principles of materiality, inclusivity, responsiveness and the accounting policies. In our opinion, they give a true and fair view of the organisation’s environmental, social and governance performance in accordance with these principles. In our opinion, the Annual Report of Novozymes A/S for the nancial year January 1 - December 31, 2020 identied as NOVOZYMES-2020-12-31.zip is prepared in all material respects, in compliance with the ESEF Regulation. We recommend that the Annual Report be adopted at the Annual Shareholders’ Meeting. Bagsvaerd, February 2, 2021 Executive Management Board of Directors Ester Baiget President & CEO Thomas Videbæk Lars Green Jørgen Buhl Rasmussen Chair Sharon James Kim Stratton Cornelis (Cees) de Jong Vice Chair Anders Hentze Knudsen Mathias Uhlén Heine Dalsgaard Kasim Kutay Lena Bech Holskov Lars Bo Køppler Statements 139Accounts and performane StatementsNovozymes A/S Independent Auditor’s Reports To the shareholders of Novozymes A/S Report on the audit of the Financial Statements Opinion In our opinion, the Consolidated Financial Statements give a true and fair view of the Group’s nancial position at December 31, 2020 and of the results of the Group’s operations and cash ows for the nancial year January 1 to December 31, 2020 in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act. Moreover, in our opinion, the Parent Company Financial Statements give a true and fair view of the Parent Company’s nancial position at December 31, 2020 and of the results of the Parent Company’s operations for the nancial year January 1 to December 31, 2020 in accordance with the Danish Financial Statements Act. In our opinion, the Consolidated environmental data and the Consolidated social and governance data for the nancial year January 1 to December 31, 2020 are prepared in accordance with the accounting policies for the Consolidated environmental data and the Consolidated social and governance data. Our opinions are consistent with our Auditor’s Long-form Report to the Audit Committee and the Board of Directors. What we have audited The Consolidated Financial Statements of Novozymes A/S, pages 52-60 and 65-116, for the nancial year January 1 to December 31, 2020 comprise the consolidated income statement and statement of comprehensive income, the consolidated balance sheet, the consolidated statement of shareholders’ equity, the consolidated statement of cash ows and the notes, including signicant accounting policies. The Parent Company Financial Statements of Novozymes A/S, pages 143-158, for the nancial year January 1 to December 31, 2020 comprise the income statement, the balance sheet, the statement of changes in equity and the notes, including signicant accounting policies. Collectively referred to as the “Financial Statements”. The Consolidated environmental data and the Consolidated social and governance data of Novozymes A/S, pages 61-64 and 117-137, for the nancial year January 1 to December 31, 2020 comprise the environmental performance and consolidated environmental data, the social and governance performance and consolidated social and governance data and the related notes, including signicant accounting policies. These are collectively referred to as the “Environmental, Social and Governance Data.” Basis for opinion We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor’s responsibilities for the audit of the Financial Statements and the Environmental, Social and Governance Data section of our report. We believe that the audit evidence we have obtained is sucient and appropriate to provide a basis for our opinion. Independence We are independent of the Group in accordance with the International Ethics Standards Board for Accountants’ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark. We have also fullled our other ethical responsibilities in accordance with the IESBA Code. To the best of our knowledge and belief, prohibited non-audit services referred to in Article 5(1) of Regulation (EU) No 537/2014 were not provided,except for an insignicant breach that was reported to the Audit Committee and which did not aect our independence. Appointment We were appointed as auditors of Novozymes A/S for the rst time aer the initial public oering on March 21, 2001. We have been reappointed annually by shareholder resolution for a total period of uninterrupted engagement of 20 years, including the nancial year 2020. 140Accounts and performane StatementsNovozymes A/S Key audit matter How our audit addressed the key audit matter Collaboration agreements Novozymes has entered into collaboration agreements. Some of these collaboration agreements include complex mechanisms for sharing prot and expenses. Due to the complexity of the agreements, there are uncertainties in relation to the interpretation of the agreements. In 2020, the most signicant of these collaboration agreements, the Bioag collaboration agreement, was amended to a supply agreement. The amendment of the agreement included uncertainties and assessments of income and accruals. We focused on this area because the agreements and the related accounting treatment of prot-sharing and expenses are complex and because the amendment of the Bioag collaboration agreement required signicant judgment and estimation by Management. Refer to Note 2.2 and 3.1 to the Consolidated Financial Statements. We tested relevant controls including applicable information systems and monitoring controls implemented to ensure that prot-sharing and expenses from the collaboration agreements are recognized and measured appropriately on an ongoing basis. We assessed the accounting treatment applied by Management of the amendment of the Bioag collaboration agreement, including settlement of income and cost associated with the change to the supply agreement. We also assessed the accounting treatment applied by Management of the amendment of the Bioag collaboration agreement in relation to impairment of intangible assets. We read the amended Bioag collaboration agreement and assessed Management’s interpretation of the amended agreement and the nancial impact. We tested Management’s subjective estimation of prot-sharing and related accruals etc. under the applicable remaining collaboration agreements, as well as reconciled data inputs and signicant assumptions – to both internal and external sources – and we assessed the accuracy of the accruals in previous periods. We assessed whether the disclosures in relation to revenue and intangible assets are appropriate and meet the requirements of accounting standards. Key audit matters Key audit matters are those matters that, in our professional judgment, were of most signicance in our audit of the Financial Statements for 2020. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in Statement on Management’s Review Management is responsible for Management’s Review, pages 3-51. Our opinion on the Financial Statements and on the Environmental, Social and Governance Data does not cover Management’s Review, forming our opinion thereon, and we do not provide a separate opinion on these matters. and we do not express any form of assurance conclusion thereon. In connection with our audit of the Financial Statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the Financial Statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. Moreover, we considered whether Management’s Review includes the disclosures required by the Danish Financial Statements Act. Based on the work we have performed, in our view, Management’s Review is in accordance with the Consolidated Financial Statements, the Parent Company Financial Statements, and the Environmental, Social and Governance Data, and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management’s Review. 141Accounts and performane StatementsNovozymes A/S Management’s responsibilities for the Financial Statements and the Environmental, Social and Governance Data Management is responsible for the preparation of Consolidated Financial Statements that give a true and fair view in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act and for the preparation of Parent Company Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of nancial statements that are free from material misstatement, whether due to fraud or error. Furthermore, Management is responsible for preparing the Environmental, Social and Governance Data in accordance with the accounting policies stated in the Environmental, Social and Governance Data, and for such internal control as Management determines is necessary to enable the preparation of Environmental, Social and Governance Data that are free from material misstatement, whether due to fraud or error. In preparing the Financial Statements, Management is responsible for assessing the Group’s and the Parent Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Management either intends to liquidate the Group or the Parent Company or to cease operations, or has no realistic alternative but to do so. Auditor’s responsibilities for the audit of the Financial Statements and the Environmental, Social and Governance Data Our objectives are to obtain reasonable assurance about whether the Financial Statements and the Environmental, Social and Governance Data as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to inuence the economic decisions of users taken on the basis of these Financial Statements and the Environmental, Social and Governance Data. As part of an audit in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also: • Identify and assess the risks of material misstatement of the Financial Statements and the Environmental, Social and Governance Data, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sucient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. • Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the eectiveness of the Group’s and the Parent Company’s internal control. • Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management. • Conclude on the appropriateness of Management’s use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast signicant doubt on the Group’s and the Parent Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group or the Parent Company to cease to continue as a going concern. • Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation. • Obtain sucient appropriate audit evidence regarding the nancial, environmental, social and governance information of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements and the Environmental, Social and Governance Data. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and signicant audit ndings, including any signicant deciencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most signicance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, 142Accounts and performane StatementsNovozymes A/S we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benets of such communication. Report on compliance with the ESEF Regulation As part of our audit of the Financial Statements we performed procedures to express an opinion on whether the Annual Report of Novozymes A/S for the nancial year January 1 to December 31, 2020 with the lename NOVOZYMES-2020-12-31. zip is prepared, in all material respects, in compliance with the Commission Delegated Regulation (EU) 2019/815 on the European Single Electronic Format (ESEF Regulation) which includes requirements related to the preparation of the Annual Report in XHTML format and iXBRL tagging of the Consolidated Financial Statements. Management is responsible for preparing an Annual Report that complies with the ESEF Regulation. This responsibility includes: • The preparing of the Annual Report in XHTML format; • The selection and application of appropriate iXBRL tags, including extensions to the ESEF taxonomy and the anchoring thereof to elements in the taxonomy, for all nancial information required to be tagged using judgement where necessary; • Ensuring consistency between iXBRL tagged data and the Consolidated Financial Statements presented in human-readable format; and • For such internal control as Management determines necessary to enable the preparation of an Annual Report that is compliant with the ESEF Regulation. Our responsibility is to obtain reasonable assurance on whether the Annual Report is prepared, in all material respects, in compliance with the ESEF Regulation based on the evidence we have obtained, and to issue a report that includes our opinion. The nature, timing and extent of procedures selected depend on the auditor’s judgement, including the assessment of the risks of material departures from the requirements set out in the ESEF Regulation, whether due to fraud or error. The procedures include: • Testing whether the Annual Report is prepared in XHTML format; • Obtaining an understanding of the company’s iXBRL tagging process and of internal control over the tagging process; • Evaluating the completeness of the iXBRL tagging of the Consolidated Financial Statements; • Evaluating the appropriateness of the company’s use of iXBRL elements selected from the ESEF taxonomy and the creation of extension elements where no suitable element in the ESEF taxonomy has been identied; • Evaluating the use of anchoring of extension elements to elements in the ESEF taxonomy; and • Reconciling the iXBRL tagged data with the audited Consolidated Financial Statements. In our opinion, the Annual Report of Novozymes A/S for the nancial year January 1 to December 31, 2020 with the le name NOVOZYMES-2020-12-31.zip is prepared, in all material respects, in compliance with the ESEF Regulation. Hellerup, February 2, 2021 PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab CVR no 3377 1231 Lars Baungaard State Authorized Public Accountant mne23331 Rasmus Friis Jørgensen State Authorized Public Accountant mne28705 Financial statements for Novozymes A/S Financial statements Income statement Balance sheet Statement of shareholders' equity 1 Basis of reporting 1 Accounting policies 2 Primary operations 2.1 Revenue 2.2 Employee costs 2.3 Other operating income 3 Other assets and liabilities 3.1 Intangible assets 3.2 Property, plant and equipment 3.3 Leases 3.4 Financial xed assets 3.5 Other receivables 3.6 Deferred tax 3.7 Other provisions 4 Financial activities 4.1 Financial income and costs 4.2 Credit institutions 4.3 Proposed appropriation of net prot 5 Other notes 5.1 Contingent liabilities and pending litigation 5.2 Related party transactions 5.3 Fees to statutory auditors 5.4 Common stock and treasury stock 5.5 Derivatives 5.6 Events aer the reporting date 143Novozymes A/S Accounts and performanceFinancial statements for Novozymes A/S 144Novozymes A/S DKK million Note 2020 2019 Revenue 2.1 8,519 8,260 Cost of goods sold (3,847) (3,867) Gross prot 4,672 4,393 Sales and distribution costs (1,325) (1,285) Research and development costs (1,512) (1,621) Administrative costs (543) (598) Other operating income 2.3 1,214 1,237 Operating prot / EBIT 2,506 2,126 Income from investments in subsidiaries 3.4 772 1,494 Share of result in associates 3.4 (4) (5) Financial income 157 105 Financial costs (227) (278) Prot before tax 3,204 3,442 Tax (592) (371) Net prot 2,612 3,071 Proposed appropriation of net prot Dividend to shareholders 1,496 1,528 Revaluation reserve according to the equity method 1,307 2,147 Retained earnings (191) (604) 4.3 2,612 3,071 Proposed dividend per share DKK 5.25 DKK 5.25 Income statement, Novozymes A/S Accounts and performanceFinancial statements for Novozymes A/S 145Novozymes A/S Balance sheet, Novozymes A/S Assets DKK million Note Dec. 31, 2020 Dec. 31, 2019 Intangible assets 3.1 3,547 3,064 Property, plant and equipment 3.2 4,400 4,471 Investments in subsidiaries 3.4 7,157 8,581 Investments in associates 3.4 33 37 Other long-term receivables 3.5 9 2 Receivables from Group enterprises 3.4 295 352 Financial xed assets 7,494 8,972 Fixed assets 15,441 16,507 Raw materials and consumables 146 155 Work in progress 432 476 Finished goods 648 707 Inventories 1,226 1,338 Trade receivables 1,103 924 Receivables from Group enterprises - 158 Tax receivables 186 344 Other receivables 3.5 204 138 Receivables 1,493 1,564 Cash at bank and in hand 475 141 Current assets 3,194 3,043 Assets 18,635 19,550 Liabilities and shareholders’ equity DKK million Note Dec. 31, 2020 Dec. 31, 2019 Common stock 570 582 Treasury stock (3,314) (4,142) Revaluation reserve according to the equity method 441 2,116 Reserve for development costs 219 166 Cash ow hedges 127 19 Retained earnings 10,352 10,100 Proposed dividend 1,496 1,477 Shareholders’ equity 9,891 10,318 Provisions for deferred tax 3.6 555 448 Other provisions 3.7 159 10 Provisions 714 458 Lease liabilities 154 176 Credit institutions 3,254 2,716 Transitional holiday accrual - 58 Non-current liabilities 3,408 2,950 Lease liabilities 63 92 Credit institutions 1,126 1,408 Transitional holiday accrual 180 - Trade payables 494 512 Payables to Group enterprises 2,228 3,083 Other payables 531 729 Current liabilities 4,622 5,824 Liabilities 8,744 9,232 Liabilities and shareholders’ equity 18,635 19,550 Accounts and performanceFinancial statements for Novozymes A/S 146Novozymes A/S DKK million Common stock Treasury stock Revaluation reserve according to the equity method Reserve for development costs Cash ow hedges Retained earnings Proposed dividend Total Shareholders’ equity at January 1, 2020 582 (4,142) 2,116 166 19 10,100 1,477 10,318 Net prot for the year 1,307 1,305 2,612 Capitalized development costs 53 (53) - Dividend received (2,255) 2,255 - Dividend paid (1,513) (1,513) Dividend paid relating to treasury stock 30 30 Proposed dividend (1,496) 1,496 - Purchase of treasury stock (1,500) (1,500) Sale of treasury stock 508 508 Write-down of common stock (12) 1,820 (1,808) - Currency translation adjustments of investments in subsidiaries, etc. (765) (765) Fair value adjustments 108 108 Other adjustments 38 49 6 93 Shareholders’ equity at December 31, 2020 B/S 570 (3,314) 441 219 127 10,352 1,496 9,891 Statement of shareholders’ equity, Novozymes A/S Accounts and performanceFinancial statements for Novozymes A/S 147Novozymes A/S The nancial statements of Novozymes A/S have been prepared in accordance with the Danish Financial Statements Act (accounting class D). The accounting policies are unchanged from 2019. The accounting policies are consistent with those applied for the consolidated nancial statements except as described below. For a description of the Group’s accounting policies, please refer to the consolidated nancial statements. No separate statement of cash ows has been prepared for Novozymes A/S; please refer to the consolidated statement of cash ows. Recognition and measurement in general Income is recognized in the income statement as earned. All costs incurred in generating the year’s revenue are also recognized in the income statement, including depreciation, amortization and impairment losses. Value adjustments of nancial assets and liabilities measured at fair value or amortized cost are also recognized in the income statement. Assets are recognized in the balance sheet when it is considered probable that future economic benets will ow to the company and the value of the asset can be measured reliably. Liabilities are recognized in the balance sheet when they are considered probable and can be measured reliably. At initial recognition, assets and liabilities are measured at cost. Assets and liabilities are subsequently measured as described below for each item. The recognition and measurement principles take due account of predictable losses and risks occurring prior to the presentation of nancial statements that conrm or refute the conditions prevailing at the reporting date. Intangible assets The accounting policies for intangible xed assets follow those of the Group with the exception of goodwill, which is amortized over a period of 10 years using the straight-line method. An amount equal to the total capitalized development costsaer taxis recognized under Shareholders’ equity in Reserve for development costs. Financial assets Investments in subsidiaries and investments in associates are recognized initially at cost and subsequentlymeasured using the equity method. The company’s share of the equity of subsidiaries, based on the fair value of the identiable net assets at the acquisition date, less or plus unrealized intercompany prots or losses,with the addition of any residual value of goodwill, is recognized under Investments in subsidiaries and Investments in associates respectively in the balance sheet. If the shareholders’ equity of subsidiaries or associates is negative and Novozymes A/S has a legal or constructive obligation to cover the company’s negative equity, a provision is recognized. Net revaluation of investments in subsidiaries and associates is recognized under Shareholders’ equity in the Revaluation reserve according to the equity method. The reserve is reduced by payments of dividends to the parent company and adjusted to reect other changes in the equity of subsidiaries. The proportionate share of the net prots of subsidiaries less goodwill amortization is recognized under Income from investments in subsidiaries in the income statement. Goodwill in subsidiaries is amortized over a period of 10 years using the straight-line method. Dividend The dividend proposed for the nancial year is shown as a separate item under Shareholders’ equity. NOTES SECTION 1 1 Accounting policies Accounts and performanceFinancial statements for Novozymes A/S 148Novozymes A/S DKK million 2020 2019 Geographical distribution: Denmark 173 166 Rest of Europe, Middle East & Africa 5,542 5,318 North America 1,038 1,032 Asia Pacic 1,331 1,316 Latin America 435 428 Revenue I/S 8,519 8,260 DKK million 2020 2019 Wages and salaries 1,739 1,767 Pensions - dened contribution plans 180 186 Other social security costs 12 22 Other employee costs 135 88 Employee costs 2,066 2,063 Average number of employees in Novozymes A/S 2,607 2,688 2.3 Other operating income DKK million 2020 2019 Royalty income relating to subsidiaries 1,205 1,228 Other 9 9 Other operating income I/S 1,214 1,237 2.1 Revenue NOTES SECTION 2 2.2 Employee costs Accounts and performanceFinancial statements for Novozymes A/S The employee costs in 2020 included severance costs of DKK 80 million related to the organizational changes, of which DKK 65 million was related to the changes to the Executive Leadership Team announced in 2020. The employee costs in 2019 included restructuring costs related to organizational changes of around DKK 100 million. The one-o impact in 2019 was partly oset by reduced employee costs during the remainder of the year. In addition, changes made to the Executive Leadership Team during 2019 resulted in severance costs of DKK 58 million. Reference is made to Note 6.1 to the consolidated nancial statements concerning remuneration of the Board of Directors and the Executive Leadership Team. Reference is made to Note 2.1 to the consolidated nancial statements segment information. 149Novozymes A/S 3.1 Intangible assets 2020 2019 DKK million Goodwill Acquired patents, licenses and know-how, etc. Completed IT development projects IT development projects in progress Total Total Cost at January 1 2,597 1,911 653 25 5,186 4,108 Additions during the year 757 191 27 113 1,088 1,078 Disposals during the year - - (6) - (6) - Transfers to/(from) other items - - 56 (56) - - Cost at December 31 3,354 2,102 730 82 6,268 5,186 Amortization and impairment losses at January 1 (602) (1,055) (465) (2,122) (1,662) Amortization for the year (376) (158) (71) (605) (460) Disposals during the year - - 6 6 - Amortization and impairment losses at December 31 (978) (1,213) (530) (2,721) (2,122) Carrying amount at December 31 B/S 2,376 889 200 82 3,547 3,064 NOTES SECTION 3 Accounts and performanceFinancial statements for Novozymes A/S 150Novozymes A/S 3.2 Property, plant and equipment Capitalized interest No interest was capitalized under Additions during the year (2019: DKK 2 million). Capitalization rate 2019: 0.9%. Land and buildings with a carrying amount of DKK 1,516 million (2019: DKK 1,526 million) were pledged as security to credit institutions. The mortgage loans expire in 2029 and 2039. 2020 2019 DKK million Land and buildings Production equipment and machinery Other equipment Property, plant and equipment under construction Total Total Cost at January 1 3,594 5,075 1,234 329 10,232 9,675 Lease assets at January 1 - - - - - 218 Additions during the year 83 82 65 142 372 363 Disposals during the year (91) (27) (95) - (213) (24) Transfers to/(from) other items 77 111 22 (210) - - Cost at December 31 3,663 5,241 1,226 261 10,391 10,232 Depreciation and impairment losses at January 1 (1,492) (3,483) (786) (5,761) (5,420) Depreciation for the year (111) (184) (96) (391) (360) Impairment losses - - - - (5) Disposals during the year 43 25 93 161 24 Depreciation and impairment losses at December 31 (1,560) (3,642) (789) (5,991) (5,761) Carrying amount at December 31 B/S 2,103 1,599 437 261 4,400 4,471 NOTES SECTION 3 Accounts and performanceFinancial statements for Novozymes A/S 151Novozymes A/S 3.3 Leases NOTES SECTION 3 Accounts and performanceFinancial statements for Novozymes A/S DKK million 2020 2019 Land and buildings 53 73 Plant and machinery 97 100 Other equipment 65 91 Carrying amount of lease assets 215 264 Additions to the lease assets during 2020 amounted to DKK 9 million (2019: DKK 10 million). Maturity analysis of the lease liability DKK million 2020 2019 Lease liability Less than 1 year 62 92 Between 1 and 5 years 70 79 More than 5 years 89 103 Undiscounted lease liability at December 31 221 274 DKK million 2020 2019 Amounts recognized in prot or loss Interest on lease liabilities 4 5 Depreciation of lease assets per asset class Land and buildings 15 19 Plant and machinery 5 5 Other equipment 31 32 Depreciation of lease assets 51 56 Amounts recognized in the statement of cash ows Total cash outow for leases 54 58 At December 31, 2020, the revaluation reserve included an amount of DKK 2,820 million from the elimination of prot on internal asset transfer. Reference is made to Note 6.8 to the consolidated nancial statements concerning investments in subsidiaries, joint operations and associates. 152Novozymes A/S 3.4 Financial xed assets NOTES SECTION 3 Accounts and performanceFinancial statements for Novozymes A/S DKK million Investments in subsidiaries Investments in associates Receivables from Group companies Total Cost at January 1, 2020 8,655 128 352 9,135 Additions during the year 798 - 9 807 Disposals during the year (12) - (66) (78) Cost at December 31, 2020 9,441 128 295 9,864 Revaluation reserve at January 1, 2020 (74) (91) (165) Share of net prot/(loss) 1,311 (4) 1,307 Elimination of prot on internal asset transfers (539) - (539) Dividends received (2,255) - (2,255) Currency translation adjustment (765) - (765) Other adjustments 38 - 38 Revaluation reserve at December 31, 2020 (2,284) (95) (2,379) Carrying amount at December 31, 2020 B/S 7,157 33 295 7,485 153Novozymes A/S 3.5 Other receivables DKK million 2020 2019 Prepaid expenses 50 68 Derivatives 119 15 Other receivables 44 57 Other receivables at December 31 213 140 Recognized in the balance sheet as follows: Non-current B/S 9 2 Current B/S 204 138 Other receivables at December 31 213 140 NOTES SECTION 3 Accounts and performanceFinancial statements for Novozymes A/S 154Novozymes A/S Reference is made to Note 3.5 to the consolidated nancial statements concerning business acquisitions, as the gures and information applying to Novozymes A/S are identical to the information provided there. Deferred tax assets Deferred tax liabilities DKK million 2020 2019 2020 2019 Intangible assets - - 214 191 Property, plant and equipment - - 383 347 Inventories - 6 1 - Stock options 61 79 - - Other - 5 18 - 61 90 616 538 Osetting items (61) (90) (61) (90) Deferred tax at December 31 B/S - - 555 448 DKK million 2020 2019 Deferred tax at January 1 448 380 Prior-year adjustments 25 24 Tax related to the income statement 34 51 Tax on shareholders’ equity items 48 (7) Deferred tax at December 31 B/S 555 448 3.6 Deferred tax NOTES SECTION 3 3.7 Other provisions Accounts and performanceFinancial statements for Novozymes A/S 155Novozymes A/S 4.2 Credit institutions 4.3 Proposed appropriation of net prot DKK million 2020 2019 Long-term debt to credit institutions falling due aer 5 years 1,332 1,229 DKK million 2020 2019 Proposed appropriation of net prot Dividend to shareholders 1,496 1,528 Revaluation reserve according to the equity method 1,307 2,147 Retained earnings (191) (604) Net prot 2,612 3,071 4.1 Financial income and costs NOTES SECTION 4 Accounts and performanceFinancial statements for Novozymes A/S DKK million 2020 2019 Interest income relating to subsidiaries 27 35 Interest costs relating to subsidiaries (14) (26) 156Novozymes A/S 5.1 Contingent liabilities and pending litigation DKK million 2020 2019 Other commitments Contractual obligations to third parties relating to property, plant and equipment 129 92 Other guarantees Other guarantees and commitments to related companies 315 2,357 Other guarantees and commitments 196 151 NOTE SECTION 5 Accounts and performanceFinancial statements for Novozymes A/S Pending litigation and arbitration Reference is made to Note 6.3 to the consolidated nancial statements concerning pending litigation and arbitration. 157Novozymes A/S 5.2 Related party transactions In 2020, Novozymes purchased from Novo Holding 1,530,000 of its own B shares with the approval of the Board of Directors, at a price of DKK 537 million (2019: 1,530,000 B shares at a price of DKK 475 million). The transactions were based on the market price. There were no transactions with related parties other than the transactions described and normal remuneration of the Board of Directors and Executive Leadership Team, which is presented in Note 6.1 in the consolidated nancial statements. Reference is made to Note 6.4 to the consolidated nancial statements concerning transactions with related parties. Novozymes A/S is included in the consolidated nancial statements of Novo Nordisk Foundation. Transactions Outstanding balances DKK million 2020 2019 DKK million 2020 2019 Novo Holdings A/S Novo Holdings A/S Sales 1 - Receivables - - The Novo Nordisk Group The Novo Nordisk Group Sales 72 103 Receivables 8 9 Purchases (113) (129) Payables (85) (98) The NNIT Group The NNIT Group Purchases (43) (27) Payables (14) (7) The Chr. Hansen Group The Chr. Hansen Group Sales 60 45 Receivables - 10 Purchases (3) (9) Microbiogen Pty. Ltd. Microbiogen Pty. Ltd. Purchase of services (30) (15) Payables (7) (4) NOTES SECTION 5 Accounts and performanceFinancial statements for Novozymes A/S 158Novozymes A/S 5.3 Fees to statutory auditors Reference is made to Note 5.5 to the consolidated nancial statements concerning common stock and treasury stock. Reference is made to Note 5.4 to the consolidated nancial statements concerning derivatives, as thegures and information applying to Novozymes A/S are identical to the information provided there. Reference is made to Note 6.7 to the consolidated nancial statements concerning events aer the reporting date. DKK million 2020 2019 Reference is made to Note 6.5 to the consolidated Statutory audit 5 5 nancial statements concerning fees to statutory Other assurance engagements - - auditors. Tax advisory services 3 1 Other services 1 - Fees to statutory auditors 9 6 5.4 Common stock and treasury stock 5.5 Derivatives 5.6 Events aer the reporting date NOTES SECTION 5 Accounts and performanceFinancial statements for Novozymes A/S Financial Glossary Earnings per share (diluted) Net prot (attributable to shareholders in Novozymes A/S) divided by the weighted average number of shares outstanding (diluted). EBIT/Operating prot Prot before interest and tax. EBIT margin Prot before interest and tax as a percentage of revenue. EBITDA Prot before interest, tax, depreciation and amortization. EBITDA margin Prot before interest, tax, depreciation and amortization as a percentage of revenue. Economic prot Economic prot is dened as adjusted operating prot (NOPAT) less (average invested capital * WACC). Eective tax rate Income tax expense as a percentage of prot before tax. Equity ratio Total shareholders’ equity as a percentage of total assets at year-end. Glossary Free cash ow before acquisitions Cash ow from operating activities less cash ow from investing activities, changes in net working capital, business acquisitions, divestments and purchase of nancial assets. Invested capital Total assets excluding interest-bearing assets and minority investments less interest-bearing liabilities. iXBRL tags iXBRL tags is hidden meta-information embedded in the source code of an XHTML document in accordance with the Inline XBRL specication, which enables the conversion of XHTML-formatted information into a machine- readable XBRL data record by appropriate soware. Net interest-bearing debt (NIBD) The market value of interest-bearing liabilities (nancial liabilities) less the market value of cash at bank and in hand and other readily convertible interest-bearing current assets. Net working capital Current assets less current liabilities used in, or necessary for, the company’s operations. The main components are inventories, trade receivables and trade payables. Adjusted operating prot aer tax Operating prot adjusted for exchange gains/ losses, share of prot in associates less tax on adjusted operating prot using the eective tax rate. Operating costs Operating costs consist of Sales and distribution costs, Research and development costs and Administrative costs. Organic sales growth Sales growth from existing business, excluding divestments, measured in local currency. For acquisitions pro forma sales for the prior year is included in the calculation. Return on invested capital (ROIC) Adjusted operating prot (NOPAT) aer tax as a percentage of average invested capital Taxonomy Taxonomy is an electronic dictionary of business reporting elements used to report business data. A taxonomy element is an element dened in a taxonomy that is used for the machine-readable labeling of information in an XBRL data record. XHTML XHTML (eXtensible HyperText Markup Language) is a text-based markup language used to structure and mark up content such as text, images, and hyperlinks in documents that are displayed as Web pages in an updated standard Web browser like Chrome and Internet Explorer. CO2 The term “CO2” is used to represent all greenhouse gasses (CO2, CH4, N2O etc.) on an equivalency basis in this report. Zero waste Zero waste means that >90% of all non- biomass waste is diverted from landll or incineration without energy recovery – excluding when those are to fulll regulatory requirements. Other termsFinancial terms 159Novozymes A/S Accounts and performanceGlossary Novozymes’ reporting ambition is to provide a single integrated report connecting our business model, strategy, targets and performance through integrated nancial and nonnancial data About the report Editorial team Editor in chief Ann Lauritzen Steel, Global Communications & Brand [email protected] | tel. +45 3077 2027 Finance Jens Breitenstein, Finance [email protected] | tel. +45 3077 1087 Investor Relations Ulrik Wu Svare, Investor Relations [email protected] | tel. +45 3077 3187 Corporate Sustainability Santosh Govindaraju, Sustainability [email protected] | tel. +45 30772563 Text The editorial team from Novozymes, headed by Global Communications & Brand Photography Lars Just, Thorbjørn Hansen and Ty Stange Design & web BystedFFW A/S Editing & proofreading Fokus Translations Reporting and audits The website contains The Novozymes Report 2020, which, pursuant to section 149 of the Danish Financial Statements Act, is an extract of the company’s annual report. It also contains the nancial statements of the parent company Novozymes A/S. Together, these constitute the company’s annual report as led with the Danish Business Authority. PwC has audited the consolidated nancial statements, the parent company nancial statements, and the environmental and social data. The audit covers nancial, environmental and social data. These are marked “Audited by PwC.” See also the statements in the report. PwC has not audited the sections of the report under the headings The big picture, Our business, Governance, and Sustainability. The Sustainability section includes our Communication on Progress prepared in accordance with the UN Global Compact principles. The report has been prepared in accordance with the International Financial Reporting Standards (IFRS), the Danish Financial Statements Act and additional requirements of Nasdaq Copenhagen A/S for the presentation of nancial statements by listed companies. It is also inspired by the GRI’s G4 Sustainability Reporting Guidelines. See Basis of reporting in the report for more details. Forward-looking statements This annual report contains forward-looking statements, including statements about future events, future nancial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, “believe,” “anticipate,” “expect,” “estimate,” “intend,” “plan,” “project,” “could,” “may,” “might” and other words with a similar meaning. Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to dier materially from expectations, both positively and negatively. These risks and uncertainties may include unexpected developments in i) the ability to develop and market new products; ii) the demand for Novozymes’ products, market- driven price decreases, industry consolidation, and launches of competing products or disruptive technologies in Novozymes’ core areas; iii) the ability to protect and enforce the company’s intellectual property rights; iv) signicant litigation or breaches of contract; v) the materialization of the company’s growth platforms, notably the opportunity for marketing biomass conversion technologies or the development of microbial solutions for broad-acre crops; vi) political conditions, such as acceptance of enzymes produced by genetically modied organisms; vii) global economic and capital market conditions, including, but not limited to, currency exchange rates (USD/DKK and EUR/DKK in particular, but not exclusively), interest rates and ination; and viii) signicant price decreases for inputs and materials that compete with Novozymes’ biological solutions. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information. 160Novozymes A/S Accounts and performanceAbout the report © Novozymes A/S, Krogshoejvej 36 2880 Bagsvaerd, Denmark Explore interactive highlights from the report at report2020.novozymes.com 161Novozymes A/S 529900T6WNZXD2R3JW382020-01-012020-12-31529900T6WNZXD2R3JW382020-01-012020-12-31cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-311cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-312cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-313cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-311cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-312cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-313cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-314cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-315cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-316cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-317cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-318cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-319cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-3110cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-311cmn:ConsolidatedMember529900T6WNZXD2R3JW382020-01-012020-12-312cmn:ConsolidatedMember529900T6WNZXD2R3JW382019-01-012019-12-31cmn:ConsolidatedMember529900T6WNZXD2R3JW382019-01-012019-12-31529900T6WNZXD2R3JW382020-01-01529900T6WNZXD2R3JW382020-12-31529900T6WNZXD2R3JW382019-01-01529900T6WNZXD2R3JW382019-12-31529900T6WNZXD2R3JW382020-01-01ifrs-full:IssuedCapitalMember529900T6WNZXD2R3JW382020-01-012020-12-31ifrs-full:IssuedCapitalMember529900T6WNZXD2R3JW382020-12-31ifrs-full:IssuedCapitalMember529900T6WNZXD2R3JW382020-01-01ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900T6WNZXD2R3JW382020-01-012020-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900T6WNZXD2R3JW382020-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900T6WNZXD2R3JW382020-01-01ifrs-full:ReserveOfCashFlowHedgesMember529900T6WNZXD2R3JW382020-01-012020-12-31ifrs-full:ReserveOfCashFlowHedgesMember529900T6WNZXD2R3JW382020-12-31ifrs-full:ReserveOfCashFlowHedgesMember529900T6WNZXD2R3JW382020-01-01ifrs-full:RetainedEarningsMember529900T6WNZXD2R3JW382020-01-012020-12-31ifrs-full:RetainedEarningsMember529900T6WNZXD2R3JW382020-12-31ifrs-full:RetainedEarningsMember529900T6WNZXD2R3JW382020-01-01ifrs-full:EquityAttributableToOwnersOfParentMember529900T6WNZXD2R3JW382020-01-012020-12-31ifrs-full:EquityAttributableToOwnersOfParentMember529900T6WNZXD2R3JW382020-12-31ifrs-full:EquityAttributableToOwnersOfParentMember529900T6WNZXD2R3JW382020-01-01ifrs-full:NoncontrollingInterestsMember529900T6WNZXD2R3JW382020-01-012020-12-31ifrs-full:NoncontrollingInterestsMember529900T6WNZXD2R3JW382020-12-31ifrs-full:NoncontrollingInterestsMember529900T6WNZXD2R3JW382019-01-01ifrs-full:IssuedCapitalMember529900T6WNZXD2R3JW382019-01-012019-12-31ifrs-full:IssuedCapitalMember529900T6WNZXD2R3JW382019-12-31ifrs-full:IssuedCapitalMember529900T6WNZXD2R3JW382019-01-01ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900T6WNZXD2R3JW382019-01-012019-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900T6WNZXD2R3JW382019-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900T6WNZXD2R3JW382019-01-01ifrs-full:ReserveOfCashFlowHedgesMember529900T6WNZXD2R3JW382019-01-012019-12-31ifrs-full:ReserveOfCashFlowHedgesMember529900T6WNZXD2R3JW382019-12-31ifrs-full:ReserveOfCashFlowHedgesMember529900T6WNZXD2R3JW382019-01-01ifrs-full:RetainedEarningsMember529900T6WNZXD2R3JW382019-01-012019-12-31ifrs-full:RetainedEarningsMember529900T6WNZXD2R3JW382019-12-31ifrs-full:RetainedEarningsMember529900T6WNZXD2R3JW382019-01-01ifrs-full:EquityAttributableToOwnersOfParentMember529900T6WNZXD2R3JW382019-01-012019-12-31ifrs-full:EquityAttributableToOwnersOfParentMember529900T6WNZXD2R3JW382019-12-31ifrs-full:EquityAttributableToOwnersOfParentMember529900T6WNZXD2R3JW382019-01-01ifrs-full:NoncontrollingInterestsMember529900T6WNZXD2R3JW382019-01-012019-12-31ifrs-full:NoncontrollingInterestsMember529900T6WNZXD2R3JW382019-12-31ifrs-full:NoncontrollingInterestsMemberiso4217:DKKiso4217:DKKxbrli:sharesNovozymes A/SDenmarkStock-based corporationDenmarkKrogshoejvej 36, 2880 BagsvaerdDenmarkThe objects of the company are to carry out research in, development and production of and trade in biological solutions, including enzymes, microorganisms and other biotechnological processes and products as well as any other related activities as may be specified by the Board of Directors. The company strives to operate in a sustainable and responsible manner, inter alia in a financial, environmental and social regard.Novo Holdings A/SNovo Nordisk FoundationN/AAnnual reportAuditor's report on audited financial statementsParsePort XBRL Converter2020-01-012020-12-312019-01-012019-12-31529900T6WNZXD2R3JW38Novozymes A/SReporting class D10007127Krogshoejvej362880BagsvaerdDenmarkhttps://investors.novozymes.com/investors/corporategovernance/articles-of-associationand-reportson-corporate-governance/default.aspxhttps://www.novozymes.com/en/about-us/sustainability/transparencyaccountabilityhttps://investors.novozymes.com/investors/corporategovernance/articles-of-associationand-reportson-corporate-governance/default.aspx6,099634126072688Ester BaigetPresident & CEOThomas VidebækLars GreenJørgen Buhl RasmussenChairCornelis (Cees) de JongVice ChairHeine DalsgaardLena Bech HolskovSharon JamesAnders Hentze KnudsenKasim KutayLars Bo KøpplerKim StrattonMathias Uhlén529900T6WNZXD2R3JW3810007127Novozymes A/SKrogshoejvej 362880 BagsvaerdOpinionBasis for OpinionHellerup2021-02-02Lars BaungaardState Authorized Public Accountantmne2333133771231PricewaterhouseCoopers Statsautoriseret RevisionspartnerselskabStrandvejen442900HellerupRasmus Friis JørgensenState Authorized Public Accountantmne2870533771231PricewaterhouseCoopers Statsautoriseret RevisionspartnerselskabStrandvejen442900Hellerup
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.